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CHAPTER 1:  Introduction and Aim 
Bradykinin, Angiotensin-(1-7), and ACE Inhibitors: How Do 
They Interact? 
Summary 
The beneficial effect of angiotensin-converting enzyme (ACE) inhibitors in 
hypertension and heart failure may relate, at least in part, to their capacity to interfere 
with bradykinin metabolism. In addition, recent studies have provided evidence for 
bradykinin-potentiating effects of ACE inhibitors that are independent of bradykinin 
hydrolysis, i.e., ACE-bradykinin type 2 (B2) receptor ‘crosstalk’, resulting in B2 
receptor upregulation and/or more efficient activation of signal transduction pathways, 
as well as direct activation of bradykinin type 1 (B1) receptors by ACE inhibitors. This 
review critically reviews the current evidence for hydrolysis-independent bradykinin 
potentiation by ACE inhibitors, evaluating not only the many studies that have been 
performed with ACE-resistant bradykinin analogues, but also paying attention to 
angiotensin-(1-7) (Ang-(1-7)), a metabolite of both angiotensin (Ang) I and II, that 
could act as an endogenous ACE inhibitor. The levels of Ang-(1-7) are increased 
during ACE inhibition, and most studies suggest that its hypotensive effects are 
mediated in a bradykinin-dependent manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on: Tom B., Dendorfer A. & Danser A.H.J. (2003). Bradykinin, 
angiotensin-(1-7), and ACE inhibitors: How do they interact? Int. J. Biochem. Cell. 
Biol. 35,792-801. 
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1.1. Introduction 
Bradykinin and Ang II are important peptides involved in the regulation of vascular 
tone. Ang II is a vasoconstrictor and growth-promoting substance, whereas bradykinin 
is a potent vasodilator and growth inhibitor. ACE inhibitors, which are now widely 
used for the treatment of hypertension and heart failure, not only block the generation 
of Ang II from Ang I, but also prevent the degradation of bradykinin (Figure 1). 
Although originally it was thought that their beneficial effects were mainly due to 
blockade of Ang II generation, recent evidence suggests that bradykinin accumulation 
may be of equal importance. For instance, plasma and tissue Ang II concentrations are 
not always decreased during chronic ACE inhibition (Campbell et al., 1999; 
Farquharson et al., 2002; van Kats et al., 2000), possibly due to the presence of 
alternative Ang I-II converting enzymes like chymase (Maassen van den Brink et al., 
1999). Furthermore, combined inhibition of ACE and neutral endopeptidase (NEP), a 
second bradykinin-metabolising enzyme, is more cardioprotective than ACE 
inhibition alone (d'Uscio et al., 2001; Rouleau et al., 2000). An interesting observation 
in this regard is that ACE inhibitors appear to potentiate bradykinin beyond blocking 
its hydrolysis, either through ACE-B2 receptor ‘cross-talk’ (Benzing et al., 1999; 
Marcic et al., 1999; 2000a; 2000b; Minshall et al., 1997b) or via direct stimulation of 
B1 receptors (Ignjatovic et al., 2002).  
This review addresses the various ways through which ACE inhibitors potentiate 
bradykinin, paying attention in particular to Ang-(1-7), a metabolite of both Ang I and 
Ang II (Ferrario et al., 1997) (Figure 1) that inhibits ACE. Its levels are increased 
during ACE inhibitor treatment (Campbell et al., 1993b; Yamada et al., 1998), and 
according to some reports it may also stimulate a new, as yet unidentified, receptor. 
1.2. Bradykinin synthesis, metabolism, receptors and function 
Bradykinin is generated from kininogen by kallikrein, either directly or via the 
intermediate kallidin (Figure 1). In-vivo, bradykinin is rapidly degraded (half life 
<0.5 min) (Cyr et al., 2001) by kininases, the most important of which are the 
metallopeptidases ACE and NEP, aminopeptidase P, and the carboxypeptidases M 
and N (Dendorfer et al., 1997b; Kokkonen et al., 2000). In view of its short half life, it 
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is generally assumed that bradykinin, in order to have a local effect, is synthesized at 
tissue sites. In support of this concept, the various components required to generate 
bradykinin locally are present in heart and vessel wall (Nolly et al., 1992; 1994), 
bradykinin is released from tissue sites into the circulation (Baumgarten et al., 1993; 
Duncan et al., 2000), and tissue bradykinin levels are higher than those in circulating 
blood (Campbell et al., 1993a). 
ACE
NEP
Bradykinin
Bradykinin (1-7)
Bradykinin (1-5)
Kininogen
kallikrein
ACE
Bradykinin (2-9)
carboxypeptidase
aminopeptidase
Kallidin=Lys0-Bradykinin
Angiotensin II
Angiotensin (1-7)
Angiotensin (1-5)
Angiotensinogen
renin
PCP
PEP
ACE
ACE
chymase
NEP
PEP
Angiotensin I
Bradykinin (1-8)
 
Figure 1. Synthesis and metabolism of angiotensins and bradykinin. ACE, angiotensin-
converting enzyme; NEP, neutral endopeptidase; PEP, prolyl endopeptidase; PCP, prolyl 
carboxypeptidase.  
 
Bradykinin exerts its actions via binding to B1 and B2 receptors. Both receptors 
are G protein-coupled receptors (Marceau et al., 1998). B2 receptors are constitutively 
expressed in a variety of cells, including endothelial cells, vascular smooth muscle 
cells (Raidoo et al., 1997), and cardiomyocytes (Minshall et al., 1995).  B1 receptors 
are weakly detectable under physiological conditions, but strongly expressed in 
pathological states (Marceau et al., 1998). B1 receptor upregulation also occurs in B2 
receptor gene knockout mice (Duka et al., 2001).  
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Activation of endothelial B2 receptors results in vasorelaxation, an effect that is 
mediated, at least in part, via stimulation of endothelial nitric oxide synthase (eNOS) 
and subsequent nitric oxide (NO) generation. Alternative mediators of the B2 receptor-
stimulated vasorelaxation are the so-called endothelium-derived hyperpolarizing 
factors (EDHF), the identity of which has not yet been established. Putative candidates 
include prostacyclin, potassium, S-nitrosothiols and epoxyeicosatrienoic acid (Danser 
et al., 1998; Mombouli et al., 1997). B2 receptors on vascular smooth muscle cells and 
cardiomyocytes mediate contractile (Dendorfer et al., 2001a; Gobeil et al., 2002) and 
inotropic (Tom et al., 2001b) effects, respectively. In addition, B2 receptor activation 
has been associated with anti-hypertrophic and/or anti-proliferative effects in 
cardiomyocytes and fibroblasts (Ishigai et al., 1997; McAllister et al., 1993). B1 
receptors, once induced by inflammatory mediators and tissue damage, assume some 
of the hemodynamic properties of the B2 receptor (e.g., vasorelaxation) (Duka et al., 
2001; Su et al., 2000). In this regard, it is important to realize that bradykinin and 
kallidin (Lys-bradykinin) display less affinity for B1 receptors than for B2 receptors, 
and that their carboxypeptidase metabolites, des-Arg9-bradykinin and in particular 
des-Arg10-kallidin, might act as the endogenous agonists of B1 receptors (Marceau et 
al., 1998). 
1.3. Bradykinin potentiation by ACE inhibitors: inhibition of hydrolysis? 
ACE is responsible for 45-100 % of kininase activity in blood plasma and tissues 
(Blais et al., 1997; Dendorfer et al., 2001b; Taylor-McCabe et al., 2001), and it is 
therefore not surprising that ACE inhibitors potentiate the actions of bradykinin (i.e., 
cause a leftward shift of the bradykinin concentration-response curve) by a factor of 
5-120, both in-vivo and in- vitro (Bönner et al., 1990; Dendorfer et al., 2000; 
Mombouli et al., 1992; Tom et al., 2001a). Unexpectedly, this increase in potency was 
also observed under conditions where bradykinin concentrations were barely affected 
by degradation, for instance in organ bath experiments (Auch-Schwelk et al., 1993). 
Moreover, ACE inhibitors also exerted potent relaxant effects when applied on top of 
subthreshold doses of bradykinin (Auch-Schwelk et al., 1993), or when given in the 
presence of high bradykinin concentrations designed to desensitize B2 receptors 
(Hecker et al., 1994). These findings have provoked hypotheses about degradation-
independent mechanisms of kinin potentiation, particularly because the degradation-
independent effects were initially confirmed when using bradykinin analogues that 
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were assumed to be ACE-resistant (Auch-Schwelk et al., 1993; Danser et al., 2000; 
Minshall et al., 1997a; 2000; Mombouli et al., 2002). However, for two frequently 
applied analogues, D-Arg-[Hyp3]-bradykinin and [Hyp3-Tyr(Me)8]-bradykinin, this 
assumption has been proven to be wrong (Dendorfer et al., 2001a; Gobeil et al., 
2002). More importantly, the potentiating and resensitizing actions of ACE inhibitors 
were entirely absent when studied in combination with truly stable B2 receptor 
agonists in physiological models such as the perfused rat heart, the rabbit jugular vein, 
and the porcine coronary artery (Dendorfer et al., 2000; 2001a; Gobeil et al., 2002; 
Tom et al., 2002). These latter observations permit two possible explanations. Either 
the stable agonists lack an undefined property that is required to allow ACE inhibitors 
to potentiate bradykinin in a degradation-independent manner, or potentiation is 
exclusively related to kinin degradation in those physiological models. The latter 
hypothesis would imply that ACE co-localizes with B2 receptors in a compartment in 
which degradation dramatically impairs bradykinin availability. Application of an 
ACE inhibitor under such conditions has the potential to increase the bradykinin 
concentrations in the micro-environment of the B2 receptor several-fold as well as 
immediately. 
The existence of a tissue compartment with highly effective bradykinin 
degradation has been demonstrated in the isolated rat heart during bradykinin 
distribution studies (Dendorfer et al., 1997b). Following intracoronary bolus 
application of 3H-bradykinin, an early fraction was recovered after intravascular 
passage in which 72 % of 3H-activity represented intact bradykinin, whereas in a 
delayed fraction (representing redistribution from a tissue compartment) only 8% of 
3H-activity consisted of intact bradykinin (Dendorfer et al., 1997b). The 13-fold 
reduction of bradykinin availability in the delayed fraction corresponds well with the 
19-fold potentiation of bradykinin during combined inhibition of the major kininases 
in the rat myocardium (ACE and aminopeptidase P) (Dendorfer et al., 2000). 
Interestingly, the high local efficacy of ACE is not restricted to the inactivation of 
bradykinin; in vessel segments mounted in organ baths, it also effectively activates 
Ang I locally, resulting in vascular interstitial Ang II levels that are up to 27-fold 
higher than the Ang II levels in the organ bath (Schuijt et al., 2002). Since interstitial 
rather than circulating Ang II was found to determine vasoconstriction, these data 
suggest that ACE and AT1 receptors, like ACE and B2 receptors, co-localize in the 
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same compartment. Further evidence for the close anatomical localization of ACE, B2 
receptors and AT1 receptors comes from a recent observation on AT1-B2 receptor 
heterodimerization, resulting in enhanced G-protein activation and altered receptor 
sequestration (AbdAlla et al., 2000). 
Studies in cultured cells confirm that co-localization of B2 receptors and ACE is 
a prerequisite for kinin potentiation. When ACE was expressed in Chinese hamster 
ovary (CHO) cells and directed to lipid rafts by genetic modification of its membrane 
anchor (Marcic et al., 2000a), the potentiating effect of the ACE inhibitor ramiprilat 
was abolished. It only returned following restoration of the close sterical relationship 
between ACE and B2 receptors by the cholesterol-depleting agent filipin. These results 
indicate that the proposed micro-environment harboring B2 receptors and ACE may be 
constituted by membrane domains, such as caveolae or lipid rafts, the identities of 
which still need to be clarified. 
Finally, there is a quantitative relationship between kinin breakdown and the 
potentiating effect of ACE inhibitors. For instance, when stimulation is performed 
with bradykinin analogues that are partially resistant towards ACE, the potentiation of 
their actions by ACE inhibitors is impaired to about the same extent as their 
degradation (Dendorfer et al., 2001a). In addition, blockade of only one of the two 
active sites of ACE (the so-called N- and C-domain) produces bradykinin potentiation 
that is only half that during blockade of both domains (Tom et al., 2001a). The 
quantitative relation between bradykinin breakdown and potentiation is further 
demonstrated by the fact that potentiation can also be provoked by inhibition of other 
kininases, for instance aminopeptidase P in the rat heart (Dendorfer et al., 2000), and 
NEP following its overexpression in CHO cells (Deddish et al., 2002). Thus, the 
phenomenon of kinin potentiation by ACE inhibitors can be mimicked by structurally 
unrelated inhibitors of other kininases, provided that such kininases are equivalent to 
ACE in their degradation activities and localizations. 
1.4. Bradykinin potentiation by ACE inhibitors: ACE-B2 receptor crosstalk? 
Although studies with ACE-resistant bradykinin analogues did not confirm the 
hydrolysis-independent bradykinin potentiation/B2 receptor resensitization in 
physiological models (Dendorfer et al., 2001a; Gobeil et al., 2002; Tom et al., 2002), 
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it is still being argued, in view of the fact that the half life of bradykinin in such 
isolated tissue preparations is >10 minutes (Minshall et al., 2000; Tom et al., 2002), 
that the ACE inhibitor-induced effects (which occur within seconds) must be 
independent of blocking bradykinin degradation (Erdös, 2002). In support of this 
concept, NEP inhibition did not potentiate bradykinin in porcine vessels, nor did it 
potentiate its substrate atrial natriuretic peptide (Figure 2). Although an alternative 
explanation for the latter finding might be a low activity of NEP in porcine vessels, a 
recent study convincingly demonstrated NEP activity in porcine vascular tissue 
(Miyamoto et al., 2002).  
Studies in CHO cells transfected with B2 receptors and ACE, as well as in 
endothelial cells that constitutively express these proteins, more convincingly provide 
evidence for an ACE-B2 receptor ‘crosstalk’ that goes beyond blocking hydrolysis 
(Figure 3). In these cells, ACE inhibitors increase the number of cell surface B2 
receptors, block B2 receptor desensitization, and decrease B2 receptor internalization 
(Minshall et al., 1997b). The latter may relate to the fact that ACE inhibitors prevent 
bradykinin-activated B2 receptors from sequestration with caveolin-rich membranes 
(Benzing et al., 1999). Importantly, these effects are not observed in CHO cells 
transfected with B2 receptors alone (Minshall et al., 1997b), thereby arguing against a 
direct effect of ACE inhibitors on B2 receptors. Since, as discussed above, ACE 
inhibitors augment bradykinin only when B2 receptors and ACE are sterically close 
(Marcic et al., 2000a), one possibility is that B2 receptors and ACE form a 
heterodimer. ACE inhibitors might then affect heterodimer interaction, thus promoting 
a B2 receptor conformation that can more efficiently induce signal transduction. 
In cultured cells, ACE inhibitors did not resensitize B2 receptors during blockade 
of protein kinase C (PKC) or phosphatases (Marcic et al., 2000b). Although this 
finding could not be reproduced in an intact vessel preparation (Tom et al., 2002), it is 
in agreement with the concept that B2 receptor desensitization involves PKC 
activation and B2 receptor phosphorylation (Blaukat et al., 1996; Marcic et al., 
2000b). It could also relate to the possibility that PKC inhibition affects 
phosphorylation of an intermediate protein that mediates the interaction between B2 
receptors and ACE. Finally, ACE inhibitors not only induce B1 receptor upregulation 
(Marin-Castano et al., 2002), but may also act as B1 receptors agonists, stimulating 
NO release at nanomolar concentrations (Ignjatovic et al., 2002).  
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Figure 2. Relaxations of porcine arteries preconstricted with 1 µM U46619, to bradykinin or 
atrial natriuretic peptide (ANP) in the absence (control) or presence of 10 µM quinaprilat 
(ACE inhibitor), 10 µM omapatrilat (combined ACE and NEP inhibitor) or 1 µM 
phosphoramidon (NEP inhibitor). Data (mean±S.E.M. of 5-10 experiments) are expressed as 
a percentage of the contraction induced by U46619, and have been obtained from (Tom et 
al., 2002). 
 
1.5. Bradykinin and Ang-(1-7) 
Ang-(1-7) is one of the metabolites of Ang I that, like the main metabolite of Ang I, 
Ang II, might have effects of its own, for instance via stimulation of a specific 
Ang-(1-7) receptor. Ang-(1-7) can be generated both from Ang I (by NEP) and from 
Ang II (by prolyl endopeptidase, prolyl carboxypeptidase and/or ACE-related 
carboxypeptidase (‘ACE2’)) (Figure 1) (Ferrario et al., 1997; Vickers et al., 2002). Its 
levels, which are normally in the picomolar range, increase during ACE inhibition 
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(Campbell et al., 1993b), not only because the elevated Ang I levels during ACE 
inhibition result in enhanced Ang-(1-7) generation by NEP, but also because ACE is 
one of the main Ang-(1-7)-degrading enzymes (Yamada et al., 1998).  
Several lines of evidence suggest that Ang-(1-7) counteracts the effects of 
Ang II. Ang-(1-7) infusions in spontaneously hypertensive rats (SHR) lower blood 
pressure (Benter et al., 1995), and monoclonal Ang-(1-7) antibodies as well as NEP 
inhibitors raise blood pressure during renin-angiotensin system blockade in SHR (Iyer 
et al., 1998a; 1998b). However, these findings were not uniformly confirmed by 
others. Abbas et al. (Abbas et al., 1997) observed hypertensive responses to Ang-(1-7) 
in Sprague-Dawley rats. Similarly, Ang-(1-7) infusion into the forearm of 
normotensive men resulted in modest vasoconstriction (Ueda et al., 2000), whereas in 
patients with heart failure treated with an ACE inhibitor, Ang-(1-7) did not affect 
forearm blood flow (Davie et al., 1999). The doses at which Ang-(1-7) induced 
vasoconstriction were high (up to 50 nmol/min; for comparison: Ang II exerts 
maximal vasoconstrictor effects at doses that are more than 1000-fold lower) (Ueda et 
al., 2000), and the most likely explanation for this contractile response is therefore 
that Ang-(1-7) at these high doses stimulates AT1 receptors. This concept 
simultaneously implies that Ang-(1-7) will antagonize Ang II effects that are mediated 
via AT1 receptors. Combined infusions of Ang II and Ang-(1-7) in humans and rats 
(Mahon et al., 1994; Ueda et al., 2000), as well as in-vitro studies in human internal 
mammary arteries (Roks et al., 1999) and rabbit aortae (Mahon et al., 1994), 
confirmed this assumption. Thus, Ang-(1-7) binds with low affinity to AT1 receptors, 
allowing it to act as an agonist in the absence of Ang II, and as an antagonist in the 
presence of Ang II. 
Pörsti et al. (Pörsti et al., 1994) initially reported potent vasodilator effects of 
Ang-(1-7) in porcine coronary arteries, but were unable to confirm these findings 
when using a second batch of Ang-(1-7), leading the authors to suggest that the 
presence of small amounts of Ang-(1-7) with retro-inverted peptide bonds in the first 
batch may have caused the relaxant effects (Pörsti et al., 1996). Remarkably, 
vasorelaxation of isolated arteries did occur when Ang-(1-7) was added to the organ 
bath following the application of bradykinin (Fernandes et al., 2001; Gorelik et al., 
1998; Tom et al., 2001a). An alternative explanation for the discrepant findings of 
Pörsti  et al.  might therefore  be that  the relaxant  effects of  Ang-(1-7) in  their initial  
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Figure 3. Possible mechanisms 
underlying bradykinin potentiation 
by ACE inhibitors in endothelial 
cells, where B2 receptor activation 
normally results in NO synthase 
activation and subsequent NO 
generation. ACE inhibitors (i) 
either 1) increase the bradykinin 
(BK) levels in the micro-
environment of the B2 receptor, 2) 
increase the number of B2 
receptors, 3) affect ACE-B2 
receptor heterodimer interaction, 
thereby more efficiently inducing 
signal transduction, or 4) induce B1 
receptor upregulation and act as B1 
receptor agonists. 
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report were due to the fact that in this report endothelial integrity had been verified 
with bradykinin (Pörsti et al., 1994). Co-infusion of Ang-(1-7) with bradykinin in-vivo 
also potentiated the hypotensive effect of bradykinin (Abbas et al., 1997; Ueda et al., 
2001), unless an ACE inhibitor had been added before (Davie et al., 1999; Fernandes 
et al., 2001).  
The bradykinin-Ang-(1-7) interaction may involve vasodilatory AT2 receptors 
(Schuijt et al., 2001), since the AT2 receptor antagonist PD123319 partially blocked 
the Ang-(1-7) + bradykinin-induced relaxation in-vitro (Gorelik et al., 1998). 
Alternatively, Ang-(1-7) may act as an ACE inhibitor (Deddish et al., 1998; Roks et 
al., 1999; Tom et al., 2001a). Ang-(1-7) inhibits the ACE C-domain more potently 
than the N-domain (IC50 1-8 µM versus 28-71 µM) (Deddish et al., 1998), and is 
cleaved to Ang-(1-5) by the N-domain (Chappell et al., 1998). Since ACE is 
predominantly located on endothelial cells, the ACE inhibitory capacity of Ang-(1-7) 
not only explains why the relaxant effects of Ang-(1-7) are endothelium-dependent 
(Brosnihan et al., 1996) and why Ang-(1-7) does not potentiate bradykinin in subjects 
treated with ACE inhibitors (Davie et al., 1999), but also puts into perspective the 
existence of a low-affinity (IC50 2.9 µM) binding site for Ang-(1-7) on bovine aortic 
endothelial cells (Tallant et al., 1997). This binding site may in fact be ACE. It must 
be realised that the physiological concentrations of Ang-(1-7) are several orders of 
magnitude below the range required to block ACE (Campbell et al., 1993b), and that 
beneficial effects of Ang-(1-7) will therefore only be observed when infused in 
sufficiently high amounts (Loot et al., 2002). 
Finally, a high-affinity (IC50 19.3 nM) binding site for Ang-(1-7) has also been 
reported (Tallant et al., 1997). D-Ala7-Ang-(1-7) (A779) selectively blocks this site 
(but not ACE), and some (Fernandes et al., 2001; Iyer et al., 2000; Ren et al., 2002), 
but not all (Widdop et al., 1999), studies support the concept that Ang-(1-7) induces 
vasodilation via activation of this ‘Ang-(1-7) receptor’ in rats and rabbits. Inhibitors of 
nitric oxide synthase (NOS) and cyclooxygenase, but not the B2 receptor antagonist 
Hoe140 (Fernandes et al., 2001; Ferreira et al., 2001; Ren et al., 2002), block the 
Ang-(1-7) effects mediated via this receptor, suggesting coupling of the receptor to 
NO and prostaglandins, but not to B2 receptors and bradykinin. Evidence for the 
occurrence of Ang-(1-7) receptors in humans is currently not available. 
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1.6. Conclusion and perspective  
The reduction of bradykinin availability in the micro-environment of B2 receptors due 
to degradation appears to account in full for the potentiating effects observed with 
ACE inhibitors, as long as kinin potentiation is defined as a leftward shift of the 
bradykinin concentration-response relationship. The arousal of bradykinin responses 
by ACE inhibitors in the presence of high bradykinin concentrations that served to 
induce B2 receptor desensitization is mostly addressed as 'receptor resensitization' and 
may occur more universally. Although this phenomenon is also absent in vascular 
preparations after stimulation with degradation-resistant bradykinin analogues 
(Dendorfer et al., 2000; Gobeil et al., 2002; Tom et al., 2002), it may occur in other 
models, for instance because competitors for alternative bradykinin binding sites 
displace local kinins and increase their concentrations in a degradation-independent 
manner. The possibility of such an indirect action prohibits the interpretation of 
'resensitization' as a direct interaction of ACE inhibitors with B2 receptors, so long as 
the mechanism of such an interaction is not clarified at the molecular level. A further 
potential for ACE inhibitors to act as kinin-mimetics not requiring ACE-B2 receptor 
‘crosstalk’ is offered by the recent observation that ACE inhibitors may act as potent 
B1 receptor agonists. Finally, the blood pressure-lowering effects of Ang-(1-7) appear 
to be largely bradykinin-dependent, and most likely reflect its capacity to potentiate 
bradykinin due to the fact that Ang-(1-7) acts as an ACE inhibitor. 
1.7. Aim of the thesis 
ACE generates Ang II from Ang I, and inactivates bradykinin. ACE inhibitors are 
widely used for the treatment of hypertension and heart failure. The beneficial 
cardiovascular effects of ACE inhibitors may therefore be attributed to both 
diminished Ang II production and increased bradykinin levels. Both aspects were 
clarified in this thesis. 
First, we investigated ACE inhibitor-induced potentiation of bradykinin 
(Chapters 2, 4 and 5). Although it seems logical to attribute this to inhibition of 
bradykinin metabolism, recent studies in isolated cells propose that such potentiation 
is of non-metabolic origin, and is based on interference of ACE inhibitors with ACE-
bradykinin type 2 (B2) receptor ‘crosstalk’. We addressed this issue by studying 
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bradykinin-induced relaxation in isolated human and porcine coronary arteries, using 
ACE-resistant bradykinin analogues, ACE inhibitors (captopril and quinaprilat), and 
the ACE-inhibiting angiotensin metabolite Ang-(1-7). In addition, bradykinin 
potentiation following inhibition of other bradykinin-metabolizing enzymes (neutral 
peptidase) was evaluated. Subsequently, we investigated the mediator(s) of 
bradykinin-induced effects in porcine coronary arteries and isolated trabeculae, 
focussing in particular on NO and NO-containing factors (Chapters 2 and 3).  
Second, we quantified Ang II generation in human coronary arteries (Chapter 6). 
Ang II levels are not always lowered during chronic ACE inhibitor therapy, and one 
reason for this absence of Ang II suppression might be that alternative converting 
enzymes, the most important of which is chymase, contribute to Ang II generation 
during chronic ACE inhibitor therapy. In this study we made use of both Ang I and 
the chymase-specific substrate Pro11-D-Ala12-Ang I. By unraveling the site of Ang II 
generation, we tried to address the physiological importance of Ang II generated by 
ACE and chymase.  
Finally, we studied to what degree superoxide mediates the acute vasoconstrictor 
effects of Ang II (Chapter 7). A wide range of studies suggests that Ang II stimulates 
the generation of superoxide through activation of NAD(P)H and/or xanthine oxidase. 
Since superoxide induces vasoconstriction by inactivating NO, ACE inhibition may 
result in increased NO release, not only because of bradykinin potentiation, but also 
due to reduced superoxide generation. 
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CHAPTER 2 
L-NAME-Resistant Bradykinin-Induced Relaxation in Porcine 
Coronary Arteries is NO-Dependent:  Effect of ACE Inhibition  
Summary 
NOS inhibitors partially block bradykinin-mediated vasorelaxation. Here we 
investigated whether this is due to incomplete NOS inhibition and/or NO release from 
storage sites. We also studied the mechanism behind ACE inhibitor-mediated 
bradykinin potentiation. Porcine coronary arteries were mounted in organ baths, 
preconstricted, and exposed to bradykinin or the ACE-resistant bradykinin analogue 
[Hyp3-Tyr(Me)8]-bradykinin with or without the NOS inhibitor L-NAME (100 µM), 
the NO scavenger hydroxocobalamin (200 µM), the Ca2+-dependent K+-channel 
blockers charybdotoxin + apamin (both 100 nM), or the ACE inhibitor quinaprilat 
(10 µM). Bradykinin and [Hyp3-Tyr(Me)8]-bradykinin dose-dependently relaxed 
preconstricted vessels (pEC50 8.0±0.1 and 8.5±0.2, respectively). pEC50’s were ≈10-
fold higher with quinaprilat, and ≈10-fold lower with L-NAME or charybdotoxin + 
apamin. Complete blockade was obtained with hydroxocobalamin or L-NAME + 
charybdotoxin + apamin. Repeated exposure to 100 nM bradykinin or [Hyp3-
Tyr(Me)8]-bradykinin, to deplete NO storage sites, produced progressively smaller 
vasorelaxant responses. With L-NAME, the decrease in response occurred much more 
rapidly. L-Arginine (10 mM) reversed the effect of L-NAME. Adding quinaprilat to the 
bath following repeated exposure (with or without L-NAME), at the time bradykinin 
and [Hyp3-Tyr(Me)8]-bradykinin no longer induced relaxation, fully restored 
vasorelaxation, while quinaprilat alone had no effect. Quinaprilat also relaxed vessels 
that, due to pretreatment with hydroxocobalamin or L-NAME + charybdotoxin + 
apamin, previously had not responded to bradykinin. In conclusion, L-NAME-resistant 
bradykinin-induced relaxation in porcine coronary arteries depends on NO from storage 
sites, and is mediated via stimulation of guanylyl cyclase and/or Ca2+-dependent K+-
channels. ACE inhibitors potentiate bradykinin independent of their effect on 
bradykinin metabolism. 
 
 
Based on: Danser A.H.J., Tom B., de Vries R., Saxena P.R. (2000). L-NAME 
resistant bradykinin-induced relaxation in porcine coronary arteries is NO-dependent: 
effect of ACE inhibition, Br. J. Pharmacol., 131:195-202. 
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2.1. Introduction 
Bradykinin induces vasodilation via endothelial bradykinin type 2 (B2) receptors. This 
effect can be blocked partly by inhibitors of NOS, suggesting a role for de-novo 
synthesis of NO from L-arginine by NOS (Bjornstad-Ostensen et al., 1997; Gardiner 
et al., 1990; Mombouli et al., 1992; Palmer et al., 1988; Rees et al., 1990). The 
relaxant effect of bradykinin that is not blocked by NOS inhibitors is generally 
attributed to so-called endothelium-derived hyperpolarizing factors, of which the exact 
identity has not yet been established. Several candidates have been proposed, 
including prostacyclin, potassium and cytochrome P-450 products of arachidonic acid 
(Edwards et al., 1998; Fisslthaler et al., 1999; Mombouli et al., 1997). However, NOS 
inhibitors, even at high concentrations, do not block NO release completely (Cohen et 
al., 1997). Moreover, in-vivo studies in the rat hindlimb (Davisson et al., 1996) and in-
vitro studies in the isolated perfused rat heart (Danser et al., 1998) have shown that 
bradykinin also induces release of NO from stores of NO-containing factors, such as 
S-nitroso-thiols and dinitrosyl iron (II) thiol complexes (Ignarro, 1990; Myers et al., 
1990; Vedernikov et al., 1992). Depletion of such stores occurred only after repeated 
exposure to bradykinin or after prolonged inhibition of NOS, treatments which 
themselves do not alter the response to NO (Danser et al., 1998; Davisson et al., 
1996). Taken together therefore, bradykinin-induced relaxation in the presence of 
NOS inhibitors might also be due to NO generated by residual NOS activity or to NO 
released from storage sites.  
ACE inhibitors block bradykinin degradation. Accumulation of bradykinin is 
believed to contribute to the beneficial effects of ACE inhibitors in hypertension and 
heart failure, although elevated bradykinin levels were not always found during ACE 
inhibitor treatment (Campbell et al., 1999; Miki et al., 1996). Two recent studies 
propose that ACE inhibitors potentiate bradykinin beyond blocking its hydrolysis, by 
inhibiting desensitization of its receptor. These studies were performed in CHO cells 
transfected with human B2 receptors and human ACE (Minshall et al., 1997b) and in 
porcine aortic endothelial cells that naturally express these proteins (Benzing et al., 
1999). The mechanism underlying the ACE inhibitor-induced inhibition of B2 receptor 
desensitization is currently unknown, but it may involve interference with the 
translocation of B2 receptor to caveolin-rich membrane domains (Benzing et al., 1999; 
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Haasemann et al., 1998; Marcic et al., 1999). Dendorfer et al. (Dendorfer et al., 2000) 
however, using the isolated perfused rat Langendorff heart, found no evidence for 
ACE inhibitor-induced B2 receptor upregulation and suggested that the ACE inhibitor-
induced potentiation of bradykinin was due to inhibition of bradykinin degradation in 
the vicinity of B2 receptors (e.g., in caveolae). 
It was the aim of the present study to investigate, in intact porcine coronary 
arteries (PCAs), 1) whether the NOS inhibitor-resistant bradykinin-induced 
vasorelaxation involves NO, and 2) whether the ACE inhibitor quinaprilat potentiates 
bradykinin via blockade of bradykinin metabolism or via other mechanisms. To 
address the second question, we used the ACE-resistant bradykinin analogue [Hyp3-
Tyr(Me)8]-bradykinin (Minshall et al., 1997b; Rhaleb et al., 1990).  
2.2. Methods 
Drugs 
Bradykinin (acetate salt), prostaglandin F2α (PGF2α), 9,11-dideoxy-11α,9α- 
epoxymethano-prostaglandin F2α  (U46619), substance P (acetate salt), L-arginine 
HCl, Nω-nitro-L-arginine methyl ester HCl (L-NAME), aminoguanidine, 
7-nitroindazole (7-NI), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), 
hydroxocobalamin (acetate salt), indomethacin, glibenclamide, charybdotoxin, 
apamin, sulfaphenazole and captopril were from Sigma-Aldrich Chemie (Zwijndrecht, 
The Netherlands). [Hyp3-Tyr(Me)8]-bradykinin was from Calbiochem/Novabiochem 
AG, Läufelfingen, Switzerland. D-Arg[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin (Hoe140) 
was a kind gift of dr. W. Linz, Hoechst, Frankfurt, Germany. Quinaprilat was a kind 
gift of dr. H. van Ingen, Parke-Davis, Hoofddorp, The Netherlands. 7-NI, 
indomethacin, glibenclamide and quinaprilat were dissolved in dimethylsulfoxide. 
Sulfaphenazole was dissolved in ethanol. Hydroxocobalamin was dissolved in 
methanol. All other chemicals were dissolved in saline. 
Tissue collection 
PCAs were obtained from 31 2-3 month-old pigs (Yorkshire x Landrace, weight 
10-15 kg). The pigs had been used in in-vivo experiments studying the effects of 
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α-adrenoceptor and serotonin receptor agonists and antagonists under pentobarbital 
(600 mg, i.v.) anaesthesia (de Vries et al., 1999; Willems et al., 1999). The Ethics 
Committee of the Erasmus University Rotterdam dealing with the use of animals for 
scientific experiments approved the protocol for this investigation. Hearts were 
explanted at the end of the experiment, and the coronary arteries were removed 
immediately and stored overnight in a cold, oxygenated Krebs bicarbonate solution of 
the following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 
1.2, NaHCO3 25 and glucose 8.3; pH 7.4. Vessels were then cut into segments of 
approximately 4 mm length, suspended on stainless steel hooks in 15 mL organ baths 
containing Krebs bicarbonate solution, aerated with 95% O2 / 5% CO2, and 
maintained at 37°C.  
Organ bath studies 
All vessel segments were allowed to equilibrate for at least 30 min and the organ bath 
fluid was refreshed every 15 min during this period. Changes in tissue contractile 
force were recorded with a Harvard isometric transducer (South Natick, MA, USA). 
The vessel segments, stretched to a stable force of about 15 mN, were exposed to 
30 mM KCl twice. The functional integrity of the endothelium was verified by 
observing relaxation to 1 nM substance P after preconstriction with 1 µM PGF2α. 
Subsequently, the tissue was exposed to 100 mM KCl to determine the maximal 
contractile response to KCl. The segments were then allowed to equilibrate in fresh 
organ bath fluid for 30 min. Thereafter, the following experiments were performed. 
First, possible mediators of the relaxant effect of bradykinin with and without 
NOS inhibition were investigated. Vessels were pre-incubated for 30 min in the 
absence or presence of the non-selective NOS inhibitor L-NAME (100 µM), the 
inducible NOS inhibitor aminoguanidine (1 mM), the neuronal NOS inhibitor 7-NI 
(10 µM), the guanylyl cyclase inhibitor ODQ (10 µM), the NO scavenger 
hydroxocobalamin (200 µM), the cyclooxygenase inhibitor indomethacin (10 µM), 
the ATP-sensitive K+-channel inhibitor glibenclamide (1 µM), the large-conductance 
voltage and Ca2+-activated K+-channel (BKCa) blocker charybdotoxin + the small-
conductance Ca2+-activated K+-channel (SKCa) blocker apamin (both 100 nM), the 
cytochrome P-450 inhibitor sulfaphenazole (10 µM) or the B2 receptor antagonist 
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Hoe140 (1 µM). Vessels were then preconstricted with 10 µM PGF2α or 1 µM 
U46619 and concentration-response curves (CRCs) to bradykinin (0.1 nM-1 µM) 
were constructed.  
Second, to test whether desensitization of the bradykinin-induced relaxation 
occurs more rapidly with NOS inhibition (due to more rapid depletion of NO storage 
sites), preconstricted vessel segments were exposed three times to a concentration of 
bradykinin (0.1 µM) that is capable of inducing maximal relaxation. Each next 
exposure was started as soon as the effect of the previous exposure had disappeared, 
i.e., after approximately 15 min. To investigate whether L-arginine could reverse the 
effect of L-NAME, the repetitive exposure experiments were repeated in the presence 
of L-arginine (10 mM), using a concentration of bradykinin (10 nM) that induces 
submaximal relaxation. To rule out NOS inhibitor-related differences in B2 receptor 
desensitization, we constructed two consecutive bradykinin CRCs in a preconstricted 
vessel segment in the presence or absence of L-NAME.  
Third, the effect of ACE inhibition on bradykinin-induced relaxation was 
investigated. Vessel segments were preconstricted with 10 µM PGF2α or 1 µM 
U46619 and CRCs were constructed to quinaprilat (1 nM-10 µM) to verify the 
presence of endogenous bradykinin. Next, in the presence of the highest concentration 
of quinaprilat, CRCs were constructed to bradykinin and the ACE-resistant bradykinin 
analogue [Hyp3-Tyr(Me)8]-bradykinin (0.1 nM-1 µM). In addition, quinaprilat 
(10 µM) or captopril (100 µM) were added to preconstricted vessels with desensitized 
B2 receptors (i.e., vessels that had been exposed three times to a concentration of 
bradykinin (0.1 µM) that is capable of inducing maximal relaxation; see above). For 
comparison, quinaprilat (10 µM) was also added to preconstricted vessels that had 
been exposed three times to another ACE substrate, substance P, at a concentration 
(1 nM) that is capable of inducing maximal relaxation. 
Statistical analysis 
Data are given as mean±S.E.M. and expressed as a percentage of the contraction in 
response to PGF2α or U46619. CRCs were analyzed using the logistic function 
described by de Lean et al. (de Lean et al., 1978) to obtain pEC50 (-10log EC50) values. 
The addition of L-NAME, ODQ, hydroxocobalamin, L-NAME + ODQ or L-NAME + 
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hydroxocobalamin caused an increase in basal tone of 6±1 mN (n=31), 11±2 mN 
(n=6), 8±1 mN (n=6), 8±1 mN (n=6) and 9±2 mN (n=6), respectively. The PGF2α- 
and U46619-induced preconstrictions were corrected for this increase in baseline. 
Statistical analysis was by ANOVA, followed by post hoc evaluation (according to 
Tukey or Dunnett where appropriate). P values <0.05 were considered significant.  
2.3. Results 
Precontractions 
The PGF2α- and U46619-induced precontractions in control vessels did not differ and 
amounted to approximately 30% (13±1 mN, n=31) of the maximal contraction 
induced by 100 mM KCl. Precontractions were not affected by aminoguanidine, 7-NI, 
indomethacin, glibenclamide, charybdotoxin + apamin, sulfaphenazole or Hoe140. In 
the vessel segments pretreated with L-NAME, ODQ, hydroxocobalamin, L-NAME + 
ODQ, or L-NAME + hydroxocobalamin, the precontractions (23±1 mN, n=31; 
20±2 mN, n=6; 28±2 mN, n=6; 21±3 mN, n=6; and 24±2 mN, n=6, respectively) were 
approximately 2-fold higher than in control vessel segments (p<0.01), which 
illustrates the importance of endogenous NO generation by eNOS in this preparation. 
Mediators of the relaxant effect of bradykinin 
Bradykinin caused complete relaxation of preconstricted vessel segments in a 
concentration-dependent manner (pEC50=8.03±0.05, n=31; Figure 1). The bradykinin 
CRC was not affected by aminoguanidine (pEC50=8.21±0.11, n=5), 7-NI 
(pEC50=7.98±0.22, n=5), indomethacin (pEC50=7.58±0.22, n=5), glibenclamide 
(pEC50=8.35±0.28, n=5) or sulfaphenazole (pEC50=7.63±0.07, n=6). L-NAME 
(pEC50=6.93±0.07, n=25, P<0.01 vs. control) and ODQ (pEC50=7.19±0.30, n=5; 
P<0.05 vs. control) shifted the CRC of bradykinin to the right, while in the presence 
of hydroxocobalamin (n=6) relaxation was only observed at the highest concentration 
of bradykinin (Figure 1). Charybdotoxin + apamin also shifted the CRC of bradykinin 
to the right (pEC50=6.47±0.10, n=6; p<0.01 vs. control, Figure 1). Complete blockade 
of the response was obtained with Hoe140 (Figure 1).   
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Figure 1. Relaxations of porcine coronary arteries, preconstricted with 10 µM PGF2α or 
1 µM U46619, to bradykinin in the absence (control) or presence of 1 µM Hoe140, 10 µM 
quinaprilat, 100 nM charybdotoxin (char) + 100 nM apamin (apa), 10 µM sulfaphenazole, 
100 µM L-NAME, 200 µM hydroxocobalamin, 10 µM ODQ, 10 µM 7-NI, 1 mM 
aminoguanidine, 10 µM indomethacin or 1 µM glibenclamide. For the sake of clarity, data 
have been divided across 3 panels, and the control curve is shown in each panel. Data 
(mean±S.E.M. of 5-31 experiments) are expressed as a percentage of the contraction induced 
by PGF2α or U46619. 
 
The addition of indomethacin (pEC50=7.19±0.16, n=4) or sulphaphenazole 
(pEC50=7.08±0.04, n=6) on top of L-NAME did not cause a further rightward shift of 
the bradykinin CRC as compared to L-NAME alone (data not shown), nor did the 
addition of ODQ on top of L-NAME (pEC50=7.24±0.12, n=5; Figure 2). 
Charybdotoxin + apamin in combination with L-NAME completely blocked the 
response to all bradykinin concentrations tested (Figure 2), whereas in the presence of 
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L-NAME + hydroxocobalamin (n=6) relaxation was again observed at the highest 
concentration of bradykinin only (Figure 2).  
 
Figure 2. Relaxations of porcine coronary arteries, following preconstriction with 10 µM 
PGF2α or 1 µM U46619, to bradykinin in the presence of 100 µM L-NAME without (control) 
or with 10 µM ODQ, 10 µM quinaprilat, 100 nM charybdotoxin (char) + 100 nM apamin 
(apa) or 200 µM hydroxocobalamin. Data (mean±S.E.M. of 5-25 experiments) are expressed 
as a percentage of the contraction induced by PGF2α or U46619. 
 
Desensitization of the bradykinin-induced effect 
The construction of a bradykinin CRC resulted in B2 receptor desensitization, as 
evidenced by the approximate 10-fold rightward shift that was observed when 
constructing a second bradykinin CRC in the same vessel segment (Figure 3). A 
similar rightward shift was observed in the presence of L-NAME. 
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Repeated exposure of preconstricted vessel segments to 0.1 µM bradykinin 
produced progressively smaller relaxant responses (Figure 4, top panel). The response 
to the third bradykinin dose was less than 50% of the response to the first bradykinin 
dose (Figure 4, bottom panel). A similar pattern was observed in the presence of 
charybdotoxin + apamin, although the relaxation to bradykinin in the presence of 
these drugs was always smaller than under control conditions (Figure 4, bottom 
panel). In the presence of L-NAME (Figure 4, top panel) or hydroxocobalamin 
(Figure 4, bottom panel), the relaxation observed in response to the first dose of  
bradykinin was significantly smaller than under control conditions, and relaxation was 
virtually absent in response to the second and third bradykinin dose. Results obtained 
with L-NAME + hydroxocobalamin were not different from those with 
hydroxocobalamin alone (data not shown). Charybdotoxin + apamin combined with 
L-NAME fully prevented all responses to bradykinin (Figure 4, bottom panel).  
 
Figure 3. Two consecutive concentration response curves, obtained in the same porcine 
coronary artery segment following preconstriction with 10 µM PGF2α, to bradykinin in the 
absence (left panel) or presence (right panel) of 100 µM L-NAME. Data (mean±S.E.M. of 5 
experiments) are expressed as a percentage of the contraction induced by PGF2α. 
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Figure 4.  
Top panel: Original tracings of an 
experiment in which a porcine 
coronary artery in the absence 
(control; top) or presence (bottom) of 
100 µM L-NAME was preconstricted 
with 10 µM PGF2α and subsequently 
exposed to 0.1 µM bradykinin (BK, 
three times), 10 µM quinaprilat and 
0.1 µM bradykinin.   
 
 
Bottom panel: Relaxations of porcine coronary arteries, following preconstriction with 
10 µM PGF2α or 1 µM U46619, to three consecutive bradykinin doses (0.1 µM; BK1, BK2, 
BK3), 10 µM quinaprilat (QUIN) and a fourth bradykinin dose (0.1 µM; BK4) in the absence 
or presence of 100 µM L-NAME, 200 µM hydroxocobalamin, 100 nM charybdotoxin (char) 
+ 100 nM apamin (apa), or 100 µM L-NAME + 100 nM charybdotoxin (char) + 100 nM 
apamin (apa). Data (mean±S.E.M. of 6-24 experiments) are expressed as a percentage of the 
contraction induced by PGF2α or U46619. * P<0.01 vs. control; # P<0.05 vs. BK1. 
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Exposing preconstricted vessels three times to a submaximal concentration of 
bradykinin (10 nM) revealed that, under control conditions, the relaxation in response 
to the third bradykinin dose was not significantly different from the response to the 
first bradykinin dose (Figure 5). 
 
Figure 5. Relaxations of porcine coronary arteries, following preconstriction with 10 µM 
PGF2α, to three consecutive bradykinin doses (10 nM; BK1, BK2, BK3) in the absence 
(control) or presence of 100 µM L-NAME, 100 µM L-NAME + 10 mM L-arginine, or 10 mM 
L-arginine. Data (mean±S.E.M. of 5-7 experiments) are expressed as a percentage of the 
contraction induced by PGF2α. * P<0.01 vs. control; # P<0.05 vs. BK1.  
 
In the presence of L-NAME, the first bradykinin dose induced a modest 
relaxation, and no further response was observed at the second and third exposure to 
bradykinin. L-Arginine reversed the inhibitory effect of L-NAME, and tended to 
enhance the effect of bradykinin in the absence of L-NAME (P=NS). 
Effect of ACE inhibition on bradykinin-induced relaxation  
Quinaprilat alone did not cause relaxation of preconstricted vessel segments (data not 
shown), thereby ruling out the presence of endogenous bradykinin. In the presence of 
the ACE inhibitor, the CRC to bradykinin was shifted to the left (pEC50=8.89±0.20, 
Bradykinin, NO and ACE Inhibition in Coronary Arteries 
34 
n=5; P<0.05 vs. control, see Figure 1). This was also the case in vessel segments that 
had been pre-incubated with L-NAME (pEC50=8.03±0.23, n=5; P<0.05 vs. L-NAME 
alone, see Figure 2). Quinaprilat caused a similar leftward shift of the CRC to the 
ACE-resistant analogue [Hyp3-Tyr(Me)8]-bradykinin (pEC50’s resp. 8.50±0.18 and 
9.18±0.06 without and with quinaprilat, n=4; P<0.05, Figure 6). Hoe140 fully blocked 
the effects of [Hyp3-Tyr(Me)8]-bradykinin, confirming that this agonist induces 
relaxation via stimulation of B2 receptors.  
 
 
Figure 6. Relaxations of porcine coronary 
arteries, preconstricted with 10 µM 
PGF2α, to [Hyp3-Tyr(Me)8]-bradykinin in 
the absence (control) or presence of 1 µM 
Hoe140 or 10 µM quinaprilat. Data 
(mean±S.E.M. of 4 experiments) are 
expressed as a percentage of the 
contraction induced by PGF2α. 
 
 
 
Quinaprilat added to vessel segments that had been exposed three times to 
0.1 µM bradykinin, after the effect of the last dose of bradykinin had disappeared, 
caused complete relaxation, even in L-NAME- or hydroxocobalamin-pretreated vessel 
segments that previously had not responded to bradykinin (Figure 4). Quinaprilat also 
induced complete relaxation of vessel segments pretreated with charybdotoxin + 
apamin, whereas in vessel segments pretreated with L-NAME combined with 
charybdotoxin + apamin, which previously had not shown any response to bradykinin, 
the ACE inhibitor induced a modest relaxant response. Similar results were obtained 
with captopril (n=5, data not shown). A fourth bradykinin dose, added after the effect 
of quinaprilat or captopril had disappeared, induced no further effect.  
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Results obtained with bradykinin and quinaprilat in the presence of 
aminoguanidine (n=5), 7-NI (n=5), indomethacin (n=4), glibenclamide (n=4) and 
sulfaphenazole (n=6) were not different from those obtained in the absence of these 
inhibitors (data not shown). Moreover, results obtained with [Hyp3-Tyr(Me)8]-
bradykinin and quinaprilat (n=4) exactly mimicked those with bradykinin and 
quinaprilat (data not shown). Hoe140 completely prevented the quinaprilat-induced 
potentiation (data not shown). The effect of quinaprilat was specific for bradykinin, 
since it was not observed in combination with substance P (Figure 7). 
 
Figure 7. Relaxations of porcine coronary arteries, following preconstriction with 10 µM 
PGF2α, to three consecutive doses of substance P (1 nM; SP1, SP2, SP3), 10 µM quinaprilat 
(QUIN) and a fourth dose of substance P (1 nM; SP4). Data (mean±S.E.M. of 5 experiments) 
are expressed as a percentage of the contraction induced by PGF2α. # P<0.01 vs. SP1. 
 
2.4. Discussion 
NO is responsible for bradykinin-induced vasorelaxation in porcine coronary 
arteries 
The results of the present study show that the B2 receptor-mediated relaxant effects of 
bradykinin in PCAs, at doses up to 0.1 µM, depend on NO, either synthesized de-novo 
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by eNOS or derived from NO storage sites. These data fully support the interaction 
between eNOS and B2 receptors that was recently described by Golser et al. (Golser et 
al., 2000). We found no evidence for a role of NO synthases other than eNOS in 
PCAs, since neither aminoguanidine, a preferential inhibitor of inducible NOS 
(Boulanger et al., 1998; Joly et al., 1994), nor 7-NI, a preferential inhibitor of 
neuronal NOS (Boulanger et al., 1998; Moore et al., 1993) affected basal tone or the 
bradykinin CRC. Furthermore, neither prostaglandins, ATP-sensitive K+-channels nor 
cytochrome P-450 products appeared to be involved in the bradykinin-induced 
vasodilation in PCAs. The latter contrasts with a recent observation in PCAs showing 
that bradykinin-induced relaxation in the presence of the NOS inhibitor Nωnitro-L-
arginine was due to the release of 11,12-epoxyeicosatrienoic acid, an arachidonic acid 
metabolite formed by cytochrome P-450 (Fisslthaler et al., 1999). However, the EC50 
of this effect was approximately 1 µM (Fisslthaler et al., 1999), and we did not test 
bradykinin concentrations above 1 µM. 
The 10-fold rightward shift of the bradykinin CRC induced by both the non-
selective NOS inhibitor L-NAME and the guanylyl cyclase inhibitor ODQ contrasts 
with the much more complete blockade observed in the presence of the NO scavenger 
hydroxocobalamin. Hydroxocobalamin did not block the effect of 1 µM bradykinin. 
This is not due to the formation of relaxant prostaglandins or cytochrome P-450 
products at this concentration of bradykinin, since indomethacin and sulfaphenazole 
did not affect the bradykinin CRC in the presence of L-NAME. The most likely 
explanation is that, at the concentration used in the present study (200 µM), 
hydroxocobalamin did not completely scavenge all NO (Li et al., 1999). The 
maximum solubility of hydroxocobalamin in methanol (10 mg/mL) prevented us from 
reaching higher concentrations in the organ bath. Taken together therefore, NO release 
is responsible for the bradykinin-induced relaxation in PCAs, at least at bradykinin 
concentrations up to 0.1 µM, and NOS blockade as well as guanylyl cyclase blockade 
cannot prevent this relaxation completely.  
The modest effect of ODQ might be due to the fact that this drug inhibits 
guanylyl cyclase reversibly (Garthwaite et al., 1995). Alternatively, NO-induced 
relaxation may occur independently of guanylyl cyclase. In support of the first 
possibility, we observed that ODQ fully inhibited the relaxant effects of low (<1 µM) 
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but not of high (≥1 µM) concentrations of the NO donor S-nitroso-N-
acetylpenicillamine (Danser et al., 1999, unpublished observations). In support of the 
second possibility, NO has been described to induce hyperpolarization directly via 
activation of Ca2+-dependent K+-channels (Bolotina et al., 1994), and bradykinin is 
known to activate these channels through stimulation of tyrosine kinase (Lee et al., 
1993; Ogiwara et al., 1995). Indeed, in the present study the BKCa blocker 
charybdotoxin and the SKCa blocker apamin partially blocked the bradykinin-induced 
relaxation when given together, and fully blocked the bradykinin-induced effects 
when given in combination with L-NAME. Charybdotoxin plus apamin also blocked 
the bradykinin-induced hyperpolarization of PCA rings (Quignard et al., 1999). Thus, 
the most likely explanation for our findings is that the bradykinin-induced NO release 
causes vasodilation via stimulation of guanylyl cyclase and/or via direct activation of 
Ca2+-dependent K+-channels.  
Release of NO from storage sites? 
The limited effect of NOS blockade on NO release has been described before in rabbit 
carotid arteries (Cohen et al., 1997), and may involve either residual NOS activity or 
release of NO from storage sites (Danser et al., 1998; Davisson et al., 1996). To 
investigate the latter, we exposed coronary arteries repeatedly to the same 
concentration of bradykinin. Previous studies have shown that repetitive exposure to 
bradykinin or acetylcholine will cause depletion of NO storage sites, and that this will 
occur more rapidly in the presence of NOS inhibitors (Colombari et al., 1998; Danser 
et al., 1998; Davisson et al., 1996). In the present study, exposure to bradykinin, both 
with and without L-NAME, resulted in a relaxant effect which lasted approximately 
10-15 minutes. The disappearance of the relaxation is suggestive for bradykinin B2 
receptor desensitization and/or bradykinin metabolism. Desensitization was similar 
with and without L-NAME (Figure 3). Subsequent exposures to bradykinin initiated 
progressively smaller relaxant effects, and the decrease in response was much more 
rapid in the presence of L-NAME. L-Arginine reversed the rapid decrease in response 
to consecutive bradykinin doses in the presence of L-NAME. Taken together, these 
findings support the concept of bradykinin-coupling to NO storage sites. With NOS 
activity intact, the NO pools are continuously supplied with fresh NO and relaxation 
can be obtained multiple times, even when B2 receptors are desensitized. During NOS 
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inhibition the NO storage sites will become depleted, especially during exposure to 
drugs that cause release of NO from these sites. In an earlier study in isolated perfused 
rat hearts, we found that a 30 minute-exposure to L-NAME was sufficient to cause 
depletion of all existing NO pools (Danser et al., 1998). Depletion may also occur 
during exposure to high levels of superoxide anion (Arnal et al., 1996), although in 
PCAs superoxide anions scavengers did not affect the response to bradykinin 
(Pomposiello et al., 1999).  
The nature and localization of NO pools is currently unknown. Although NO 
pools have been demonstrated in vascular smooth muscle cells (Venturini et al., 
1993), the pools in the present study are most likely localized in endothelial cells, in 
view of the fact that we (Danser et al., 1999, unpublished results) and others 
(Mombouli et al., 1992) have found that bradykinin-induced relaxations are virtually 
absent following endothelium removal. The long half life of NO present at storage 
sites, evidenced by the fact that bradykinin was still capable of inducing relaxation 
after the vessels had been exposed to L-NAME for more than 30 minutes, is 
compatible with the idea that NO pools consist of stable NO-containing compounds, 
such as S-nitroso-thiols and dinitrosyl iron (II) thiol complexes (Ignarro, 1990; Myers 
et al., 1990; Vedernikov et al., 1992). 
ACE inhibitors potentiate bradykinin independently of their effect on bradykinin 
metabolism 
Finally, the ACE inhibitor quinaprilat, added at a time when the relaxant effect of 
bradykinin had disappeared, immediately restored the vasorelaxation, both with and 
without L-NAME. The effect of quinaprilat could be mimicked by captopril, and did 
not occur in combination with the B2 receptor antagonist Hoe140 or without prior 
exposure to bradykinin. The latter finding suggests that not all bradykinin has been 
metabolized at the time the ACE inhibitor is added to the organ bath. When added 
prior to bradykinin, quinaprilat shifted the bradykinin CRC approximately tenfold to 
the left, both with and without L-NAME. It is unlikely that the potentiating effects of 
ACE inhibition are due simply to inhibition of bradykinin metabolism, as suggested 
by Dendorfer et al. (Dendorfer et al., 2000), because 1) the effect of quinaprilat was 
also observed in combination with the ACE-resistant bradykinin analogue [Hyp3-
Tyr(Me)8]-bradykinin, 2) the effect of quinaprilat was not observed in relationship 
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with the vasorelaxant ACE substrate substance P, and 3) quinaprilat even induced 
complete relaxation in vessel segments that had previously not responded to 
bradykinin, i.e., vessel segments that had been pre-incubated with hydroxocobalamin 
or charybdotoxin + apamin + L-NAME. Taken together therefore, our data support the 
concept of ACE inhibitor-induced bradykinin potentiation independently of the effect 
of these drugs on bradykinin metabolism. The mechanism underlying this 
phenomenon is currently unknown, but it may involve the ACE inhibitor-induced 
resensitization of desensitized B2 receptors that has been described in isolated cells 
(Benzing et al., 1999; Minshall et al., 1997b). Resensitized B2 receptors may still 
cause relaxation via coupling to remaining NO pools, even after exposure to L-NAME 
and hydroxocobalamin, since we do not know whether these drugs, combined with 
repetitive exposure to bradykinin, have resulted in complete depletion of all existing 
NO pools. Alternatively, non-NO-related mechanisms may have come into play. 
These mechanisms do not involve prostaglandins, ATP-sensitive K+-channels or 
cytochrome P-450 products, since indomethacin, glibenclamide and sulfaphenazole 
did not affect the quinaprilat-induced relaxation.   
2.5. Conclusions and possible clinical implications 
In conclusion, the L-NAME-resistant bradykinin-induced relaxation, at least at 
physiological bradykinin concentrations (i.e., concentrations up to 0.1 µM; Campbell 
et al., (Campbell et al., 1993a)), is NO-dependent, and is mediated via stimulation of 
guanylyl cyclase and/or Ca2+-dependent K+-channels. NO is either synthesized 
de-novo by eNOS or released from storage sites. Depletion of such sites or a decrease 
in their number might be involved in the impaired endothelium-dependent 
vasodilatory response observed in subjects with hypertension or atherosclerosis 
(Hirooka et al., 1992; Zeiher et al., 1993). ACE inhibitors potentiate bradykinin-
induced vasorelaxation independently of their effect on bradykinin metabolism. Such 
potentiation has also been observed in-vivo in human subjects (Hornig et al., 1997; 
Kuga et al., 1997). Since elevated bradykinin levels have not been found consistently 
during ACE inhibitor treatment (Campbell et al., 1999; Miki et al., 1996), our findings 
might explain, at least in part, the beneficial effects of ACE inhibitors in hypertension 
and heart failure, as well as the ACE inhibitor-induced reversal of the impaired 
endothelium-dependent vasorelaxation in hypertensive patients (Hirooka et al., 1992). 
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CHAPTER 3 
Negative Inotropic Effect of Bradykinin in Porcine Isolated Atrial 
Trabeculae: Role of NO 
Summary 
We investigated whether bradykinin affects cardiac contractility independently of its 
effects on coronary flow and noradrenaline release, and whether such inotropic effects, 
if present, are mediated via NO. Right atrial trabeculae were obtained from 35 pigs, 
suspended in organ baths and attached to isometric transducers.  Resting tension was 
set at approximately 750 mg and tissues were paced at 1.5 Hz.  Tissue viability was 
checked by constructing a concentration response curve to noradrenaline.  Next, 
concentration response curves were constructed to bradykinin (1 nM-1 µM), either 
under baseline conditions or after pre-stimulation with the positive inotropic agent 
forskolin (1 or 10 µM), in the absence or presence of the B2 receptor antagonist 
Hoe 140 (1 µM), the NOS inhibitor L-NAME (100 µM) and/or the NO scavenger 
hydroxocobalamin (200 µM). Bradykinin exerted a negative inotropic effect, both with 
and without forskolin pre-stimulation, reducing contractility by maximally 22±3.6% 
(mean±S.E.M.) and 23±3.6%, respectively (pEC50 8.37±0.23 and 8.62±0.22, 
respectively).  L-NAME reduced this effect in pre-stimulated, but not in unstimulated, 
trabeculae. Hoe 140 and hydroxocobalamin fully blocked the inotropic effect of 
bradykinin. In conclusion, bradykinin induces a modest negative inotropic effect in 
porcine atrial trabeculae that is mediated via B2 receptors and NO.  The inconsistent 
results obtained with L-NAME suggest that it depends on de-novo synthesised NO 
and/or NO from storage sites. 
 
 
 
 
 
 
 
 
Based on: Tom B., de Vries R., Saxena P.R. and Danser A.H.J., (2001). Negative 
inotropic effect of bradykinin in porcine isolated atrial trabeculae: role of NO, 
J. Hypertension, 19(7): 1289-1293. 
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3.1. Introduction 
Accumulation of bradykinin is believed to contribute to the beneficial cardiac effects 
of ACE inhibitors, not only during myocardial ischaemia but also during the 
development of left ventricular hypertrophy (Gohlke et al., 1994; 1997; Kitakaze et 
al., 1995; McDonald et al., 1995; Tio et al., 1991).  The mechanism behind these 
beneficial effects has not yet been clarified, but most likely involves stimulation of B2 
receptors.  In support of the importance of cardiac B2 receptors, Emanueli et al. 
(Emanueli et al., 1999) have recently shown that disruption of the B2 receptor in mice 
results in left ventricular remodelling and cardiac functional impairment.  
Cardiac B2 receptors are localized on endothelial cells, sympathetic nerve 
endings and myocytes, and their respective stimulation leads to NO synthesis and 
release (Danser et al., 2000), facilitation of noradrenaline release (Minshall et al., 
1994; Rump et al., 1997; Seyedi et al., 1997), and hydrolysis of phosphatidylinositol 
4,5-biphosphate into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (Clerk et al., 
1996; Minshall et al., 1995).  Noradrenaline and IP3 will cause a rise in cardiac 
contractility, whereas NO, depending on its concentration may both increase and 
decrease contractility (Kojda et al., 1999; Vila-Petroff et al., 1999).  Moreover, NO 
affects cardiac inotropy indirectly through its effects on coronary flow (Minshall et 
al., 1997c; Munch et al., 1991).  In this light, it is of no surprise that both positive and 
negative inotropic responses to bradykinin have been reported (Anning et al., 1995; 
Cheng et al., 1998; Kasel et al., 1996; Minshall et al., 1997c; Munch et al., 1991).  
In the present study, we set out to investigate the flow- and catecholamine-
independent inotropic effects of bradykinin, using isolated porcine atrial trabeculae.  
We also studied whether these effects are mediated via NO. 
3.2. Methods 
Drugs 
Bradykinin (acetate salt), Nω-nitro-L-arginine methyl ester HCl (L-NAME), 
hydroxocobalamin (acetate salt), forskolin and carbachol were from Sigma-Aldrich 
Chemie, Zwijndrecht, The Netherlands.  L(-)-noradrenaline bitartrate was from 
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Research Biochemicals International, Zwijndrecht, The Netherlands.  
D-Arg [Hyp3-Thi5, D-Tic7, Oic8]-bradykinin (Hoe 140) was a kind gift of Dr. W. Linz, 
Hoechst, Frankfurt, Germany.  Hydroxocobalamin was dissolved in methanol.  
Forskolin was dissolved in dimethylsulfoxide.  All other chemicals were dissolved in 
saline. 
Tissue collection 
Trabeculae were obtained from 35 female 3 month-old pigs (Yorkshire x Landrace; 
weight 10-15 kg).  The pigs had been used in in-vivo experiments, studying the effects 
of α-adrenergic and/or serotonergic (ant)agonists under pentobarbital anaesthesia (de 
Vries et al., 1999).  The Ethics Committee of the Erasmus University Rotterdam 
dealing with the use of animals for scientific experiments approved the protocol for 
this investigation.  At the end of the experiments, cardiac arrest was induced by 
pouring ice-cold saline in the thorax.  Right atrial tissue was rapidly removed and 
stored in a cold, oxygenated, high KCl-containing Krebs bicarbonate solution 
modified according to HTK-Bretschneider (composition in mM: NaCl 113.7, KCl 9, 
CaCl2 2.5, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, D-glucose 8.3; pH 7.4).  After 
overnight storage, trabeculae (1 mm thickness; 6-12 per atrium) were carefully 
dissected free, mounted in 15 mL organ baths containing Krebs bicarbonate solution 
(composition in mM: NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25, 
KH2PO4 1.2, D-glucose 8.3; pH 7.4) and attached to Harvard isometric transducers 
(South Natick, MA, USA).  The baths were kept at 37°C and continuously aerated 
with 95% O2/ 5% CO2.  Resting tension was set at approximately 750 mg and tissues 
were paced at 1.5 Hz using field stimulation (5 ms, voltage 20% above threshold for 
contractile response) (Schoemaker et al., 1992).   
Experimental protocol 
After a stabilization period of 60 min, during which the organ bath fluid was refreshed 
every 15 min, tissue viability was tested by constructing a concentration response 
curve (CRC) to noradrenaline (10 nM-10 µM).  Each next noradrenaline dose was 
added as soon as a maximum contraction to the previous dose had been reached 
(usually within 5 min).  Tissue viability was not affected by overnight storage, since 
the noradrenaline response of stored trabeculae was indistinguishable from that of 
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freshly obtained trabeculae (n=4, data not shown).  After finalization of the 
noradrenaline CRC, the baths were washed and the trabeculae were allowed to 
stabilise for 30 min. 
Next, bradykinin CRCs (1 nM-1 µM) were constructed, both under baseline 
conditions and after pre-stimulation with forskolin (1 or 10 µM), in the presence or 
absence of the B2 receptor antagonist Hoe 140 (1 µM), the NOS inhibitor L-NAME 
(100 µM), the NO scavenger hydroxocobalamin (200 µM) (Danser et al., 2000; Li et 
al., 1999) or L-NAME (100 µM) + hydroxocobalamin (200 µM).  In the forskolin 
pre-stimulated trabeculae, at the end of each bradykinin CRC, the negative inotropic 
response to carbachol (1 µM) was studied. 
Data analysis 
Data are expressed as mean±S.E.M. and represent percent change, either from 
baseline contractile force or from the contractile force obtained after pre-stimulation 
with forskolin.  Tissues with less than 25 mg contractile response to noradrenaline as 
well as trabeculae showing less than 5% relaxation to bradykinin in the absence of 
inhibitors were excluded from further analysis.  CRCs were analysed using the logistic 
function described by de Lean et al. (de Lean et al., 1978) to obtain 
pEC50 (-10log EC50) values.  Statistical analysis was by Student's paired or unpaired 
t-test.  P values < 0.05 were considered significant.  
3.3. Results  
Forskolin-induced pre-stimulation and the effect of inhibitors 
Baseline contractility ranged from 35 mg to 260 mg.  In the absence of inhibitors, 
forskolin increased contractility from 78±11 mg to 162±14 mg (n=13, p<0.01).  This 
increase in contractility is comparable to the increase in contractility observed in 
response to 10 µM noradrenaline.  The forskolin-induced contraction remained stable 
for at least 45 min.  Hoe 140 and L-NAME did not effect baseline contractility or the 
response to forskolin.  Hydroxocobalamin reduced baseline contractility from 
123±46 mg to 61±30 mg (n=4, p<0.05).  This reduction in baseline contractility also 
occurred when applying the hydroxocobalamin solvent, methanol (reduction in 
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contractility from 182±71 mg to 102±60 mg, n=4, p<0.05), indicating that it was due 
to methanol rather than to hydroxocobalamin itself. However, following forskolin, 
contractility in methanol-pretreated (210±56 mg) and methanol+hydroxocobalamin-
pretreated (193±34 mg) trabeculae was indistinguishable from control. 
Effects of bradykinin 
Bradykinin decreased contractile force both in unstimulated (n=8) and in forskolin 
pre-stimulated (n=13) trabeculae in a concentration-dependent manner (pEC50 of 
8.62±0.22 and 8.37±0.23, respectively; Figure 1).  Relaxations were maximal within 
1 min and contractile force returned to baseline after approximately 3 min (Figure 1).  
No differences in bradykinin-induced responses were observed between trabeculae 
obtained from untreated pigs and trabeculae from pigs exposed to α-adrenergic and/or 
serotonergic (ant)agonists (data not shown).  Hoe 140 fully blocked the 
bradykinin-mediated effects (Figure 1).  L-NAME did not affect the 
bradykinin-induced effects in unstimulated trabeculae (n=8; Figure 1).  In forskolin 
pre-stimulated trabeculae L-NAME reduced the maximal negative inotropic effect of 
bradykinin by approximately 50% (n=13, p<0.05; Figure 1). 
Full blockade of the bradykinin-induced negative inotropic effects was obtained 
in the presence of hydroxocobalamin, with or without L-NAME (Figure 2).  Methanol 
did not affect the response to bradykinin (pEC50 of 8.51±0.11; P=NS vs. control). 
Carbachol, added to the organ bath following the finalization of the bradykinin 
CRC, reduced contractile force by 88±1.4% (n=4) in the absence of inhibitors and by 
87±1.5%, 86±2.0%, 85±2.0%, 83±3.5% (n=4 each) in the presence of L-NAME, 
hydroxocobalamin, L-NAME+ hydroxocobalamin, and methanol respectively.  
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Figure 1. Bradykinin-induced negative inotropic effect in porcine atrial trabeculae under 
baseline conditions (left) or after pre-stimulation with 1 or 10 µM forskolin (right) without 
(control) or with Hoe 140 (1 µM) or L-NAME (100 µM). Top panel: original tracing; bottom 
panel: percent decrease (mean±S.E.M. of 7-13 exp.) from baseline contractile force or from 
the contractile force obtained after prestimulation with forskolin. 
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Figure 2. Bradykinin-induced negative inotropic effect in porcine atrial trabeculae 
pre-stimulated with 1 or 10 µM forskolin, in the absence (control) or presence of 
hydroxocobalamin (200 µM) or L-NAME (100 µM) + hydroxocobalamin (200 µM).  Data 
(mean±S.E.M. of 4 experiments) represent percent change from the contractile force obtained 
after pre-stimulation with forskolin.  
 
3.4. Discussion 
The results of the present study show that bradykinin exerts a modest negative 
inotropic effect on isolated porcine atrial trabeculae that is mediated exclusively via 
B2 receptors and NO.  The effect is short lasting and most likely depends on NO from 
storage sites and/or de-novo synthesised NO. 
The lack of effect of L-NAME and the NO scavenger hydroxocobalamin on 
baseline and stimulated contractility contrasts with our earlier findings in isolated 
porcine coronary arteries, where the addition of these drugs not only resulted in a 
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strong contractile response but also in an augmentation of the contraction to 
prostaglandin F2α (Danser et al., 2000).  These coronary arteries, like the trabeculae in 
the present study, had been stored overnight in an organ-protecting solution.  Since 
storage does not affect tissue viability or endothelial function (Maassen van den Brink 
et al., 1999), it appears that endogenous NO in isolated trabeculae does not contribute 
importantly to contractility under baseline conditions.  The strong NO-independent 
negative inotropic effect of the muscarinic agonist carbachol reveals that the modest 
effects of bradykinin in the present study were not due to our inability to detect a 
negative inotropic response.  
NO has been reported to induce a positive inotropic effect in submicromolar 
concentrations, and a negative inotropic effect in submillimolar concentrations, via 
activation of adenylyl cyclase and guanylyl cyclase, respectively (Vila-Petroff et al., 
1999).  We studied the effects of bradykinin both with and without forskolin 
pre-stimulation, and observed a negative inotropic response of similar magnitude 
under both conditions.  It appears therefore that the amount of NO released in 
response to bradykinin, even at nanomolar concentrations of the agonist, is in the 
submillimolar range.  Remarkably however, despite the presence of such high NO 
levels, NO does not seem to play a major role in cardiac contractility.  
The limited effect of L-NAME on the bradykinin-induced inotropic response in 
forskolin pre-stimulated trabeculae, combined with the full blockade of this response 
by hydroxocobalamin, suggests that L-NAME does not block NOS completely and/or 
that bradykinin induces NO release from NO storage pools.  Incomplete NOS 
blockade, even at high NOS inhibitor doses, has been demonstrated before (Cohen et 
al., 1997). NO release from storage sites might also offer an explanation for the lack 
of effect of L-NAME in unstimulated trabeculae during exposure to bradykinin.  
NO pools, which consist of stable NO-containing compounds such as 
S-nitroso-thiols (Ignarro, 1990), are present in endothelial cells (Danser et al., 1998; 
2000; Davisson et al., 1996), and may also exist in other NOS-synthesising cells such 
as cardiomyocytes (Kojda et al., 1999).  From our data, it cannot be concluded 
whether endothelial cells and/or myocytes are the source of the NO released by 
bradykinin.  Both cell types express B2 receptors (Minshall et al., 1995; Sung et al., 
1988).  The short duration of action of bradykinin in trabeculae is in full agreement 
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with the rapid B2 receptor desensitization that is known to occur upon bradykinin 
stimulation (Danser et al., 2000; Minshall et al., 1997b). 
Finally, stimulation of B2 receptors on sympathetic nerve endings and neonatal 
rat cardiomyocytes, via facilitation of noradrenaline release (Seyedi et al., 1997) and 
generation of IP3 (Minshall et al., 1995), respectively, might result in a positive 
inotropic response independently of NO.  No such response was observed in the 
present study, neither under baseline conditions, nor after forskolin pre-stimulation in 
the presence of hydroxocobalamin and/or L-NAME.  Moreover, in the same 
experimental set-up, propranolol did not affect baseline contractility (Du et al., 1993). 
Thus, endogenous noradrenaline release from isolated porcine trabeculae does not 
appear to occur, and in porcine adult cardiomyocytes either B2 receptors are not 
expressed, or their stimulation does not result in sufficient IP3 formation.  Similar 
species-related differences have been observed for Ang II (Holubarsch et al., 1993; 
Ishihata et al., 1995). 
In conclusion, in the absence of B2 receptor-mediated coronary vasodilatation 
and/or facilitation of noradrenaline release, bradykinin decreases cardiac contractility 
in a NO-dependent manner.  These data may explain not only the previously reported 
conflicting results on bradykinin-induced inotropic effects (Anning et al., 1995; 
Cheng et al., 1998; Kasel et al., 1996; Minshall et al., 1997c; Munch et al., 1991), but 
also help to understand the beneficial bradykinin-dependent effects of ACE inhibitors 
on cardiac function (Gohlke et al., 1994; 1997; Kitakaze et al., 1995; McDonald et al., 
1995; Tio et al., 1991).  
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CHAPTER 4 
Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors 
Correlates with ACE C- and N- Domain Blockade 
Summary 
ACE inhibitors block B2 receptor desensitization, thereby potentiating bradykinin 
beyond blocking its hydrolysis. Ang-(1-7) also acts as an ACE inhibitor, and, in 
addition, may stimulate bradykinin release via AT2 receptors. Here, we compared the 
bradykinin-potentiating effects of Ang-(1-7), quinaprilat and captopril. Porcine 
coronary arteries, obtained from 32 pigs, were mounted in organ baths, preconstricted 
with PGF2α, and exposed to quinaprilat, captopril, Ang-(1-7) and/or bradykinin. 
Bradykinin induced complete relaxation (pEC50=8.11±0.07, mean±S.E.M.), while 
quinaprilat, captopril and Ang-(1-7) alone were without effect. Quinaprilat shifted the 
bradykinin curve to the left in a biphasic manner: a 5-fold shift at concentrations that 
specifically block the C-domain (0.1-1 nM), and a 10-fold shift at concentrations that 
block both domains. Captopril and Ang-(1-7) monophasically shifted the bradykinin 
curve to the left, by a factor of 10 and 5, respectively. A 5-fold shift was also observed 
when Ang-(1-7) was combined with 0.1 nM quinaprilat. Repeated exposure of porcine 
coronary arteries to 0.1 µM bradykinin induced B2 receptor desensitization. The 
addition of 10 µM quinaprilat or Ang-(1-7) to the bath, at a time when bradykinin alone 
was no longer able to induce relaxation, fully restored the relaxant effects of 
bradykinin. AT1 or AT2 receptor blockade did not affect any of the observed effects of 
Ang-(1-7). In conclusion, Ang-(1-7), like quinaprilat and captopril, potentiates 
bradykinin by acting as an ACE inhibitor. Bradykinin potentiation is maximal when 
both the ACE C- and N-terminal domain are inhibited. The inhibitory effects of 
Ang-(1-7) are limited to the ACE C-domain, raising the possibility that Ang-(1-7) 
synergistically increases the blood pressure lowering effects of N-domain-specific ACE 
inhibitor. 
 
 
 
 
Based on: Tom B., de Vries R., Saxena P.R. and Danser A.H.J., (2001). Bradykinin 
potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N- 
domain blockade, Hypertension, 38: 95-99. 
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4.1. Introduction 
Ang-(1-7) is a heptapeptide that is formed endogenously from both Ang I and Ang II 
(Ferrario et al., 1997). In rats and dogs, Ang-(1-7) exerts direct vasodilatory effects 
via non-AT1, non-AT2 receptors, possibly by stimulating bradykinin and NO release 
(Brosnihan et al., 1996; Ferrario et al., 1997). In contrast, in humans or pigs, no direct 
vasodilatory effects of Ang-(1-7) were observed (Davie et al., 1999; Gorelik et al., 
1998; Pörsti et al., 1996; Roks et al., 1999; Ueda et al., 2000), although Ang-(1-7) did 
antagonize the pressor effects of Ang II, suggesting that it may cause vasodilation 
indirectly, by acting as an AT1 receptor antagonist (Roks et al., 1999; Ueda et al., 
2000). In addition, Ang-(1-7) potentiates bradykinin, either via an AT2 receptor-
dependent mechanism, or through inhibition of ACE (Deddish et al., 1998; Gorelik et 
al., 1998; Roks et al., 1999). The latter effect is not necessarily based on blockade of 
bradykinin hydrolysis, since recent studies have shown that ACE inhibitors, including 
Ang-(1-7), potentiate bradykinin by inhibiting desensitization of its receptor (Benzing 
et al., 1999; Danser et al., 2000; Minshall et al., 1997b). Somatic ACE has two 
homologous domains, each containing an active center. According to their position 
(N- or C-terminal), these domains are designated as the N- and C-domain, 
respectively. Interestingly, Ang-(1-7) inhibits the C-domain more potently than the N-
domain (by one order of magnitude) (Deddish et al., 1998), and is cleaved to 
Ang-(1-5) by the N-domain (Chappell et al., 1998).    
In the present study, we set out to investigate the bradykinin-potentiating effects 
of Ang-(1-7) in porcine coronary arteries (PCAs), its dependency on ACE, and the 
possible involvement of AT1 and/or AT2 receptors. The effects of Ang-(1-7) were 
compared with those of quinaprilat and captopril, two ACE inhibitors with preference 
for the ACE C- and N-domain, respectively (Michaud et al., 1997; Perich et al., 
1994). We also verified the effect of Ang-(1-7) in human coronary arteries (HCAs). 
4.2. Methods 
Tissue collection 
HCAs were obtained from 4 ‘heart beating’ organ donors (2 men and 2 women; age 
14-38 years, mean±S.E.M. 23±5 years) who died of non-cardiac causes 
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(1 subarachnoidal bleeding, 3 head trauma) less than 24 hours before the heart was 
taken to the laboratory. Hearts were provided by the Rotterdam Heart Valve Bank 
(Bio Implant Services/Eurotransplant Foundation) after removal of the aortic and 
pulmonary valves for transplantation purposes. The study was approved by the joint 
Ethics Committee of the Erasmus University Rotterdam and the University Hospital 
Rotterdam. Immediately after circulatory arrest, the hearts were stored in an ice-
cooled sterile organ-protecting solution. After arrival in the laboratory, the HCA was 
removed and stored overnight in a cold, oxygenated Krebs bicarbonate solution of the 
following composition (mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 
1.2, NaHCO3 25, and glucose 8.3; pH 7.4. Vessels were then cut into segments of 
approximately 4 mm length, suspended on stainless steel hooks in 15 mL organ baths 
containing Krebs bicarbonate solution, aerated with 95% O2 / 5% CO2, and 
maintained at 37°C. Segments containing macroscopically visible atherosclerotic 
lesions were not used. 
PCAs were obtained from 32 2-3 month-old pigs (Yorkshire x Landrace, weight 
10-15 kg). The pigs had been used in in-vivo experiments studying the effects of 
α-adrenoceptor and serotonin receptor agonists and antagonists under pentobarbital 
(600 mg, i.v.) anesthesia (de Vries et al., 1999). The Ethics Committee of the Erasmus 
University Rotterdam dealing with the use of animals for scientific experiments 
approved the protocol for this investigation. Hearts were explanted at the end of the 
experiment, and the coronary arteries were removed immediately and handled in the 
same way as HCAs.  
Organ bath studies 
All vessel segments were allowed to equilibrate for at least 30 min and the organ bath 
fluid was refreshed every 15 min during this period. Changes in tissue contractile 
force were recorded with a Harvard isometric transducer (South Natick, MA, USA). 
The vessel segments, stretched to a stable force of about 15 mN, were exposed to 
30 mM KCl twice. The functional integrity of the endothelium was verified by 
observing relaxation to 1 nM substance P after preconstriction with 1 µM PGF2α 
(Maassen van den Brink et al., 1999). Subsequently, the tissue was exposed to 
100 mM KCl to determine the maximal contractile response to KCl. The segments 
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were then allowed to equilibrate in fresh organ bath fluid for 30 min., thereafter, the 
following experiments were performed. 
First, Ang-(1-7) concentration response curves (CRCs) (0.1 nM-10 µM) were 
constructed in HCAs and PCAs, both at baseline and after preconstriction with 10 µM 
PGF2α, in the absence or presence of the AT1 receptor antagonist irbesartan (1 µM) or 
the AT2 receptor antagonist PD123319 (1 µM).  
Second, the effects of Ang-(1-7), quinaprilat and captopril on bradykinin-
induced vasorelaxation were studied in PCAs. Vessels were pre-incubated for 30 min 
in the absence or presence of Ang-(1-7) (10 pM-10 µM), quinaprilat (0.1 pM-
0.1 mM), captopril (0.1 pM-0.1 mM), 10 µM Ang-(1-7) + 1 µM irbesartan, 10 µM 
Ang-(1-7) + 1 µM PD123319, 10 µM Ang-(1-7) + 0.1 nM quinaprilat, or 10 µM 
Ang-(1-7) + 10 µM quinaprilat. Vessels were then preconstricted with 10 µM PGF2α 
or 1 µM U46619 and CRCs to bradykinin (0.1 nM-1 µM) were constructed.  
Third, the effect of quinaprilat and Ang-(1-7) on desensitized B2 receptors was 
studied in PCAs. Vessels were pre-incubated for 30 min with or without 1 µM 
irbesartan or 1 µM PD123319. Vessels were then preconstricted with 10 µM PGF2α 
and exposed three times to a concentration of bradykinin (0.1 µM) that is capable of 
inducing maximal relaxation. Each next exposure was started as soon as the effect of 
the previous exposure had disappeared, i.e., after approximately 15 min. After the 
third exposure, when bradykinin no longer exerted a vasodilatory effect, quinaprilat 
(10 µM) or Ang-(1-7) (10 µM) was added to the organ bath. Thereafter, when the 
effects of quinaprilat and Ang-(1-7) had disappeared, a fourth bradykinin dose 
(0.1 µM) was added to the organ bath. 
Statistical analysis 
Data are given as mean±S.E.M. and expressed as a percentage of the contraction in 
response to PGF2α or U46619. CRCs were analyzed using the logistic function 
described by de Lean et al. (de Lean et al., 1978) to obtain pEC50 (-10log EC50) values, 
EC50 representing the concentration at which 50% of the maximal relaxant effect has 
been reached. Statistical analysis was by ANOVA, followed by post hoc evaluation 
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(according to Tukey or Dunnett where appropriate). P values <0.05 were considered 
significant. 
4.3. Results 
Effect of Ang-(1-7) on human and porcine coronary arteries 
Ang-(1-7), at concentrations up to 10 µM, did not exert a response in HCAs (n=4) and 
PCAs (n=5-12), neither at baseline nor after preconstriction with PGF2α, nor in the 
presence of irbesartan or PD123319. 
Effects of Ang-(1-7), quinaprilat and captopril on bradykinin-induced relaxation in 
porcine coronary arteries 
Bradykinin caused complete relaxation of preconstricted PCAs in a concentration 
dependent-manner (pEC50=8.11±0.07, n=12; Figure 1, left panel). Quinaprilat 
(10 µM) and captopril (10 µM), like Ang-(1-7) at this concentration, did not exert any 
effect on preconstricted PCAs. However, in the presence 10 µM Ang-(1-7), the 
bradykinin CRC was shifted ≈5-fold to the left (pEC50 8.72±0.09, n=12; P<0.05 vs. 
control), while in the presence of 10 µM quinaprilat or 10 µM captopril the bradykinin 
CRC was shifted ≈10-fold to the left (pEC50 9.03±0.21 and 8.91±0.09, respectively, 
n=8; P<0.01 vs. control) (Figure 1, left panel). The effect of Ang-(1-7) on the 
bradykinin CRC was not affected by irbesartan or PD123319 (Figure 1, right panel). 
To study the concentration-dependency of the Ang-(1-7)- and ACE-inhibitor-
induced leftward shifts, bradykinin CRCs were also constructed in the presence of a 
wide range of Ang-(1-7), quinaprilat and captopril concentrations (Figure 2). The 
leftward shift caused by quinaprilat occurred in a biphasic manner, with a 5-fold shift 
at concentrations in the subnanomolar range, and a 10-fold shift at concentrations 
above 1 nM. This biphasic shift is in agreement with earlier studies (Perich et al., 
1994) demonstrating different quinaprilat binding affinities of the ACE C- (Kd=7 pM) 
and N-domain (Kd=1267 pM), and suggests that the 5- and 10-fold shifts represent C-
domain inhibition and complete (i.e., C- plus N-domain) ACE inhibition, respectively. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1. Left panel: Relaxations of porcine coronary arteries preconstricted with 10 µM PGF2α or 1 µM U46619, to bradykinin in the absence 
(control) or presence of 10 µM Ang-(1-7), 10 µM quinaprilat or 10 µM captopril. Right panel: The effect of Ang-(1-7) on bradykinin-induced 
relaxations was also studied in the presence of 1 µM irbesartan or 1 µM PD123319. Data (mean±S.E.M. of 5-12 experiments) are expressed as 
a percentage of the contraction induced by PGF2α or U46619. Ang-(1-7), quinaprilat and captopril significantly shifted the bradykinin 
concentration response curve to the left (P<0.05 vs. control for Ang-(1-7), P<0.01 vs. control for the two ACE inhibitors), and the effect of 
Ang-(1-7) was not influenced (P=NS) by the presence of irbesartan or PD123319.   
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The 10-fold leftward shift caused by captopril occurred monophasically 
(Figure 2), suggesting that captopril is bound with similar affinity by the two ACE 
domains. The 5-fold leftward shift 
caused by Ang-(1-7) also occurred 
monophasically (Figure 2), suggesting 
either that Ang-(1-7) inhibits one ACE 
domain only, or that Ang-(1-7) 
potentiates bradykinin independently 
of its effects on ACE. To sort out the 
latter, the effect of 10 µM Ang-(1-7) 
on top of quinaprilat, either at a 
concentration that selectively inhibits 
the ACE C-domain (0.1 nM) or at a 
concentration that inhibits both ACE 
domains (10 µM), was studied.  
 
Figure 2. Change in -log(EC50) of the 
bradykinin concentration response curve 
in the presence of increasing 
concentrations of quinaprilat (top panel), 
captopril (middle panel) or Ang-(1-7) 
(bottom panel). An increase in -log(EC50) 
represents a leftward shift of the 
bradykinin concentration response curve. 
Data (mean±S.E.M. of 6-8 experiments) 
were obtained in porcine coronary 
arteries preconstricted with 1 µM 
U46619. Con, control. Significant 
differences (P<0.05) vs. control were 
obtained for quinaprilat, captopril and 
Ang-(1-7) at concentrations ≥ 0.1, 100 
and 1000 nM, respectively. 
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Ang-(1-7) affected neither the 5-fold leftward shift of the bradykinin CRC at 
0.1 nM quinaprilat (pEC50 8.59±0.39 and 8.68±0.29 with and without Ang-(1-7), 
n=13; P=NS) nor the 10-fold shift at 10 µM quinaprilat (pEC50 9.06±0.20 and 
9.03±0.21 with and without Ang-(1-7), n=11; P=NS) (Figure 3). Most likely therefore, 
Ang-(1-7), at concentrations up to 10 µM, acts as a selective inhibitor of the ACE C-
domain. 
Figure 3. Relaxations of 
porcine coronary arteries 
preconstricted with 10 µM 
PGF2α or 1 µM U46619, to 
bradykinin in the absence 
(control) or presence of 0.1 nM 
quinaprilat or 10 µM 
quinaprilat, with or without 
10 µM Ang-(1-7). Data (mean± 
S.E.M. of 11-13 experiments) 
are expressed as a percentage 
of the contraction induced by 
PGF2α or U46619. The 
addition of Ang-(1-7) on top of 
quinaprilat did not have a 
significant effect. 
 
 
Effect of Ang-(1-7) and quinaprilat on desensitized B2 receptors in porcine coronary 
arteries 
Repeated exposure of preconstricted vessel segments to 0.1 µM bradykinin produced 
progressively smaller responses (Figure 4, top panel). The response to the third 
bradykinin dose was less than 50% of the response to the first bradykinin dose.  
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Figure 4.  
Top panel: Original 
tracings of an experiment 
in which a porcine 
coronary artery, 
following preconstriction 
with 10 µM PGF2α, is 
subsequently exposed to 
0.1 µM bradykinin (BK, 
three times), 10 µM 
quinaprilat (top) or 
10 µM Ang-(1-7) 
(bottom), and 0.1 µM 
bradykinin. 
Bottom panel: Relaxations of porcine coronary arteries, following preconstriction with 
10 µM PGF2α, to three consecutive bradykinin doses (0.1 µM; BK1, BK2, BK3), 10 µM 
Ang-(1-7), and a fourth bradykinin dose (0.1 µM; BK4) in the absence or presence of 1 µM 
irbesartan or 1 µM PD123319. Data (mean±S.E.M. of 4-8 experiments) are expressed as a 
percentage of the contraction induced by PGF2α. 
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Quinaprilat or Ang-(1-7), added to the organ bath after the effect of the third 
bradykinin dose had disappeared, both at a concentration of 10 µM, completely 
restored the relaxant effect of bradykinin (90±10% and 83±8% relaxation, 
respectively, n=8; P=NS). A fourth bradykinin dose, added after the effect of 
quinaprilat or Ang-(1-7) had disappeared, induced no further effect. The effect of 
Ang-(1-7) was not different in the presence of irbesartan or PD123319 (Figure 4, 
bottom panel). 
4.4. Discussion 
The present study shows that Ang-(1-7) potentiates the vasodilator effects of 
bradykinin in PCAs through inhibition of the ACE C-domain. AT1 or AT2 receptors 
are not involved in this effect, nor did Ang-(1-7) exert direct (i.e., independently of 
bradykinin) relaxant effects in either HCAs or PCAs. Furthermore, the maximal 
potentiating effect of Ang-(1-7) was smaller than that of the ACE inhibitors 
quinaprilat and captopril, suggesting that full potentiation will only be obtained when 
both ACE domains are inhibited.  
The concentrations of Ang-(1-7) required to obtain ACE C-domain inhibition 
(≥1 µM) are in agreement with previously reported values (Deddish et al., 1998; Roks 
et al., 1999). These concentrations exceed the in-vivo tissue and plasma Ang-(1-7) 
concentrations in rats and humans by at least four orders of magnitude. Ang-(1-7) 
levels increase during ACE inhibition (Campbell et al., 1993b; 1999; Lawrence et al., 
1990; Yamada et al., 1998), because ACE inhibitors block the ACE N-domain-
mediated degradation of Ang-(1-7) (Deddish et al., 1998; Ferrario et al., 1997). 
However, the fact that most ACE inhibitors also block the ACE C-domain will mask 
any potential C-domain-blocking effect of the high Ang-(1-7) levels during ACE 
inhibition. Indeed, Ang-(1-7) did not enhance bradykinin-induced vasodilation in the 
forearm in human subjects treated with an ACE inhibitor (Davie et al., 1999). 
Therefore, the effects of Ang-(1-7) described in the present study may only be of 
physiological importance if sufficiently high concentrations of Ang-(1-7) are reached 
in the immediate vicinity of ACE (the levels measured per g tissue do not exclude this 
possibility) and/or in combination with ACE inhibitors that specifically block the 
ACE N-domain. 
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Studies with the N-domain-specific substrate N-acetyl-seryl-aspartyl-lysyl-
proline (AcSDKP) have revealed that the ACE inhibitor captopril inhibits AcSDKP 
hydrolysis 16 times more potently than Ang I hydrolysis (Michaud et al., 1997). Since 
the ACE N- and C-domains exhibit similar catalytic activities towards Ang I (Jaspard 
et al., 1993), these data suggest that captopril, at low concentrations, preferentially 
inhibits the ACE N-domain. Using captopril, however, we were unable to make a 
clear distinction between the effects of ACE N- and C-domain inhibition on the 
relaxant effects of bradykinin. In contrast, using the ACE inhibitor quinaprilat, which 
binds to the ACE C-domain with almost 200-fold greater affinity than to the ACE N-
domain (Perich et al., 1994), we could make such a distinction: quinaprilat shifted the 
bradykinin CRC to the left in a biphasic manner, with a ≈5-fold shift occurring at 
concentrations that selectively block the C-domain, and a ≈10-fold shift at 
concentrations that block both domains. Our inability to find a similar biphasic shift in 
the presence of increasing concentrations of captopril most likely relates to the limited 
selectivity of this ACE inhibitor for the ACE N-domain.  
Ang-(1-7), like captopril, induced a monophasic leftward shift of the bradykinin 
CRC. At the highest Ang-(1-7) concentration that was tested (10 µM), however, the 
shift was only half of that caused by similar concentrations of quinaprilat or captopril. 
Adding quinaprilat, at a concentration that selectively blocks the ACE C-domain, to 
10 µM Ang-(1-7) did not cause a further leftward shift, thereby demonstrating that 
Ang-(1-7), at least at this concentration, blocks the ACE C-domain only. Since a 
concentration of 10 µM is already many orders of magnitude above the measured 
concentrations of Ang-(1-7) in-vivo (Campbell et al., 1993b; 1999; Lawrence et al., 
1990; Yamada et al., 1998), we did not evaluate whether even higher concentrations 
of Ang-(1-7) resulted in ACE N-domain inhibition. 
Does ACE inhibition result in bradykinin potentiation by blocking its 
hydrolysis? Since bradykinin, like Ang I, is cleaved equally well by the two ACE 
domains (Jaspard et al., 1993), our finding that blockade of both domains results in a 
twice as large leftward shift as blockade of one domain, appears to support this 
possibility. However, the long half life of bradykinin in this preparation (30 minutes) 
(Gorelik et al., 1998), as well as our previous finding in PCAs that the quinaprilat-
induced leftward shift of the ACE-resistant bradykinin analogue [Hyp3-Tyr(Me)8]-
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bradykinin was not different from that of bradykinin (Danser et al., 2000), argue 
against this concept. Moreover, under conditions of B2 receptor desensitization 
(induced by repeated exposure to a concentration of bradykinin that causes maximal 
relaxation), when bradykinin itself was no longer active, both quinaprilat and 
Ang-(1-7) immediately restored the effect of bradykinin. Taken together therefore, a 
more likely explanation for the Ang-(1-7)-, quinaprilat- and captopril-induced 
bradykinin potentiation is the upregulation (or resensitization) of B2 receptors that has 
recently been described in CHO cells transfected with the human B2 receptor and 
human ACE (Deddish et al., 1998; Marcic et al., 1999; 2000a; Minshall et al., 1997b). 
This effect only occurs when ACE and B2 receptors are sterically closely associated, 
probably forming a heterodimer (Marcic et al., 2000a). ACE inhibitors are believed to 
alter the heterodimer interaction, thereby promoting a conformation in the B2 receptor 
that affects its sequestration and coupling to second messengers (Marcic et al., 2000a). 
Our findings in intact PCAs show that ACE-B2 receptor crosstalk is not limited to 
transfected CHO cells, and, in addition, suggest that the conformational changes 
underlying bradykinin potentiation correlate directly with inhibition of the ACE C- 
and N-domain.     
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CHAPTER 5 
Bradykinin Potentiation by ACE Inhibitors:                                       
A Matter of Metabolism 
Summary 
Studies in isolated cells overexpressing ACE and B2 receptors suggest that ACE 
inhibitors potentiate bradykinin by inhibiting B2 receptor desensitization, via a 
mechanism involving protein kinase C and phosphatases. Here we investigated, in 
intact porcine coronary arteries, endothelial ACE/B2 receptor ‘crosstalk’ as well as 
bradykinin potentiation through neutral endopeptidase (NEP) inhibition. NEP inhibition 
with phosphoramidon did not affect the bradykinin concentration response curve, nor 
did combined NEP/ACE inhibition with omapatrilat exert a further leftward shift on top 
of the ≈10-fold leftward shift of the bradykinin concentration response curve observed 
with ACE inhibition alone. In arteries that, following repeated exposure to 0.1 µM 
bradykinin, no longer responded to bradykinin (‘desensitized’ arteries), the ACE 
inhibitors quinaprilat and Ang-(1-7) both induced complete relaxation, without 
affecting the organ bath fluid levels of bradykinin. This phenomenon was unaffected by 
inhibition of protein kinase C or phosphatases (with calphostin C and okadaic acid, 
respectively). When using bradykinin analogues that were either completely or largely 
ACE-resistant ([Phe8Ψ(CH2-NH)Arg9]-bradykinin and [∆Phe5]-bradykinin, 
respectively), the ACE inhibitor-induced shift of the bradykinin concentration response 
curve was absent, and its ability to reverse desensitization was absent or significantly 
reduced, respectively. Caveolar disruption with filipin did not affect the quinaprilat-
induced effects. Filipin did however reduce the bradykinin-induced relaxation by ≈25-
30%, thereby confirming that B2 receptor-eNOS interaction occurs in caveolae. In 
conclusion, in porcine arteries, in contrast to transfected cells, bradykinin potentiation 
by ACE inhibitors is a metabolic process, that can only be explained on the basis of 
ACE-B2 receptor co-localization on the endothelial cell membrane. NEP does not 
appear to affect the bradykinin levels in close proximity to B2 receptors, and the ACE 
inhibitor-induced bradykinin potentiation precedes B2 receptor coupling to eNOS in 
caveolae.   
 
Based on: Tom B., Dendorfer A., de Vries R., Saxena P.R. and Danser A.H.J., 
(2002). Bradykinin potentiation by ACE inhibitors: A matter of metabolism, Br. J. 
Pharmacol., 137:276-284. 
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5.1. Introduction 
Bradykinin accumulation is believed to contribute to the beneficial effects of ACE 
inhibitors in hypertension and heart failure, although elevated bradykinin levels have 
not always been found during ACE inhibitor treatment (Campbell et al., 1999). Recent 
studies in isolated cells propose that ACE inhibitors potentiate bradykinin beyond 
blocking its hydrolysis, by inhibiting desensitization of its receptor (Benzing et al., 
1999; Minshall et al., 1997b). The mechanism behind this phenomenon is currently 
unclear, but may involve 'crosstalk' between ACE and B2 receptors (Benzing et al., 
1999; Marcic et al., 1999; 2000a; 2000b; Minshall et al., 1997b). Although these 
findings were subsequently confirmed in intact coronary arteries (Danser et al., 2000; 
Mombouli et al., 2002; Tom et al., 2001a), it has recently been proposed, on the basis 
of experiments performed in isolated perfused rat Langendorff hearts (Dendorfer et 
al., 2000) and rabbit jugular veins (Dendorfer et al., 2001a) that inhibition of ACE in 
the immediate vicinity of B2 receptors (e.g., in caveolae) is a more likely explanation 
for the potentiation of bradykinin by ACE inhibitors than a direct interaction between 
ACE and B2 receptors. In support of this concept, aminopeptidase P inhibition resulted 
in a similar leftward shift of the bradykinin concentration response curve (CRC) as 
ACE inhibition (Dendorfer et al., 2000), and no ACE inhibitor-induced leftward shift 
was observed when studying B2 receptor-mediated vasoconstriction in response to 
ACE-resistant bradykinin analogues (Dendorfer et al., 2001a; Gobeil et al., 2002). 
However, the latter data were obtained in endothelium-denuded vessels, i.e. a 
preparation that lacks the B2 receptor- and ACE-expressing endothelial cells that are 
responsible for the ACE inhibitor-induced potentiation of B2 receptor-mediated 
coronary vasorelaxation (Danser et al., 2000; Mombouli et al., 2002; Tom et al., 
2001a).  
Neutral endopeptidase 24.11 (NEP) is a membrane-bound metalloprotease with a 
catalytic unit similar to that of ACE.  It is widely distributed in endothelial and 
vascular smooth muscle cells (Gonzalez et al., 1998; Graf et al., 1993; Llorens-Cortes 
et al., 1992; Soleilhac et al., 1992; Wang et al., 1994). NEP catalyzes the degradation 
of a number of endogenous vasoactive peptides, including bradykinin and angiotensin 
(Blais et al., 2000; Graf et al., 1993; Kokkonen et al., 1999; Raut et al., 1999).  Recent 
studies have shown that combined inhibition of ACE and NEP with so-called 
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vasopeptidase inhibitors is more cardioprotective than ACE inhibition alone (d'Uscio 
et al., 2001; Rouleau et al., 2000).  
It was the aim of the present study to further investigate the possibility that the 
ACE inhibitor-induced potentiation of bradykinin in intact (i.e., endothelium-
containing) porcine coronary arteries (PCAs) has a non-metabolic origin. First, we 
studied whether bradykinin potentiation also occurs with NEP inhibitors, and whether 
dual ACE/NEP inhibition results in even further potentiation of bradykinin. Second, 
we studied the effect of protein kinase C (PKC) and phosphatase inhibition (with 
calphostin C and okadaic acid, respectively) on the ACE inhibitor-induced bradykinin 
potentiation, since such inhibition was found to fully eliminate the ACE/B2 receptor 
crosstalk in CHO cells (Marcic et al., 2000b). Third, we studied whether potentiation 
occurs when using truly ACE-resistant bradykinin analogues. This is particularly 
important, since most studies that investigated ACE-B2 receptor crosstalk so far made 
use of a bradykinin analogue ([Hyp3-Tyr(Me)8]-bradykinin) that was recently shown 
not to be ACE-resistant at all (Dendorfer et al., 2001a; Gobeil et al., 2002). Finally, in 
view of the possibility that ACE and B2 receptors co-localize in caveolae, we studied 
the effect of caveolar disruption (with filipin, cyclodextrin or nystatin) on the ACE 
inhibitor-induced bradykinin potentiation.  
5.2. Methods 
Chemicals 
Ang-(1-7), bradykinin, calphostin C, captopril, cyclodextrin, 9,11-dideoxy-11α, 9α-
epoxymethano-prostaglandin F2α (U46619), filipin, S-nitroso-N-acetylpenicillamine 
(SNAP), nystatin, okadaic acid, phosphoramidon, and substance P were purchased 
from Sigma (Zwijndrecht, The Netherlands). Quinaprilat was a kind gift of dr. H. van 
Ingen, Parke-Davis, Hoofddorp, The Netherlands. Omapatrilat was a kind gift of dr. 
N.C. Trippodo, Bristol-Myers Squibb, Princeton, NJ, USA. [Phe8Ψ(CH2-NH)Arg9]-
bradykinin (PA-bradykinin) was bought from Calbiochem (Breda, The Netherlands). 
[∆Phe5]-bradykinin (DP-bradykinin) was synthesized by a solid-phase method by 
means of the Boc-strategy (Reissmann et al., 1996). All chemical were dissolved in 
water, with the exception of calphostin C and phosphoramidon, which were dissolved 
in dimethylsulfoxide, and of filipin, which was dissolved in ethanol.  
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Tissue collection 
PCAs were obtained from 5 2-3 month-old pigs (Yorkshire x Landrace, weight 
10-15 kg) that had been used in in-vivo experiments studying the effects of 
α-adrenoceptor and calcitonin-gene related peptide receptor (ant)agonists or capsaicin 
under pentobarbital (600 mg, i.v.) anesthesia (Willems et al., 2001), and from 38 pigs 
at the local slaughtherhouse. The Ethics Committee of the Erasmus MC dealing with 
the use of animals for scientific experiments approved the protocol for this 
investigation. Arteries were either removed at the end of the experiment, or after the 
heart from the slaughtherhouse had been brought to the laboratory in cold Krebs 
bicarbonate solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2 
2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and glucose 8.3; pH 7.4. Vessels were 
stored overnight in cold, oxygenated Krebs bicarbonate solution, They were then cut 
into segments of approximately 4 mm length, suspended on stainless steel hooks in 
15 mL organ baths containing Krebs bicarbonate solution, aerated with 95% O2 / 5% 
CO2, and maintained at 37°C. 
Organ bath studies 
All vessel segments were allowed to equilibrate for at least 30 min and the organ bath 
fluid was refreshed every 15 min during this period. Changes in tissue contractile 
force were recorded with a Harvard isometric transducer (South Natick, MA, USA). 
The vessel segments, stretched to a stable force of about 15 mN, were exposed to 
30 mM KCl twice. The functional integrity of the endothelium was verified by 
observing relaxation to 1 nM substance P after preconstriction with 1 µM U46619. 
Subsequently, the tissue was exposed to 100 mM KCl to determine the maximal 
contractile response to KCl. The segments were then allowed to equilibrate in fresh 
organ bath fluid for 30 min. Thereafter, the following experiments were performed. 
First, vessels were preincubated for 30 min in the presence or absence of 10 µM 
quinaprilat (ACE inhibitor) and/or 10 µM captopril (ACE inhibitor), 10 µM 
omapatrilat (vasopeptidase inhibitor), 1 µM phosphoramidon (NEP inhibitor), 10 µM 
Ang-(1-7) (inhibitor of ACE C-domain) (Tom et al., 2001a), 4 µg/mL filipin, 2% 
cyclodextrin, or 20 µg/mL nystatin. Next, vessels were preconstricted with 1 µM 
U46619, and CRCs were constructed to bradykinin, PA-bradykinin, or DP-bradykinin. 
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Second, vessels were pre-incubated for 30 min with or without 1 µM 
calphostin C, 0.5 µM okadaic acid, 4 µg/mL filipin, 2% cyclodextrin, or 20 µg/mL 
nystatin. Vessels were then preconstricted with 1 µM U46619 and exposed multiple 
times (to induce desensitization) to 0.1 µM bradykinin, 0.1 µM PA-bradykinin or 
0.03 µM DP-bradykinin. Each next exposure was started as soon as the effect of the 
previous exposure had disappeared. When bradykinin no longer exerted a vasodilatory 
effect, 10 µM quinaprilat, 10 µM omapatrilat, or 1 µM phosphoramidon was added to 
the organ bath.  
Finally, to study the metabolism of bradykinin under our experimental 
conditions, 1 mL fluid samples were taken from the organ bath at 0, 30, 60 and 120 
minutes after the addition of the highest bradykinin concentration (1 µM) in the 
absence or presence of 10 µM quinaprilat. The samples were immediately 
supplemented with 1% trifluoroacetic acid, and stored until analysis at -70°C. 
Bradykinin was determined by high performance liquid chromatography and 
photometric detection at 210 nm (Dendorfer et al., 1997a).  
Statistical analysis 
Data are given as mean±S.E.M. and expressed as a percentage of the contraction in 
response to U46619. Differences between arteries obtained from experimental pigs 
and from slaugtherhouse pigs were not observed (data not shown), and data for the 
two groups were therefore combined. CRCs were analyzed using the logistic function 
described by de Lean et al. (de Lean et al., 1978) to obtain pEC50 (-10log EC50) values, 
EC50 representing the concentration at which 50% of the maximal relaxant effect has 
been reached. Statistical analysis was performed by Analysis of Variance (ANOVA), 
followed by post hoc evaluation according to Dunnett. P values <0.05 were 
considered significant. 
5.3. Results 
Potentiation of bradykinin by inhibitors of ACE and/or NEP 
Bradykinin relaxed preconstricted PCAs in a concentration-dependent manner 
(pEC50=7.95±0.03, n=5; Figure 1). Quinaprilat and omapatrilat, but not 
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phosphoramidon, shifted the bradykinin CRC approximately 10-fold to the left 
(pEC50’s respectively 9.22±0.05 (P<0.05 vs. control), 9.28±0.08 (P<0.05 vs. control) 
and 8.06±0.13, n=5 for each condition). These drugs were without effect in the 
absence of bradykinin, indicating that PCAs do not contain endogenous bradykinin.  
 
 
 
Figure 1. Relaxations of 
porcine coronary arteries 
preconstricted with 1 µM 
U46619, to bradykinin in 
the absence (control) or 
presence of 10 µM 
quinaprilat, 10 µM 
omapatrilat or 1 µM 
phosphoramidon. Data 
(mean± S.E.M. of 5 
experiments) are expressed 
as a percentage of the 
contraction induced by 
U46619. 
 
 
Repeated exposure of preconstricted PCAs to bradykinin produced progressively 
smaller responses (Figure 2, n=5). Its effects lasted less than 10 min, and contractility 
returned to preconstriction level within 15-20 min. The response to the third 
bradykinin dose was <50% of the response to the first bradykinin dose. Quinaprilat or 
omapatrilat, added to the organ bath after the effect of the third bradykinin dose had 
disappeared, completely restored the relaxant effect of bradykinin, whereas 
phosphoramidon was without effect (n=5 for each inhibitor). Bradykinin added to the 
organ bath after the effect of the enzyme inhibitors had disappeared exerted no effect 
(data not shown). 
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Figure 2. Relaxations of porcine coronary arteries, following preconstriction with 1 µM 
U46619, to three consecutive bradykinin doses (0.1 µM; BK1, BK2, BK3), followed by 10 µM 
quinaprilat, 10 µM omapatrilat, or 1 µM phosphoramidon. Top panel: original tracing; 
Bottom panel: Mean±S.E.M. of 5 experiments (Data are expressed as a percentage of the 
contraction induced by U46619).  
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Does inhibition of phosphatases or protein kinase C block the effect of quinaprilat 
in desensitized vessels? 
The relaxant effect of quinaprilat in desensitized PCAs was not altered in the presence 
of calphostin C or okadaic acid (Figure 3). 
 
Figure 3. Relaxations of porcine coronary arteries, following preconstriction with 1 µM 
U46619, to three consecutive bradykinin doses (0.1 µM; BK1, BK2, BK3), followed by 10 µM 
quinaprilat, in the absence (control) or presence of 1 µM calphostin C or 0.5 µM okadaic 
acid. Data (mean±S.E.M. of 5 experiments) are expressed as a percentage of the contraction 
induced by U46619. 
 
Do ACE inhibitors potentiate ACE-resistant bradykinin analogues? 
In preconstricted PCAs, Ang-(1-7), like quinaprilat, shifted the bradykinin CRC to the 
left (Figure 4), although its effect was smaller than that of quinaprilat (pEC50’s 
8.40±0.09 (n=7) and 8.85±0.06 (n=23) vs. 7.94±0.05 for control (n=28); P<0.05). This 
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relates to the fact that Ang-(1-7) inhibits the ACE C-domain only, whereas quinaprilat 
inhibits both the C- and N-domain of ACE (Tom et al., 2001a). PA-bradykinin (pEC50 
8.05±0.05; n=23) and DP-bradykinin (pEC50 8.64±0.19; n=6) relaxed preconstricted 
PCAs to a similar degree as bradykinin (Figure 4). Their relaxant effects were not 
affected by either Ang-(1-7), quinaprilat, or captopril (Figure 4).  
Figure 4. Relaxations of porcine coronary arteries, preconstricted with 1 µM U46619, to 
bradykinin in the absence (control) or presence of 10 µM quinaprilat, 10 µM captopril or 
10 µM Ang-(1-7). Data (mean±S.E.M. of 5-28 experiments) are expressed as a percentage of 
the contraction induced by U46619. 
 
Moreover, in the repeated exposure experiments, in contrast with bradykinin, 
PA-bradykinin induced relaxation only once, and the application of subsequent doses 
of PA-bradykinin (Figure 5), quinaprilat (Figure 5) or Ang-(1-7) (data not shown) 
exerted no effect. DP-bradykinin, like bradykinin, was capable of exerting multiple 
relaxations. However, the effect of quinaprilat in DP-bradykinin-desensitized vessels 
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was significantly smaller than in bradykinin-desensitized preparations (Figure 5). 
Finally, adding 10 µM bradykinin to vessels that no longer responded to 0.1 µM 
bradykinin induced a vasorelaxation (74±10%, n=5) that was as large as that induced 
by quinaprilat. 
U46619 BK2 quinaprilatBK1 BK3 U46619 BK2 quinaprilatBK1 BK3
PA-BK DP-BK
10
 m
N
5 min  
 
Figure 5. Relaxations of porcine coronary arteries, following preconstriction with 1 µM 
U46619, to three consecutive bradykinin, PA-bradykinin or DP-bradykinin doses (0.1 µM, 
0.1 µM and 0.03 µM, respectively; BK1, BK2, BK3), followed by 10 µM quinaprilat. Top 
panel: Original tracings of experiments with PA-bradykinin and DP-bradykinin. Bottom 
panel: Mean±S.E.M. of 5-12 experiments (Data are expressed as a percentage of the 
contraction induced by U46619). *P<0.01 vs bradykinin. 
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Bradykinin metabolism during incubation with porcine coronary arteries 
Bradykinin disappeared mono-exponentially from the organ bath fluid (Figure 6), with 
a half-life of 96±8 min (n=5). Quinaprilat marginally (P=NS) increased the half-life to 
126±12 min. 
 
Figure 6. Metabolism of 
bradykinin by porcine coronary 
artery rings during incubation of 
15 mL organ bath fluid at 37°C 
with 1 µM bradykinin in the 
absence (control) or presence of 
10 µM quinaprilat. Data are 
mean±S.E.M. of 5 experiments and 
have been expressed as a 
percentage of the level at t=0 
(0.70±0.04 and 0.82±0.04 µM 
without and with quinaprilat). 
 
 
 
Effect of caveolar disruption on bradykinin potentiation by quinaprilat 
Pretreatment with filipin reduced the maximal relaxant effect of bradykinin and PA-
bradykinin by approximately 25-30% (Figure 7; P<0.05), but did not alter their 
potencies (7.63±0.19 (n=6) and 7.91±0.20 (n=7); P>0.05 vs. without filipin). Filipin 
did not affect the response to the endothelium-independent relaxant SNAP (Figure 8). 
Neither cyclodextrin, nor nystatin (20 µg/mL), affected the bradykinin, PA-bradykinin 
or SNAP CRCs, although there was a tendency for nystatin at this concentration to 
reduce (P=NS) the maximal relaxant effect of SNAP. At a concentration of 50 µg/mL, 
nystatin did significantly reduce the SNAP-induced relaxation (data not shown).  
Bradykinin Potentiation by ACE Inhibitors 
74 
Figure 7. Relaxations of porcine coronary arteries, preconstricted with 1 µM U46619, to 
bradykinin (top panels) or PA-bradykinin (bottom panels) in the absence (control) or 
presence of 10 µM quinaprilat, following pretreatment with 4 µg/mL filipin, 2% cyclodextrin 
or 20 µg/mL nystatin. Data (mean±S.E.M. of 4-10 experiments) are expressed as a 
percentage of the contraction induced by U46619. 
 
Quinaprilat caused a leftward shift of the bradykinin CRC in the presence of all 
caveolae-disrupting agents, and the shift was fully comparable to that observed in the 
absence of these agents (Figures 4 and 7). Quinaprilat did not affect the PA-
bradykinin CRC in the presence of filipin, cyclodextrin and nystatin.  
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Figure 8. Relaxations of porcine 
coronary arteries, preconstricted with 
1 µM U46619, to SNAP in the absence 
(control) or presence of 4 µg/mL 
filipin, 2% cyclodextrin or 20 µg/mL 
nystatin. Data (mean±S.E.M. of 5-21 
experiments) are expressed as a 
percentage of the contraction induced 
by U46619. 
 
 
 
 
Figure 9. Relaxations of porcine coronary arteries, following preconstriction with 1 µM 
U46619, to three consecutive bradykinin doses (0.1 µM; BK1, BK2, BK3), followed by 10 µM 
quinaprilat, in the absence (control) or presence of 4 µg/mL filipin, 2% cyclodextrin or 
20 µg/mL nystatin. Data (mean±S.E.M. of 5-12 experiments) are expressed as a percentage 
of the contraction induced by U46619. 
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Finally, none of the caveolar disrupting agents prevented the relaxant effect of 
quinaprilat in desensitized preparations (Figure 9). 
5.4. Discussion 
The present study shows that the ACE inhibitor-induced potentiation of bradykinin in 
intact PCAs has a metabolic origin. The explanation for this potentiation is therefore 
not that ACE and B2 receptors physically interact, as proposed on the basis of studies 
in isolated cells overexpressing ACE and B2 receptors (Benzing et al., 1999; Marcic et 
al., 2000a; 2000b; Minshall et al., 1997b), but rather that ACE is located in close 
proximity of B2 receptors, thereby directly determining the bradykinin concentration 
in the micro-environment of the B2 receptor. As a consequence, the bradykinin 
concentrations seen by the receptor will only approach those in the organ bath when 
ACE is inhibited, a phenomenon that can be achieved instantaneously by adding an 
ACE inhibitor to the organ bath. 
An extensive series of experiments, both in transfected cells (Benzing et al., 
1999; Marcic et al., 2000a; 2000b; Minshall et al., 1997b) and in intact vessel 
preparations (Danser et al., 2000; Mombouli et al., 2002; Tom et al., 2001a), supports 
the idea that bradykinin potentiation by ACE inhibitors is an effect beyond hydrolysis. 
The data suggest that ACE inhibitors, in a PKC- and phosphatase-dependent manner 
(Marcic et al., 2000b), increase the number of cell surface B2 receptors, thereby 
preventing/reversing the rapid B2 receptor desensitization that normally occurs upon 
exposure to bradykinin (Bachvarov et al., 2001; Marcic et al., 1999; 2000a; 2000b; 
Minshall et al., 1997b). In order to draw this conclusion, the studies depended on the 
use of ‘ACE-resistant’ bradykinin analogues, in particular [Hyp3-Tyr(Me)8]-
bradykinin. However, in a recent investigation Dendorfer et al. (Dendorfer et al., 
2001a) showed that rabbit ACE cleaves [Hyp3-Tyr(Me)8]-bradykinin at 71% of 
bradykinin degradation activity, and this finding was confirmed by Gobeil et al. 
(Gobeil et al., 2002).  
Potentiation of ACE-resistant bradykinin analogues by ACE inhibitors? 
In the present study we therefore re-investigated the ACE inhibitor-induced 
bradykinin potentiation in PCAs, using 2 bradykinin analogues, one (PA-bradykinin) 
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of which was truly ACE-resistant, whereas the other (DP-bradykinin) was cleaved at 
9% of bradykinin degradation activity (Dendorfer et al., 2001a; Gobeil et al., 2002). 
We followed two approaches, 1) comparison of the bradykinin CRCs in the absence 
and presence of an ACE inhibitor, and 2) the application of an ACE inhibitor to 
desensitized coronary arteries (i.e., arteries that no longer relaxed in response to 
0.1 µM bradykinin, a concentration that normally causes complete relaxation). In the 
latter experimental setup, the addition of the ACE inhibitor immediately results in full 
relaxation, an effect that depends on the prior addition of bradykinin, since it does not 
occur in the absence of bradykinin (Danser et al., 2000). Apparently, at the time the 
ACE inhibitor is added (i.e., approximately 10 min after the last bradykinin dose), the 
organ bath still contains sufficient bradykinin to allow full relaxation. Our 
measurement of the bradykinin half-life (>90 min) in the current study confirms this 
assumption. The quinaprilat-induced relaxation of desensitized preparations is not due 
to unspecific properties of this drug, since similar data have been obtained with a 
whole range of ACE inhibitors (Danser et al., 2000; Gobeil et al., 2002; Marcic et al., 
2000a).  
The results of both experimental approaches indicate that the effect of ACE 
inhibition is absent or greatly reduced when using ACE-resistant bradykinin 
analogues. First, the 10-fold leftward shift of the bradykinin CRC that normally occurs 
in the presence of the ACE inhibitors quinaprilat (Danser et al., 2000), captopril (Tom 
et al., 2001a) or perindoprilat (Mombouli et al., 2002) was absent when using PA-
bradykinin or DP-bradykinin. Moreover, the leftward shift that we (Tom et al., 2001a) 
and others (Gobeil et al., 2002) observed earlier in the presence of Ang-(1-7), also did 
not occur in combination with these agonists, indicating that this shift, too, has a 
metabolic origin. The Ang-(1-7)-induced shift is smaller than the shift induced by 
quinaprilat and captopril, because Ang-(1-7), at the high concentration that was 
applied in this study (10 µM), blocks the active center of only one (the C-terminal 
domain) of the two homologous domains of the ACE molecule, whereas quinaprilat 
and captopril at this same concentration block both domains (Tom et al., 2001a). 
These data therefore strongly argue against the idea that a non-ACE related effect of 
Ang-(1-7) (e.g., an effect mediated via the putative Ang-(1-7) receptor) underlies its 
bradykinin-potentiating capabilities (Fernandes et al., 2001).  
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Second, the above described quinaprilat-induced relaxation of desensitized 
coronary arteries did not occur following PA-bradykinin-induced desensitization, and 
was significantly reduced after DP-bradykinin-induced desensitization. Complete 
desensitization was already obtained after the application of 0.1 µM PA-BK, since the 
addition of subsequent PA-BK doses (increasing the PA-BK concentrations 2- and 3-
fold) did not exert further effects. In contrast, desensitization induced by 0.1 µM 
bradykinin or 0.03 µM DP-bradykinin was less complete, as the application of a 
second and third dose of these agonists still induced modest relaxations. 
Desensitization is due to a reduction in the number of B2 receptors on the endothelial 
cell surface, and/or to exhaustion of post-receptor mechanisms (e.g., NO depletion). In 
support of the latter, desensitization occurred much more rapidly in the presence of an 
NOS inhibitor (Danser et al., 2000). The lack of effect of quinaprilat after PA-
bradykinin suggests that the B2 receptor resensitization that has been detected upon 
ACE inhibitor administration in isolated cells (Benzing et al., 1999; Marcic et al., 
1999; 2000a; 2000b; Minshall et al., 1997b), either does not occur or is insufficient in 
intact coronary arteries.  
How then should the ACE inhibitor-induced relaxation following bradykinin 
desensitization be explained? Quinaprilat does not increase the organ bath fluid levels 
of bradykinin. In the absence of significant B2 receptor resensitization, this leaves the 
possibility that quinaprilat affects the bradykinin levels that are seen by the receptor. 
This explanation implies that ACE is located in close proximity of B2 receptors, and 
thus, that normally the bradykinin levels in the vicinity of the receptor are below those 
in the organ bath. In view of the ≈10-fold leftward shift of the bradykinin CRC in the 
presence of quinaprilat, it seems reasonable to assume that the bradykinin levels in the 
micro-environment of the B2 receptor are also ≈10-fold lower than the levels in the 
organ bath. For a fully ACE resistant bradykinin analogue (PA-bradykinin) such a 
difference will not exist, whereas for an analogue that is degraded by ACE at <10% of 
its bradykinin degrading activity (DP-bradykinin) the difference will be much smaller 
than 10-fold. This explains why we did not observe a significant leftward shift of the 
DP-bradykinin CRC, and only a modest relaxation following the addition of 
quinaprilat to DP-bradykinin desensitized vessels. It also explains why desensitization 
was already complete after one PA-BK dose (resulting in a concentration of 0.1 µM in 
the organ bath as well as in the micro-environment of B2 receptors), whereas 
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desensitization remained incomplete after the addition of 3 subsequent bradykinin 
doses (resulting in a final concentration of 0.3 µM in the organ bath, and of ≈0.03 µM 
in the micro-environment of B2 receptors). In fact, incomplete desensitization is a 
prerequisite for the quinaprilat-induced relaxation, since in completely desensitized 
preparations a 10-fold (or more) rise of the bradykinin levels in the micro-
environment of the receptor will of course have no effect. In agreement with this 
concept, exposure of bradykinin-desensitized arteries to a 100-fold higher bradykinin 
concentration (10 µM) resulted in a similar relaxation as the addition of quinaprilat.  
Blockade of phosphatases and PKC did not interfere with the quinaprilat-
induced relaxation, whereas these agents did prevent the ACE inhibitor-induced 
bradykinin potentiation in transfected CHO cells that overexpress ACE and B2 
receptors (Marcic et al., 2000b). One reason for this discrepancy might be that 
overexpression itself leads to interactions which do not occur at low expression levels. 
ACE inhibitor-induced potentiation of B2 receptor-mediated vasoconstriction 
Our study is the first to demonstrate a metabolic background for the ACE inhibitor-
induced potentiation of bradykinin-mediated vasodilation in intact arteries, i.e, for an 
interaction at the level of the endothelial cells, the same cells that were used to 
demonstrate ACE-B2 receptor crosstalk in cell culture studies (Marcic et al., 1999; 
2000b). The present data are in full agreement with two previous studies, using similar 
experimental protocols, on the lack of potentiation of PA-bradykinin-mediated 
vasoconstriction in endothelium-denuded rabbit jugular veins by either ramiprilat 
(Dendorfer et al., 2001a) or captopril (Gobeil et al., 2002). Thus, the concept of B2 
receptor-ACE co-localization may also apply to vascular smooth muscle cells.  
Bradykinin potentiation by NEP inhibitors? 
NEP inhibition, in contrast with ACE inhibition, did not potentiate bradykinin in 
isolated porcine arteries, neither alone, nor on top of ACE inhibition. These findings 
contrast with reports on the wide presence of NEP in the vascular wall (Dussaule et 
al., 1993; Gonzalez et al., 1998; Graf et al., 1993; Llorens-Cortes et al., 1992; 
Soleilhac et al., 1992; Wang et al., 1994) and its important contribution to bradykinin 
metabolism in-vivo (Kentsch et al., 1999; McClean et al., 2000; Rouleau et al., 2000). 
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Thus, either NEP is not present in PCAs and/or its contribution to bradykinin 
metabolism in this in-vitro model is of limited importance. Earlier studies in porcine 
vessels oppose the former explanation (Krassoi et al., 2000; Miyamoto et al., 2002). 
The most likely explanation is therefore that NEP in intact PCAs, unlike ACE, does 
not co-localize with B2 receptors, and thus that NEP inhibition does not increase the 
bradykinin levels in the micro-environment of B2 receptors. In support of this concept, 
bradykinin potentiation did occur following NEP inhibition when co-localization had 
been artificially induced by transfecting CHO cells with both NEP and B2 receptors 
(Deddish et al., 2002).  
Co-localization of ACE and B2 receptors in caveolae? 
Both ACE and B2 receptors have been demonstrated in caveolae (Benzing et al., 1999; 
Haasemann et al., 1998). Caveolae are small micro-invaginations of the plasma 
membrane enriched with caveolin that are involved in the compartmentalization of 
signaling molecules. For instance, B2 receptors interact with eNOS in this 
compartment (Ju et al., 1998). The structural integrity of caveolae depends on 
cholesterol, and sterol-binding agents such as filipin, cyclodextrin and nystatin are 
therefore capable of disrupting caveolae (Neufeld et al., 1996; Rothberg et al., 1992; 
Schnitzer et al., 1994). Interestingly, a recent study demonstrated that caveolar 
disruption mimics endothelial dysfunction in atheromatous vessels (Darblade et al., 
2001).  
To address the possibility of ACE-B2 receptor co-localization in caveolae, we 
studied the bradykinin-potentiating effects of quinaprilat in coronary arteries that had 
been exposed to the above sterol-binding agents. Our data confirm that caveolar 
disruption results in endothelial dysfunction, since filipin reduced the maximal 
relaxant effect of both bradykinin and PA-bradykinin by ≈25-30%, without affecting 
the relaxations induced by the endothelium-independent agent SNAP. Cyclodextrin 
and nystatin did not affect the CRCs of bradykinin and PA-bradykinin. Possibly 
therefore, the 40-50% reduction in caveolar abundance that has been reported to occur 
in rabbit aortic rings following exposure to 2% cyclodextrin (the same concentration 
that was used in the present study, and that resulted in a reduction of the effect of 
acetylcholine in rabbit aorta rings) (Darblade et al., 2001) is insufficient to affect B2 
receptor-mediated relaxations, or the reduction in PCAs is less than 40%. 
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Furthermore, nystatin at a concentration of 20 µg/mL tended to reduce the SNAP-
induced relaxations (Figure 9), and a significant reduction occurred at a concentration 
of 50 µg/mL, thus not allowing us to investigate the effect of higher nystatin 
concentrations on the bradykinin CRCs.  
Importantly however, although caveolar disruption appeared to reduce the 
relaxant effect mediated by B2 receptors (for instance because of interference with 
their interaction with eNOS in this compartment), it did not affect the leftward shift 
induced by quinaprilat (or the absence thereof in the case of PA-bradykinin), nor did it 
prevent the quinaprilat-induced relaxation in desensitized preparations. Based on these 
data, it therefore seems unlikely that ACE inhibition within caveolae underlies its 
bradykinin-potentiating effects. Apparently therefore, the ACE-B2 receptor co-
localization occurs elsewhere, for instance in coated pits or non-caveolar lipid rafts.  
5.5 Conclusion and perspective 
Bradykinin potentiation by ACE inhibitors in PCAs is a metabolic process based on 
the co-localization of ACE and B2 receptors on the endothelial cell membrane. NEP 
does not appear to be present in the micro-environment of coronary B2 receptors, and 
the ACE inhibitor-induced effect on bradykinin metabolism most likely does not 
occur in caveolae, i.e. it precedes the coupling of B2 receptors to eNOS in this 
compartment. The co-localization of ACE and B2 receptors mimics the co-localization 
of ACE and AT1 receptors (Saris et al., 2002; Schuijt et al., 2002). Thus, ACE is 
located in a strategic position to allow maximal efficiency of B2 receptor and AT1 
receptor stimulation.  
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CHAPTER 6 
ACE- versus Chymase-Dependent Angiotensin II Generation in 
Human Coronary Arteries: A Matter of Efficiency? 
Summary 
We investigated ACE- and chymase-dependent Ang I-II conversion in human coronary 
arteries. Human coronary artery rings were mounted in organ baths, and concentration 
response curves to Ang II, Ang I, and the chymase-specific substrate Pro11-D-Ala12-
angiotensin I (PA-Ang I) were constructed. All angiotensins displayed similar efficacy. 
For a given vasoconstriction, bath (but not interstitial) Ang II during Ang I and PA-
Ang I was lower than during Ang II, indicating that interstitial (and not bath) Ang II 
determines vasoconstriction. PA-Ang I increased interstitial Ang II less efficiently than 
Ang I. Separate inhibition of ACE (with captopril) and chymase (with C41 or 
chymostatin) shifted the Ang I concentration response curve ≈5-fold to the right, 
whereas a 10-fold shift occurred during combined ACE and chymase inhibition. 
Chymostatin, but not captopril and/or C41, reduced bath Ang II, and abolished PA-
Ang I-induced vasoconstriction. Perfused human coronary artery segments, exposed 
luminally or adventitially to Ang I, released Ang II into the luminal and adventitial 
fluid, respectively, and this release was blocked by chymostatin. In conclusion, both 
ACE and chymase contribute to the generation of functionally active Ang II in human 
coronary arteries. However, as Ang II ‘loss’ in the organ bath is chymase-dependent, 
ACE-mediated conversion occurs more efficiently (i.e., closer to AT1 receptors) than 
chymase-mediated conversion. 
 
 
 
 
 
 
 
 
Based on: Tom B., Garrelds I.M., Scalbert E., Stegmann A.P.A.,  Boomsma F., 
Saxena P.R. and Danser A.H.J., (2003). ACE- versus chymase-dependent 
angiotensin II generation in human coronary arteries: A matter of efficiency?, 
Arterioscler. Thromb. Vasc. Biol., 23: 251-256. 
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6.1. Introduction 
ACE inhibitors are widely used for the treatment of hypertension and heart failure. 
Their beneficial effects are believed to be due to blockade of the generation of Ang II 
from Ang I. In contrast with this concept, during chronic ACE inhibitor therapy, 
plasma and tissue Ang II levels are unchanged or elevated as compared to the pre-
treatment situation (Farquharson et al., 2002; van Kats et al., 2000). This is not a 
methodological artifact (Farquharson et al., 2002; van Kats et al., 2000). Several 
explanations may therefore be put forward. First, the ACE inhibitor dose may have 
been too low to obtain sufficient ACE inhibition. Indeed, high dose ACE inhibition 
appears to be more effective than low dose (Jorde et al., 2000). Second, the rise in 
renin and Ang I that occurs when Ang II no longer suppresses renin release may, at 
least in part, overcome ACE inhibition (Mooser et al., 1990; van Kats et al., 1998). 
Third, ACE upregulation is known to occur both as a consequence of chronic ACE 
inhibitor therapy, and during the progression of cardiovascular diseases (Farquharson 
et al., 2002). Fourth, in-vitro studies have shown that there are alternative enzymes 
capable of converting Ang I into Ang II (Maassen van den Brink et al., 1999; Richard 
et al., 2001; Urata et al., 1990). The most important of these is the serine protease 
chymase. Although one in-vivo study recently reported that the chymase-specific 
substrate Pro11-D-Ala12-Ang I (PA-Ang I) induced AT1 receptor mediated 
vasoconstriction in human dorsal hand veins (McDonald et al., 2001), in-vivo 
evidence for chymase-dependent Ang II generation from native Ang I could not be 
obtained in humans (Saris et al., 2000). 
In this respect, it is important to realize that the location of ACE and chymase 
differs greatly. ACE is a membrane-associated enzyme that, due to proteolytic 
cleavage of its membrane anchor, also occurs in a soluble form in the extracellular 
fluid. ACE-expressing cells include endothelial cells, vascular smooth muscle cells 
and cardiomyocytes (Coulet et al., 2001; van Kesteren et al., 1999). In contrast, 
chymase is located intracellularly, mainly in the cytosol of mast cells that are present 
in the adventitia (Urata et al., 1993). It has also been demonstrated in endothelial 
(Urata et al., 1993) and vascular smooth muscle cells (Guo et al., 2001) and in the 
extracellular matrix (Urata et al., 1993), although not all studies agree on this matter 
(Yamada et al., 2001). Based on this distribution pattern, it is generally believed that 
Chapter 6 
85 
chymase is predominantly active in the interstitial space (Wei et al., 1999). However, 
studies investigating interstitial Ang II generation could not (de Lannoy et al., 2001) 
or only partly (Wei et al., 1999) confirm this concept, either because interstitial fluid 
contains endogenous inhibitors of chymase (e.g., α1-antitrypsin) (Kokkonen et al., 
1997) or due to species differences (Akasu et al., 1998). 
It was the aim of the present study to provide an explanation for the discrepancy 
between in-vivo and in-vitro studies with regard to the contribution of chymase to 
Ang I-to-II conversion in humans. Previous in-vitro studies measured either Ang II 
generation in tissue homogenates (Akasu et al., 1998; Urata et al., 1990), or evaluated 
Ang II-mediated constriction following the application of Ang I or PA-Ang I to intact 
human arteries (Richard et al., 2001). Here, using human coronary arteries (HCAs), 
we measured Ang II release, Ang II-mediated contractile responses, and interstitial 
Ang II levels following the application of PA-Ang I and native Ang I, with or without 
inhibitors of ACE and/or chymase. The underlying assumption of our studies was that 
because of the different location of ACE and chymase, chymase-dependent generation 
of functionally active Ang II occurs less efficiently, i.e. further away from AT1 
receptors and thus (because of rapid angiotensin metabolism in the interstitial space) 
requires more Ang I to lead to vasoconstriction. HCAs are particularly useful for this 
purpose, because they contain ACE, chymase and AT1 receptors (Maassen van den 
Brink et al., 1999).   
6.2. Methods 
Drugs 
Ang I, Ang II, captopril, chymostatin, PD123319, prostaglandin F2α (PGF2α) and 
substance P were purchased from Sigma. C41 (3-[3,4-dimethoxyphenylsulfonyl]-1-
3,4-dimethylphenylimidazoline-2,4-dione) was synthesized by dr. M.C. Viaud, Tours, 
France. Irbesartan was a gift from Bristol-Myers Squibb and PA-Ang I (purity>95%) 
was a gift from the Institut de Recherches Internationales Servier. Chymostatin and 
C41 were dissolved in dimethylsulfoxide and irbesartan was dissolved in ethanol. All 
other compounds were dissolved in distilled water. 
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Tissue collection and preparation 
HCAs were obtained from 17 'heart beating' organ donors (6 men, 11 women; age 
18-58 years, mean±S.E.M. 46±3 years) who died of non-cardiac causes 
(14 cerebrovascular accident, 3 head trauma) <24 hours before the heart was taken to 
the laboratory. Hearts were provided by the Rotterdam Heart Valve Bank after 
removal of the aortic and pulmonary valves for transplantation purposes. The study 
was approved by the Ethics Committee of the Erasmus MC. Immediately after 
circulatory arrest, the hearts were stored in an ice-cooled sterile organ-protecting 
solution (Maassen van den Brink et al., 1999). After arrival in the laboratory, the HCA 
(diameter ≈3-4 mm) was removed and stored overnight in a cold, oxygenated Krebs 
bicarbonate solution of the following composition (mM): NaCl 118, KCl 4.7, CaCl2 
2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and glucose 8.3; pH 7.4. Vessels 
containing macroscopically visible atherosclerotic lesions were excluded.  
Organ bath studies  
Vessels were cut into segments of ≈4 mm length, suspended on stainless steel hooks 
in 15 mL organ baths containing Krebs bicarbonate solution, aerated with 95% O2 / 
5% CO2, and maintained at 37°C. Segments were allowed to equilibrate for at least 
30 min and the organ bath fluid was refreshed every 15 min during this period. 
Changes in tissue contractile force were recorded with a Harvard isometric transducer 
(South Natick). The segments, stretched to a stable force of about 15 mN, were 
exposed to 30 mM KCl twice. Subsequently, segments were exposed to 100 mM KCl 
to determine the maximal contractile response to KCl. The segments were then 
allowed to equilibrate in fresh organ bath fluid for 30 min. Next, segments were 
pre-incubated for 30 min with or without the AT1 receptor antagonist irbesartan 
(1 µM), the AT2 receptor antagonist PD123319 (1 µM), the chymase inhibitor 
chymostatin (100 µM), the ACE inhibitor captopril (10 µM) and/or the chymase 
inhibitor C41 (10 µM). Thereafter, concentration response curves (CRCs) to Ang I, 
Ang II, PA-Ang I were constructed. Endothelial integrity was verified at the end of 
each experiment by observing relaxation to 1 nM substance P after pre-contraction 
with 1 µM PGF2α.  
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To measure Ang II in organ bath fluid, a 50 µL sample was obtained from the 
organ bath at the time the vasoconstrictor response had reached a plateau. Samples 
were rapidly mixed with 10 µL angiotensinase inhibitor solution (Maassen van den 
Brink et al., 1999) and stored at -80°C. Tissue Ang II was measured in a limited 
number of vessel segments only. Based on previous measurements in vessel segments, 
showing that vascular Ang II remains stable for at least 1 hour after the addition of 
Ang I (Schuijt et al., 2002), the segments were removed 1 hour after the addition of 
1 µM Ang I or PA-Ang I, washed in fresh Krebs solution, dried on tissue paper, 
frozen in liquid nitrogen and stored at -80°C.  
Perfusion studies  
Vessels were cut into segments of 1-2 cm length. Side branches, if present, were tied 
off with silk sutures. Each segment was mounted horizontally in a double-jacketed 
4 mL organ bath and perfused from a 6 mL reservoir, using a roller pump (Ismatec 
IPS; flow 1 mL/min). Both organ bath and reservoir contained Krebs bicarbonate 
solution, aerated with 95% O2 / 5% CO2, and were maintained at 37°C. The perfusate 
was collected in the reservoir and reperfused through the vessel, thus creating a closed 
perfusion circuit (Danser et al., 1995) allowing both adventitial (i.e., into the bath) and 
luminal (i.e., into the reservoir) drug application. Ang I (1 µM) was added to the bath 
or the reservoir, under control conditions, in the presence of 10 µM captopril, and in 
the presence of 10 µM captopril plus 100 µM chymostatin, respectively. Luminal and 
adventitial fluid samples (50 µL) were obtained as described above immediately 
before, and 30 and 60 min after the addition of Ang I. Prior to each subsequent Ang I 
application, bath and reservoir fluid were refreshed. All experiments were performed 
in the presence of 1 µM irbesartan, to prevent AT1 receptor-mediated 
vasoconstriction. 
Biochemical measurements 
Ang II in organ bath and reservoir fluid was measured with sensitive 
radioimmunoassays (Maassen van den Brink et al., 1999). Ang II in vessel segments 
was measured by radioimmunoassay following SepPak extraction and HPLC 
separation (van Kats et al., 1998). 
Angiotensin II Generation in Human Arteries 
88 
Data analysis 
Data are given as mean±S.E.M. Contractile responses are expressed as a percentage of 
the maximal contraction to 100 mM KCl (63.9±4.9 mN, n=11). CRCs were analyzed 
as described earlier (Maassen van den Brink et al., 1999) to obtain pEC50 (-10log EC50) 
values. Statistical analysis was performed by one-way ANOVA, followed by post hoc 
evaluation (according to Tukey or Dunnett where appropriate). P<0.05 was considered 
significant. 
6.3. Results 
Organ bath studies 
Ang I, Ang II and PA-Ang I displayed similar maximal effects (Figure 1, Table 1). 
Irbesartan, but not PD123319, prevented the PA-Ang I-induced vasoconstriction 
(Figure 1), indicating that its contractile effects, like those of Ang I in this model 
(Maassen van den Brink et al., 1999), are mediated via AT1 receptors.  
 
Table 1.  pEC50 and Emax of Ang I, Ang II and  PA-Ang I in human coronary arteries with 
or without inhibitors.  
   Ang I  PA-Ang I Ang II 
Inhibitor pEC50 
Emax,  % of 
100 mM K+
pEC50 
Emax,  % of 
100 mM K+
pEC50 
Emax,  % of 
100 mM K+
none 7.35±0.13 23±4.4 6.87±0.14# 17±2.7 7.63±0.05 24±6.3 
10 µM captopril 7.25±0.13 20±3.9 7.00±0.12 17±2.9   
10 µM C41 7.14±0.12 18±3.7 6.75±0.11 14±2.7 7.55±0.06 17±3.8 
10 µM captopril 
+10 µM C41 
6.58±0.05* 21±6.2 6.67±0.07 17±3.7   
100 µM 
chymostatin 
6.90±0.13† 18±4.4 <6† 6.7±1.7†‡   
Data are mean±S.E.M. of 8 experiments. #, P<0.05 vs. Ang I and Ang II; *, P<0.05 and 
†, P<0.01 vs. none; ‡, contractile response at the highest concentration of Ang I that was 
tested. 
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Figure 1. Left panel: Contractions of human coronary arteries (HCAs) to Ang I, Ang II and 
PA-Ang I. Right panel: Contractions of HCAs to PA-Ang I in the absence (control) or 
presence of irbesartan or PD123319. Data (mean±S.E.M., n=8 and n=3 respectively) are 
expressed as a percentage of the response to 100 mM KCl.   
 
Figure 2. Contractions of HCAs versus organ bath fluid (left) and interstitial (right) Ang II 
levels at the time of constriction after the addition of Ang I, Ang II and PA-Ang I. Data 
(mean±S.E.M., n=8) are expressed as a percentage of the response to 100 mM KCl. 
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PA-Ang I was less potent (P<0.05) than Ang I and Ang II. At the moment of 
constriction, Ang II levels in the organ bath fluid during both Ang I and PA-Ang I 
amounted to <5% of the Ang I and PA-Ang I levels (Figure 2), and the pEC50 values 
calculated from these Ang II levels (9.20±0.25 and 8.90±0.15 for Ang I and 
PA-Ang I, respectively; P=NS) were 20-40 times higher (P<0.01) than the pEC50 for 
Ang II. Thus, for a given constriction, the organ bath fluid Ang II level was lower 
during Ang I and PA-Ang I application than during Ang II application. 
Captopril (P=NS), C41 (P=NS) and chymostatin (P<0.05) modestly shifted the 
Ang I CRC to the right, whereas a ≈5-10-fold rightward shift (P<0.01) occurred 
during C41 plus captopril (Figure 3, Table 1). Chymostatin, but not captopril and/or 
C41 abolished the effects of PA-Ang I. C41 did not affect the Ang II CRC (Table 1). 
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Figure 3. Contractions of human coronary arteries to Ang I (left) and PA-Ang I (right) in the 
absence (control) or presence of chymostatin, captopril, C41 or captopril + C41. Data 
(mean±S.E.M., n=8) are expressed as a percentage of the response to 100 mM KCl. 
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Chymostatin reduced the Ang II release into the organ bath during Ang I and 
PA-Ang I application by >75% (P<0.05, Figure 4). Neither captopril, nor C41, nor 
their combination significantly affected the Ang II levels in the organ bath during 
Ang I and PA-Ang I application. 
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Figure 4. Ang II levels in organ bath fluid measured at the moment of contraction of human 
coronary arteries during the concentration response curves to Ang I (left) and PA-Ang I 
(right) in the absence (control) or presence of chymostatin, captopril, C41 or captopril + 
C41. Data are mean±S.E.M. of 8 experiments. 
 
Interstitial Ang II and vasoconstriction 
One hour after the application of 1 µM Ang I to the organ bath, the level of Ang II in 
the arterial segment (wet weight 24±2 mg; n=24) was 18.7±4.3 pmol/g wet weight 
(n=4). Vascular Ang II was not affected by irbesartan (18.9±6.0 pmol/g; n=4) or 
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PD123319 (29.4±12.1 pmol/g; n=4). Comparable observations were made following 
the application of 1 µM PA-Ang I (vascular Ang II respectively 11.4±1.4, 9.9±1.4 and 
7.6±2.4 pmol/g; n=4 for each condition), although the vascular Ang II levels during 
PA-Ang I were 2-4 times (P<0.01) lower than during Ang I. The organ bath fluid 
levels of Ang II in these experiments were not affected by irbesartan or PD123319, 
and resembled those in Figure 4 (data not shown).  
The lack of effect of irbesartan and PD123319 on vascular Ang II indicates that 
the majority of tissue Ang II is not bound to either cell surface or internalized AT1 or 
AT2 receptors, and thus is located extracellularly (i.e., in interstitial fluid). Since 
interstitial fluid accounts for ≈15% of tissue weight (Schuijt et al., 2002), it can be 
calculated that the interstitial Ang II levels during Ang I and PA-Ang I application are 
148.7±35.6 and 64.3±5.1 nM (mean of all measurements, including those with AT 
receptor blockers), respectively. This is 9.4±4.2 and 5.1±1.5 (P<0.05 for difference) 
times higher than the organ bath fluid Ang II levels at the time of vasoconstriction. 
The interstitial Ang II levels during Ang II application are as high as the Ang II levels 
in the organ bath (Schuijt et al., 2002). The right panel of Figure 2 illustrates the 
consequence of this concept. It is clear that, for a given vasoconstriction, the 
interstitial Ang II levels during Ang I, PA-Ang I, and Ang II are comparable. 
However, it requires more PA-Ang I than Ang I to reach a certain interstitial Ang II 
level.  
Perfusion studies  
Luminal Ang I application resulted in the appearance of Ang II in luminal but not 
adventitial fluid, whereas adventitial Ang I application resulted in the appearance of 
Ang II in adventitial, but not luminal fluid (Figure 5). Ang II levels increased over 
time and were ≈4 times higher in adventitial fluid after adventitial Ang I application 
than in luminal fluid after luminal Ang I application. Chymostatin plus captopril, but 
not captopril alone, fully prevented luminal and adventitial Ang II release. 
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Figure 5. Luminal and adventitial Ang II levels following the luminal or adventitial 
application of Ang I (1 µM) under control conditions, in the presence of captopril or in the 
presence of captopril + chymostatin. In the panels providing the control data only, Ang II 
was undetectable under all conditions. S.E.M., if not shown, is smaller than the symbol. Data 
are mean±S.E.M. of 5 experiments (*, P<0.05 vs. control). 
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6.4. Discussion 
The present study compares, in HCAs mounted in organ baths, the vasoconstrictor 
efficiency of Ang II generated by ACE and by chymase, using both native Ang I and 
the chymase-specific substrate PA-Ang I. The results show that Ang I is 5 to10 times 
more potent than PA-Ang I, and that Ang II release into the organ bath is almost 
exclusively chymase-dependent. Furthermore, chymase inhibition with chymostatin is 
sufficient to block the vasoconstrictor effects of PA-Ang I, whereas, in the case of 
Ang I, combined inhibition of ACE and chymase results in a better blockade of 
vasoconstriction than separate inhibition of ACE and chymase. Thus, both ACE and 
chymase contribute to the generation of functionally active Ang II from Ang I in 
isolated HCAs, but the generation of Ang II by chymase is far less efficient, resulting 
in loss of Ang II into the organ bath fluid, thereby requiring more Ang I to obtain a 
certain degree of constriction. These data may offer an explanation for the discrepancy 
between in-vitro and in-vivo findings with regard to the enzyme(s) contributing to 
Ang I-II conversion (Maassen van den Brink et al., 1999; Richard et al., 2001; Saris et 
al., 2000). 
In agreement with previous in-vitro (Maassen van den Brink et al., 1999) and 
in-vivo (Saris et al., 2000) studies, Ang I was as potent as Ang II in the present 
experimental setup. This is remarkable in view of the low Ang II concentrations that 
were detected in the organ bath fluid during the construction of the Ang I CRC. In 
fact, for a given constriction the organ bath fluid concentrations during Ang I were 
approximately 40 times lower than those during Ang II. The explanation for this 
apparent discrepancy, confirmed in the present study, is that the vascular interstitial 
Ang II concentrations at equimolar Ang I and Ang II levels are comparable (Schuijt et 
al., 2002), and thus that vasoconstriction is determined by interstitial rather than organ 
bath fluid Ang II. The findings on PA-Ang I parallel those on Ang I. Taken together 
therefore, the levels of Ang II in the organ bath fluid are not representative for the 
Ang II levels seen by the receptor, and rather represent non-functional Ang II that has 
been ‘lost’ in the organ bath. Similarly, coronary constriction in the isolated perfused 
rat heart during exposure to either renin or Ang II did not relate to the Ang II levels in 
the effluent, suggesting that also in this preparation (representative for resistance 
vessels, as opposed to the conduit-type artery used in the present study) constriction is 
determined by tissue (interstitial) Ang II (Müller et al., 1998). 
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Chymostatin, but none of the other inhibitors used in this study (including the 
chymase-selective inhibitor C41) prevented the release of Ang II into the organ bath 
fluid during the application of both Ang I and PA-Ang I. The lack of effect of 10 µM 
C41, despite its potent inhibitory effects towards chymase in human heart 
homogenates (IC50 22 nM) (Richard et al., 2001), suggests either that C41 does not 
have sufficient access to chymase in intact tissue, or that chymostatin, being a non-
selective chymase inhibitor, inhibits alternative converting enzymes (e.g., 
cathepsin G). The latter conclusion would also imply that PA-Ang I is not a chymase-
specific substrate, as has already been suggested based on studies in rat arteries (Inoue 
et al., 1999). In humans however, using aprotinin (an inhibitor of cathepsin G but not 
chymase), evidence for cathepsin G-mediated Ang I-II conversion could not be 
obtained (Urata et al., 1990). Thus, the most likely explanation for the limited effect 
of C41 as compared to chymostatin, in agreement with a recent study in human 
mammary arteries (Richard et al., 2001), is that, at the concentration we used, its 
inhibitory capacities are more modest than those of chymostatin. It does have access 
to chymase, as evidenced by our observation that the Ang I CRC is shifted to the right 
in the presence of captopril and C41, but not when these inhibitors are given 
separately. The limited availability of C41 prevented us from constructing Ang I and 
PA-Ang I CRCs at higher C41 concentrations.  
Captopril, at a dose that is sufficient to obtain complete ACE inhibition (Danser 
et al., 1995; Tom et al., 2001a), did not reduce Ang II release in the organ bath. In 
contrast, ACE inhibition resulted in complete suppression of Ang II release during 
incubation of porcine arteries with Ang I and during perfusion of rat hearts with renin 
or Ang I (Danser et al., 1995 ; Müller et al., 1998; Schuijt et al., 2002). Thus, 
although ACE-dependent Ang II release does occur in-vitro, in human arteries it is 
apparently modest in comparison with the chymase-dependent Ang II release. In view 
of the fact that chymase is predominantly located adventitially (Urata et al., 1993), 
whereas ACE is largely present on endothelial cells (Coulet et al., 2001), we 
attempted to distinguish endothelial from adventitial Ang II release, by quantifying 
Ang II in luminal and adventitial fluid obtained from perfused HCAs following the 
application of Ang I to either the luminal or the adventitial compartment. The data 
confirm the concept that chymase is located predominantly adventitially, since the 
chymase-dependent Ang II release following adventitial Ang I application was 4 times 
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higher than that following luminal Ang II release. Angiotensin diffusion from the 
adventitial compartment to the luminal compartment or vice versa did not occur, in 
agreement with earlier work suggesting that such exchange probably takes place at the 
level of the capillaries (Danser et al., 1995; van Kats et al., 2001). Remarkably 
however, ACE inhibition did not affect luminal Ang II release. This contrasts with 
in-vivo studies measuring venous Ang II levels during arterial Ang I infusion (Saris et 
al., 2000), as well as with studies in Ang I-perfused porcine arteries (Danser et al., 
1995). Since chymase has been demonstrated in endothelial cells (Urata et al., 1993), 
release of this chymase under in-vitro conditions may have resulted in a greater 
contribution of chymase to endothelial Ang II release ex-vivo, thus making it 
impossible to detect ACE-dependent Ang II release. Along the same lines of 
reasoning, the contribution of adventitial chymase is probably also larger ex-vivo. 
Explanations for the greater role of chymase in-vitro than in-vivo, are first that tissue 
storage and handling may have resulted in chymase release from intracellular storage 
sites, and second the absence of endogenous chymase inhibitors (e.g., α1-antitrypsin 
and secretory leukocyte protease inhibitor) (Kokkonen et al., 1997; Takao et al., 2001) 
in isolated vessel preparations. 
Irrespective of the cause of the major contribution of chymase to Ang II 
generation in isolated HCAs, it is clear that ACE is located more strategically than 
chymase, i.e., closer to AT1 receptors, thereby allowing it to contribute to Ang II 
generation in a highly efficient manner, with little or no loss of Ang II to the organ 
bath. The higher interstitial Ang II levels during Ang I application as compared to PA-
Ang I application confirm this concept. Similarly efficient ACE-dependent Ang II 
generation has been demonstrated in porcine femoral arteries and in cultured rat 
cardiomyocytes (Saris et al., 2002; Schuijt et al., 2002). 
The question arises whether chymase does play a role at all in-vivo. In view of 
its location (adventitial, largely intracellular), it may not face the same Ang I levels as 
ACE. Moreover, endogenous inhibitors in interstitial fluid suppress its activity, 
thereby counteracting its more efficient cleavage of Ang I as compared to ACE 
(kcat/Km 198 vs. 125 µM-1 min-1) (Kokkonen et al., 1997; Takao et al., 2001; Urata et 
al., 1990). Thus, it will probably only generate Ang II when Ang I levels are high, e.g. 
during ACE inhibition. In support of this concept, all in-vivo studies using the 
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chymase-specific substrate PA-Ang I (Garrison et al., 1997; Inoue et al., 1999; 
McDonald et al., 2001; Nishimura et al., 1998) show that the concentrations of this 
substrate required to induce vasoconstriction are 10-100 times higher than the 
concentrations of Ang I required to reach the same degree of vasoconstriction, despite 
the fact that the affinities of Ang I and PA-Ang I for chymase are similar (Richard et 
al., 2001). Furthermore, even when Ang II is generated by adventitial chymase at high 
Ang I levels, its functional activity may be limited, since it is will be exposed to 
significant metabolism on its way to AT1 receptors (de Lannoy et al., 2001; Schuijt et 
al., 1999). 
In conclusion therefore, ACE-dependent Ang II generation results in more 
efficient AT1 receptor stimulation than chymase-dependent Ang II generation, and the 
importance of the latter pathway is overestimated under in-vitro conditions. 
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CHAPTER 7 
Superoxide Does Not Mediate the Acute Vasoconstrictor Effects 
of Angiotensin II: A Study in Human and Porcine Arteries. 
Summary 
We investigated whether superoxide mediates Ang II-induced vasoconstriction. Human 
and porcine coronary or femoral arteries (HCAs, PCAs, PFAs) were mounted in organ 
baths and concentration response curves to Ang II, the NO donor S-nitroso-N-
acetylpenicillamine (SNAP) and the NAD(P)H oxidase substrate NADH were 
constructed in the absence and presence of superoxide inhibiting and activating drugs. 
Extracellular superoxide was measured using cytochrome c reduction. Ang II 
constricted both HCAs and PFAs. In HCAs, the NAD(P)H inhibitors 
diphenyleneiodonium (DPI) and apocynin and the xanthine oxidase (XO) inhibitor 
allopurinol, but not the superoxide dismutase (SOD) mimetic tempol or the SOD 
inhibitor diethyldithiocarbamate (DETCA), reduced this constriction. Catalase 
potentiated Ang II in HCAs, indicating a vasodilator role for H2O2. DPI, tempol and 
SOD did not affect Ang II in PFAs. DPI, apocynin and allopurinol relaxed 
preconstricted HCAs. Although the relaxant effects of the NO donor SNAP in PCAs 
was reduced by DETCA, indicating that superoxide-induced constrictions depend on 
NO inactivation, the apocynin-induced relaxations were NO-independent. Moreover, 
NADH relaxed all vessels, and this effect was blocked by KCl but not DPI or NO 
removal. Xanthine plus XO also relaxed HCAs and PCAs. Incubation of human or 
porcine arteries with Ang II or NADH did not result in detectable increases of 
extracellular superoxide within 1 hour. In conclusion, acute vasoconstriction by Ang II 
is not mediated via superoxide generated through NAD(P)H oxidase and/or XO 
activation. Such activation, if occurring, rather results in the generation of the 
vasodilator H2O2. 
 
 
 
 
Based on: Schuijt M.P., Tom B., de Vries R., Saxena P.R., Sluiter W., van Kats J.P. 
and Danser A.H.J., (2003). Superoxide does not mediate the acute vasoconstrictor 
effects of angiotensin II. A study in human and porcine arteries, J. Hypertension, in 
press. 
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7.1. Introduction 
Ang II, through activation of NAD(P)H oxidase and/or xanthine oxidase (XO), 
stimulates superoxide generation in the vascular wall (Berry et al., 2000; Griendling et 
al., 1994; Mervaala et al., 2001; Touyz et al., 1999). Since superoxide inactivates the 
endothelium-derived vasodilator NO, it is generally assumed that Ang II-induced 
vasoconstriction is mediated, at least in part, via superoxide. Ang II infusion studies in 
rats and mice appear to support this concept (Laursen et al., 1997; Rajagopalan et al., 
1996; Wang et al., 2001). However, the Ang II-induced hypertensive effects in such 
studies were only observed after several days or weeks of Ang II infusion, and may 
thus reflect the well-known longterm effects of Ang II on vascular remodeling rather 
than its acute vasoconstrictor effects.  
Superoxide generation occurs in all layers of the vascular wall (Griendling et al., 
1994; Pagano et al., 1997; Rueckschloss et al., 2002; Touyz et al., 1999). However, 
since superoxide, unlike NO, is not membrane-permeable, its actions will be restricted 
to the subcellular compartment where it has been generated. This would favor a role 
as a signaling molecule rather than as an endothelial NO-inactivating agent. 
Furthermore, dismutation of superoxide anions by superoxide dismutase (SOD) yields 
hydrogen peroxide (H2O2), a membrane-permeable vasodilator that has been reported 
to act as an endothelium-derived hyperpolarizing factor (EDHF) (Kobayashi et al., 
2002; Matoba et al., 2002). The abundant presence of extracellular SOD (ecSOD) in 
blood vessels (Stralin et al., 1995) might thus be expected to immediately counteract 
any vasoconstriction due to a rise in superoxide.  
A limited number of studies have investigated the contribution of superoxide to 
the acute vasoconstrictor effects of Ang II. These studies were performed in isolated 
rat arteries (which, because of their low ecSOD content, differ from human blood 
vessels) (Karlsson et al., 1988) and depended on the use of either SOD or its mimetic 
tempol (Kawazoe et al., 2000; Shastri et al., 2002). Both drugs modestly reduced 
Ang II-induced vasoconstriction. Their effects were observed at micromolar (i.e., non-
physiological) concentrations of Ang II only, suggesting interference with AT1 
receptor desensitization (Hilgers et al., 2002) rather than superoxide inactivation as an 
explanation of their effects. Unfortunately, the drugs that are currently used to inhibit 
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NAD(P)H oxidase (diphenyleneiodonium (DPI) and apocynin) lack specificity 
(Dodd-o et al., 1997; 2000), and thus may also counteract Ang II-induced 
vasoconstriction independently of their effect on superoxide generation. 
It was the aim of the present study to address the importance of superoxide in the 
acute contractile effects of Ang II in human vessels mounted in organ baths. Because 
of the non-specificity of most of the drugs that are currently available to interfere with 
superoxide generation/degradation, and in view of the uncertainty to which degree 
these drugs reach the (intracellular) compartment where they are supposed to act, we 
used a wide range of enzyme inhibitors/mimetics, the underlying hypothesis being that 
contradictory findings could relate to their non-specific effects. For comparison, we 
also studied the effects of these drugs in combination with NO donors, the NAD(P)H 
oxidase substrates NADH and NADPH, and contractile agents that do not exert their 
actions in a  NAD(P)H oxidase- (Touyz et al., 2002) and/or superoxide-dependent 
(Shastri et al., 2002) manner ET-1 and the prostaglandin F2α analogue U46619. 
Finally, we quantified superoxide generation in parallel with the organ bath studies. 
Due to the limited availability of human arteries, some issues were addressed in 
porcine arteries. The angiotensin responsiveness of these vessels largely resembles 
that of human arteries (Maassen van den Brink et al., 1999; Schuijt et al., 2002; Tom 
et al., 2003).  
7.2. Methods 
Drugs 
Acetovanillone (apocynin),  Ang II, allopurinol, bradykinin, catalase, cytochrome c, 
diethyldithiocarbamate (DETCA), 9,11-dideoxy-11α,9α-epoxymethano-
prostaglandin F2α (U46619), DPI, ET-1, 4-hydroxy-TEMPO (tempol), 
hydroxocobalamin, NADH, NADPH, Nω-nitro-L-arginine methyl ester (L-NAME), 
prostaglandin F2α (PGF2α), sodium nitroprusside (SNP), S-nitroso-N-
acetylpenicillamine (SNAP), substance P, SOD from bovine erythrocytes, tiron, 
xanthine, and XO from buttermilk were from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). DPI, allopurinol and apocynin were dissolved in dimethylsulfoxide. All 
other compounds were dissolved in distilled water. 
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Tissue collection 
Human coronary arteries (HCAs) were obtained from 29 heart-beating organ donors 
(15 men, 14 women; ages 5-64 years, mean±S.E.M. 45±3 years) who died of 
noncardiac causes (22 cerebrovascular accident, 6 head trauma, 1 hypoxia) <24 hours 
before the heart was taken to the laboratory. Hearts were provided by the Rotterdam 
Heart Valve Bank after removal of the aortic and pulmonary valves for transplantation 
purposes. The study was approved by the Ethics Committee of the Erasmus MC. 
Immediately after circulatory arrest, the hearts were stored in an ice-cooled sterile 
organ-protecting solution (Maassen van den Brink et al., 1999). Porcine femoral and 
coronary arteries (PFAs, PCAs) were obtained from twentyfour 2-3 month-old pigs 
(Yorkshire x Landrace, weight 10-15 kg) that had been used in in vivo experiments 
studying the effects of α2 or CGRP receptor (ant)agonists under pentobarbital 
anaesthesia, and from 58 pigs at the local slaughterhouse. The Ethics Committee of 
the Erasmus MC dealing with the use of animals for scientific experiments approved 
the protocol for this investigation. Arteries were either removed at the end of the 
experiment, or after the heart from the slaughterhouse had been brought to the 
laboratory in cold Krebs bicarbonate solution of the following composition (mM): 
NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; 
pH 7.4. Vessels were stored overnight in cold, oxygenated Krebs bicarbonate solution. 
Overnight storage neither affected U46619 (30 nM)-induced constrictor responses 
(contraction of stored arteries 99±13 % of that of freshly isolated arteries, n=9) nor the 
subsequent endothelium-dependent relaxations induced by 10 nM substance P 
(relaxation of stored arteries 106±14 % of that of freshly isolated arteries, n=9). These 
data, which are in agreement with earlier data on the similar responsiveness of freshly 
isolated and stored myocardial trabeculae (Tom et al., 2001b), argue against a storage-
induced change in redox state affecting contractile or relaxant responses. 
Organ bath studies 
Vessels were cut into segments of ≈4 mm length, suspended on stainless steel hooks 
in 15 mL organ baths containing Krebs bicarbonate solution, aerated with 95% O2/5% 
CO2, and maintained at 37°C.  Vessel segments were allowed to equilibrate for at least 
30 minutes, and the organ bath fluid was refreshed every 15 minutes during this 
period. Changes in tissue contractile force were recorded with a Harvard isometric 
Chapter 7 
103 
transducer (South Natick). The segments, stretched to a stable force of ≈15 mN 
(coronary arteries) or ≈50 mN (femoral arteries), were exposed to 30 mM KCl twice. 
Subsequently, the tissue was exposed to 100 mM KCl to determine the maximal 
contractile response to KCl. The rings were then allowed to equilibrate in fresh organ 
bath fluid for 30 minutes. Next, segments were preincubated for 30 minutes with or 
without DPI (10 µM) (Berry et al., 2000; Touyz et al., 1999), apocynin (1 mM) 
(Dodd-o et al., 2000; Hamilton et al., 2002), NADH (100 µM), allopurinol (1 mM) 
(Berry et al., 2000), SOD (6 U/mL), tempol (1 mM) (Shastri et al., 2002), DETCA 
(100 µM) (Berry et al., 2000), catalase (1000 U/mL) (Hamilton et al., 2001), tiron 
(10 mM) (Didion et al., 2002b; Griendling et al., 1994), or L-NAME (100 µM) 
(Hamilton et al., 2002) + hydroxocobalamin (200 µM) (Danser et al., 2000). 
Thereafter, concentration response curves (CRCs) to Ang II, ET-1, the thromboxane 
A2 analog U46619, SNP, SNAP, NADH, NADPH, DPI, apocynin, allopurinol, or 
H2O2 were constructed, either at baseline or following preconstriction with 1 µM 
PGF2α in HCAs (to 50±5.5% of 100 mM KCl, n=7), 1 µM U46619 or 40 mM KCl in 
PCAs (to 65±3.0% (n=27) and 69±4.9% (n=8) of 100 mM KCl, respectively) and 10 
nmol/mL U46619 in PFAs (to 72±6.9% of 100 mM KCl, n=19). The effect of 
xanthine (100 µM) + XO (5 mU/mL) was studied in preconstricted HCAs and PCAs. 
Endothelial integrity was verified at the end of each experiment by observing 
relaxation to 1 nM substance P or 100 nM bradykinin after preconstriction with 
U46619 or PGF2α.   
Superoxide measurement 
Extracellular superoxide release was measured in vessel segments as SOD-inhibitable 
reduction of 10 µM oxidized cytochrome c. Segments were suspended in test tubes 
containing 1 mL Krebs bicarbonate solution, aerated with 95% O2/5% CO2, and 
maintained at 37°C. After a 15-min equilibration period, oxidized cytochrome c with 
or without 200 U/mL SOD was added in the presence or absence of 100 µM xanthine 
+ 5 mU/mL XO, 100 (HCA) or 10 (PCA, PFA) nM Ang II, 100 µM NADH, 100 µM 
NADPH, 10 µM DPI or their combination. After 15 and 60 min, 300 µl samples were 
removed and measured spectrophotometrically against Krebs bicarbonate solution at 
550 - 540 nm. The amount of reduced cytochrome c was calculated using the 
molecular extinction coefficient 21 mM-1 cm-1 (Leslie et al., 1987). 
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Data analysis 
Data are given as mean±S.E.M. Contractile responses are expressed as a percentage of 
the contraction to 100 mM KCl (59±4.0 mN in HCAs, n=19; 88±4.1 mN in PCAs, 
n=50; 109±8.6mN in PFAs, n=19). Dilator responses are expressed as a percentage of 
preconstriction. CRCs were analyzed as described (Maassen van den Brink et al., 
1999) to obtain pEC50 (-10log EC50) values. In the presence of inhibitors, agonists did 
not always reach the same maximum (Emax) at their highest concentration. In such 
cases we determined the concentration required to obtain 5% (Ang II) or 30% (ET-1) 
of the KCl-induced contraction, in order to calculate the pEC5%KCl or pEC30%KCl value 
(Maassen van den Brink et al., 1999). Statistical analysis was by paired t-test or one-
way ANOVA, followed by post hoc evaluation according to Dunnett. P<0.05 was 
considered significant. 
7.3. Results 
Ang II, ET-1 and U46619 
Ang II concentration-dependently constricted HCAs (pEC50 7.73±0.07; Emax 
15.7±2.4%, n=15; Figure 1) and PFAs (pEC50 8.84±0.06; Emax 51±5.7%, n=12; 
Figure 2). Ang II-induced constrictions were not studied in PCAs, because these 
vessels do virtually not respond to Ang II (Maassen van den Brink et al., 1999). 
SOD and tempol did not affect the contractile responses to Ang II in HCAs or 
PFAs. The SOD inhibitor DETCA decreased the Ang II-induced contractions in PFAs 
by 37±10% (P<0.05), but not in HCAs. However, in PFAs DETCA also caused a ≈5-
fold rightward shift (P<0.05) of the U46619 CRC (pEC50 and Emax under control 
conditions respectively 7.92±0.08 and 130±13%, n=4), suggesting that its inhibitory 
effect towards Ang II is non-specific (Figure 2).  
The NAD(P)H oxidase inhibitors DPI and apocynin, as well as the XO inhibitor 
allopurinol decreased the Ang II-induced Emax to 8.7±2.4, 5.5±3.1 and 3.5±1.3%, 
respectively (P<0.05 vs. control for all). DPI did not affect the Ang II CRC in PFAs. 
Catalase (n=6) potentiated Ang II ≈5-fold (pEC5%KCl 8.31±0.23 vs. 7.81±0.09; 
P<0.05) in HCAs, and a similar tendency (P=NS) was observed for the radical 
scavenger tiron (pEC5%KCl 8.18±0.14, n=6).  
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The inhibitory effects of DPI and apocynin towards Ang II in HCAs would be in 
agreement with the concept that superoxide mediates Ang II-induced vasoconstriction. 
However, the Ang II CRC was unaffected by the NAD(P)H oxidase substrate NADH 
(Figure 1), despite the rise in vascular superoxide production that has has been 
reported to occur following the addition of NADH to a vessel segment (Rajagopalan 
et al., 1996). Moreover, SOD and DETCA were still ineffective in the presence of 
NADH, and if anything, the inhibitory effects of DPI, apocynin and allopurinol were 
enhanced rather than decreased in the presence of this substrate. 
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Figure 1. Contractions of human coronary arteries to Ang II in the absence (left panel) or 
presence (right panel) of NADH without (control) or with DPI, apocynin, allopurinol, 
DETCA, tempol, tiron or catalase. Data (mean±S.E.M., n=6-15) are expressed as a 
percentage of the response to 100 mM KCl. 
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Figure 2. Top panels: Contractions of porcine femoral arteries to Ang II (left) and U46619 
(right) without (control) or with DPI, SOD, tempol or DETCA. Data (mean±S.E.M., n=4-12) 
are expressed as a percentage of the response to 100 mM KCl. Bottom panels: Relaxations of 
porcine coronary arteries (left) or porcine femoral arteries (right) to SNAP and SNP without 
(control) or with DPI or DETCA. Data (mean±S.E.M.; n=6-7) are expressed as a percentage 
of the preconstriction to U46619. 
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ET-1 constricted HCAs in a concentration-dependent manner (pEC50 7.61±0.06, 
n=7; Figure 3) and its efficacy was 4-5 times as large as that of Ang II (Emax 84±4.4%; 
P<0.01 vs. Ang II). With the exception of tiron, all drugs affecting the Ang II CRC in 
HCAs similarly affected the ET-1 CRC, although their effects were more modest as 
compared with their effects towards Ang II. 
 
 
 
 
 
Figure 3. Contractions of human 
coronary arteries to ET-1 without 
(control) or with DPI, apocynin, 
allopurinol, tiron or catalase. Data 
(mean±SEM.; n=4-7) are expressed 
as a percentage of the response to 
100 mM KCl. 
 
 
This probably relates to the much higher efficacy of ET-1. Catalase (n=4) 
marginally shifted the ET-1 CRC to the left (pEC30%KCl 7.96±0.13 vs. 7.74±0.18), and 
DPI, apocynin and allopurinol (n=7 for all) shifted the ET-1 CRC to the right 
(pEC30%KCl 7.52±0.16, 7.31±0.09 and 7.47±0.11, respectively; P<0.05 vs. control for 
all). 
NADH, NADPH, H2O2, and xanthine + XO 
Following preconstriction with U46619 or PGF2α, NADH concentration-dependently 
relaxed HCAs (pEC50 4.54±0.14, n=7), PCAs (pEC50 4.48±0.17, n=9) and PFAs 
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(pEC50 4.87±0.20, n=6) by maximally 87±4.9, 74±8.1 and 60±15%, respectively 
(Figure 4).   
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Figure 4. Relaxation of human coronary, porcine coronary, or porcine femoral arteries to 
NADH without (control) or with DPI, DETCA, L-NAME + hydroxocobalamin, tiron or 
catalase. Data (mean±S.E.M.; n=6-9) are expressed as percentage of the preconstriction to 
U46619 or PGF2α. 
 
In contrast, NADPH marginally affected U46619-preconstricted PCAs 
(relaxation <20%, n=7; data not shown). DPI and DETCA did not affect the NADH 
CRCs. Tiron, catalase, and L-NAME + hydroxocobalamin tended to reduce the 
NADH effects in PCAs, but significance (P<0.05) was reached with tiron only. 
Following preconstriction with 40 mM KCl, NADH was unable to cause relaxation 
(n=8, data not shown).  
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H2O2 relaxed U46619-preconstricted PFAs (pEC50 3.41±0.02, n=6) by 
maximally 124±25% (data not shown).  
Xanthine + XO relaxed preconstricted HCAs and PCAs by 22±7.5% (n=4) and 
57±11% (n=9). Relaxations in PCAs tended to be reduced by catalase (to 38±8.9%, 
n=9) and DETCA (to 34±16%, n=9), but the differences were not significant. 
SNAP and SNP 
The NO-donors SNAP and SNP dose-dependently relaxed preconstricted PCAs 
(pEC50 6.63±0.06, n=6) and PFAs (pEC50 6.31±0.10, n=7) by maximally 70±13 and 
123±8%, respectively (Figure 2). DPI shifted the SNAP CRC in PCAs ≈5-fold to the 
left (pEC50 6.87±0.05, n=6, P<0.05 vs. control), suggesting that superoxide inactivates 
exogenous NO. In agreement with this concept, SOD inhibition with DETCA largely 
prevented the SNAP-induced vasodilation in PCAs (maximal relaxation 22±6%, n=6, 
P<0.01 vs. control) and tended to decrease the SNP-induced vasodilation in PFAs 
(maximal relaxation 96±13%, n=7, P=0.06 vs. control). When repeated in the 
presence of NADH, the findings with SNP (n=7) and SNAP (n= 6) with or without 
DPI and DETCA were unaltered (data not shown).  
Inhibitors/mimetics of superoxide generating and degrading enzymes  
DPI, apocynin and allopurinol dose-dependently relaxed preconstricted HCAs 
(Figure 5). Relaxation amounted to 17±6.4, 107±4.1 and 89±7.1% at the highest 
concentration tested (i.e., the concentration used in the experiments with Ang II and 
ET-1). With the exception of the DPI-induced relaxation, all findings in HCAs were 
mimicked in PCAs. DPI constricted PFAs to the same degree as PCAs (n=5; data not 
shown). The apocynin-induced relaxations in PCAs were not affected by L-NAME + 
hydroxocobalamin (Figure 5). In PCAs, tiron (n=4) and catalase (n=4) had no effect 
on baseline constriction, wherease DETCA, tiron, and catalase did not affect U46619-
induced constrictions (70±5.1, 80±4.6 and 72±8.3 vs. 75±4.2% of 100 mM KCl, n=8 
for each), thereby indirectly supporting the idea that these drugs did not exert 
relaxant/constrictor effects. 
Angiotensin II and Superoxide 
110 
34567
-100
-75
-50
-25
0
25
34567
apocynin
allopurinol
DPI
%
 o
f p
re
co
ns
tr
ic
tio
n
-log [drug] M-log [drug] M
Porcine Coronary ArteriesHuman Coronary Arteries
apocynin+L-NAME
+hydroxocobalamin
Figure 5. Effects DPI, apocynin (without or with L-NAME + hydroxocobalamin), and 
allopurinol in preconstricted human coronary arteries (left panel) or porcine coronary 
arteries (right panel). Data (mean±S.E.M.; n=3-8) are expressed as a percentage of the 
preconstriction to U46619. 
 
Superoxide measurement  
Incubation of vessel segments with xanthine + XO resulted in an increase in 
cytochrome c reduction at 15 min (Table). SOD blocked this increase, thereby 
confirming that it was due to the generation of superoxide. Results at 60 min did not 
differ from those at 15 min, most likely due to XO deactivation during turnover 
(Hodges et al., 2000). No increases in cytochrome c reduction were observed during 
incubation of segments with Ang II (at concentrations that induced maximal 
contractile effects) for 15 or 60 minutes. NADH and NADPH both increased 
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cytochrome c reduction, but these increases were not blocked by SOD, indicating that 
they were not due to superoxide generation. DPI reduced the NADPH-induced 
increases in cytochrome c reduction, but, in view of the absence of an effect of SOD, 
this decrease could also not be attributed to a reduction in superoxide generation. 
Apocynin (in the presence of NADH or NADPH), DETCA and tiron at the 
concentration used in the organ bath set-up increased cytochrome c reduction in the 
absence of a vessel segment (n=5-7, data not shown) in a non-SOD-inhibitable 
manner, thus impairing the use of these drugs in the present assay. Results with 
tempol were identical to those with SOD (n=4 for vehicle, xanthine + XO, Ang II and 
NADH in HCAs; data not shown).  
7.4. Discussion 
This study does not support the concept that the acute vasoconstrictor effects of Ang II 
in healthy human and porcine arteries are mediated via superoxide generated through 
NAD(P)H oxidase and/or XO activation. The data rather suggest that such activation 
results in vasodilation, most likely in an H2O2-dependent manner.  
SOD and its mimetic tempol did not affect the Ang II CRCs in human and 
porcine arteries. This contrasts with previous findings in rat aortic rings, where these 
agents modestly reduced the contractions obtained at micromolar Ang II concentration 
(Kawazoe et al., 2000; Shastri et al., 2002). It could be argued that their lack of effect 
in the present study is due to the fact that human and porcine vessels possess much 
higher endogenous ecSOD levels than rat vessels (Karlsson et al., 1988), thus masking 
any vasoconstrictor effect of superoxide. Such constrictor effects should then become 
apparent during SOD inhibition with DETCA. However, DETCA was ineffective in 
HCAs and reduced (rather than increased) Ang II constrictions in PFAs. The latter 
may have been due to a non-specific action of DETCA, because it was also observed 
in relationship with U46619-induced constrictions. The absence of DETCA-induced 
Ang II potentiation is not due to its inability to block SOD in the present experimental 
setup, since DETCA did diminish the vasodilator effects of NO donors in porcine 
arteries. Thus, in agreement with a previous study in mouse aortic rings (Didion et al., 
2002b), an increase in superoxide is capable of causing vasoconstriction through NO 
inactivation. Conversely, a decrease in superoxide, as obtained with the NAD(P)H 
oxidase inhibitor DPI, enhanced the vasodilation by NO donors.  
  
 
Table: Cytochrome c reduction.  
   nmol/mL pmol/mg wet weight 
 
vessel
incubation 
time (min) 
 
SOD 
 
vehicle 
 
X+ XO 
 
vehicle
 
Ang II 
 
DPI 
DPI + 
Ang II 
 
NADH
 
NADPH
DPI + 
NADH
DPI + 
NADPH
HCA 15 - 0.81±0.19 2.85±0.35† 20±7.1 14±6.1 5.0±8.6 12±7.9 65±9.0† 80±2.5† 66±9.2† 46±5.0‡
 15 + 0.97±0.24 1.33±0.42* 24±7.8 20±9.5 3.9±15 7.7±12 68±7.2† 77±7.5† 66±3.6† 64±4.8 
             
 60 - 0.88±0.17 2.34±0.30† 25±6.4 18±5.8 12±7.9 17±8.4 127±21† 99±6.8† 114±17† 60±4.1 
 60 + 0.95±0.24 1.06±0.36* 23±8.3 23±8.9 7.5±16 12±11 121±17† 106±11† 128±22† 98±24 
             
PCA 15 - 0.32±0.12 2.45±0.44† 24±3.0 22±2.3 28±6.4 25±6.7 71±9.1† 49±8.4† 58±11† 32±4.1‡
 15 + 0.37±0.16 0.74±0.68* 26±4.8 27±5.6 20±5.1 16±2.3 60±7.7† 45±5.3† 64±11† 26±2.0‡
             
 60 - 0.46±0.10 2.03±0.27† 31±2.5 25±3.2 30±7.5 27±5.1 109±10† 60±9.1† 92±16† 38±5.3‡
 60 + 0.47±0.15 0.69±0.53* 31±4.6 28±5.3 19±2.7 18±2.1‡ 91±10† 52±5.9† 86±12† 33±2.3‡
             
PFA 15 - 0.06±0.08 1.49±0.41† 8.6±16 -7.4±14 - - - - - - 
 15 + 0.01±0.02 -0.2±0.09*† 1.7±4.5 -8.3±23 - - - - - - 
             
 60 - 0.16±0.10 1.12±0.29† 26±19 25±14 - - - - - - 
 60 + 0.11±0.08 -0.13±0.09*† 20±14 21±22 - - - - - - 
Values are mean±S.E.M. in human coronary arteries (HCA, n=7-10, except n=3 for NADPH and DPI+NADPH), porcine 
coronary arteries (PCA, n=5-19) and porcine femoral arteries (PFA, n=5). SOD, superoxide dismutase; X, xanthine; XO, 
xanthine oxidase; Ang II, angiotensin II; DPI, diphenylene iodonium;  * P<0.05 vs. without SOD, † P<0.05 vs. vehicle, 
‡ P<0.05 vs. without DPI. 
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In agreement with the absence of DETCA-induced Ang II potentiation, DPI did 
also not affect the Ang II CRC in PFAs. The contrasting data between NO donors and 
Ang II in porcine arteries may relate to 1) the high (pharmacological) NO 
concentrations that occur following the addition of SNAP or SNP, and 2) the site of 
superoxide-NO interaction. Under physiological conditions, the NO concentrations are 
~3 orders of magnitude below the levels of SOD (Koppenol, 1998), and thus 
superoxide inactivation will be due to SOD rather than its reaction with NO. DETCA 
will reverse this situation, particularly following the addition of exogenous NO donors 
(or endothelial NO-dependent vasorelaxants such as acetylcholine (de Saram et al., 
2002; Paravicini et al., 2002)). NO-superoxide interaction may occur anywhere 
between the NO generation site (i.e., NOS in endothelial cells) and the NO action site 
(i.e., guanylyl cyclase in vascular smooth muscle cells). Particularly if superoxide is of 
adventitial origin (Rey et al., 2002), the most likely site of interaction is the 
extracellular space. Using the cytochrome c reduction, we were however unable to 
demonstrate an increase in extracellular superoxide over a period of 1 hour following 
Ang II application. This implies that the previously described Ang II-induced 
increases in superoxide generation (Berry et al., 2000; Griendling et al., 1994; 
Laursen et al., 1997; Wang et al., 2001) occur intracellularly and result in limited or 
no superoxide release to the interstitium. Yet, DETCA (a cell-permeable SOD 
inhibitor), tempol (a cell-permeable SOD mimetic) nor DPI affected the Ang II-
induced vasoconstriction in PFAs. This suggests that the Ang II-induced increases in 
superoxide occur in an intracellular compartment that does not allow interaction with 
NO. The superoxide that inactivates NO following the addition of NO donors or 
acetylcholine apparently resides in a compartment (e.g., the extracellular space) that 
does allow such interaction, and may thus be of different origin.   
In apparent contrast with the above line of reasoning, DPI markedly reduced the 
effects of Ang II in HCAs, and even larger reductions of the Ang II-induced 
vasoconstriction were observed in the presence of the NAD(P)H oxidase inhibitor 
apocynin and the XO inhibitor allopurinol. These data are however difficult to 
reconcile with the lack of effect of both tempol and DETCA on Ang II-induced 
vasoconstrictions in human vessels. They also disagree with the limited contribution 
of XO to vascular superoxide generation (Berry et al., 2000). Consequently, 
functional (non-superoxide-related) antagonism might underlie these findings. Indeed, 
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all 3 inhibitors of superoxide generation concentration-dependently relaxed 
preconstricted HCAs. The relaxant effect of apocynin was unaffected by NOS 
inhibition and NO scavenging, thereby arguing against the proposal that it is due to a 
reduction in superoxide generation (and, as a consequence, a rise in NO) (Hamilton et 
al., 2002). The nonspecific actions of DPI include the blockade of many flavoprotein-
dependent enzymes other than NAD(P)H oxidase (e.g., NOS), inhibition of K+ and 
Ca2+ channels (Weir et al., 1994), and activation of guanylate cyclase (Dodd-o et al., 
1997). Thus, it is not surprising that DPI relaxed HCAs, and modestly constricted 
porcine arteries. Non-specific actions of allopurinol are supported by its 
cardioprotective properties in rabbits, a species which virtually lacks XO (Godin et 
al., 1987).  
The possibility that functional antagonism, unrelated to the inhibition of 
superoxide generation, underlies the effects of DPI, apocynin and allopurinol towards 
Ang II, is further supported by our finding that the inhibitory effects of these drugs 
were mimicked in relationship with the NAD(P)H oxidase (Touyz et al., 2002)- and/or 
superoxide (Shastri et al., 2002)-independent vasoconstrictor ET-1.    
In further agreement with the concept of functional antagonism, catalase and 
tiron potentiated Ang II. This suggests that reactive oxygen species cause vasodilation 
rather than vasoconstriction. Catalase (which does not enter the cell) also tended to 
potentiate ET-1, and a similar catalase-induced potentiation of norepinephrine has 
been reported (Kobayashi et al., 2002). Since intracellularly generated H2O2, the 
substrate of catalase, has been proposed to act as an EDHF, the most likely 
explanation of these findings is that endogenous H2O2 (a membrane-permeable factor 
derived from superoxide, either through spontaneous dismutation or generated by 
SOD) counteracts vasoconstriction following its release into the extracellular space. 
Accordingly, exogenous H2O2 was found to relax PFAs.  
H2O2-induced relaxations are believed to depend on activation of large 
conductance Ca2+-sensitive K+ channels (BKCa channels) (Barlow et al., 1998) and/or 
stimulation of eNOS-dependent NO release (Thomas et al., 2002). AT1 receptor 
mediated, H2O2-induced NO release has recently been demonstrated in endothelial 
cells following NAD(P)H oxidase stimulation by Ang II (Cai et al., 2002). 
Importantly, preliminary findings in the latter study revealed that membranes of 
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vascular smooth muscle and endothelial cells produce H2O2 rather than superoxide 
when stimulated with NADH. This finding, which the authors contributed to 
electrostatical hindrance of superoxide release (thereby favoring its spontaneous 
dismutation to H2O2), is in full agreement with our observation of NADH-induced 
relaxation in human and porcine vessels and the inability of DETCA to block this 
relaxation. It also explains why no increases in superoxide release were observed 
following the addition of either NADH or NADPH to human or porcine vessels. It 
should be noted that, although our data support the likelihood that extracellularly 
applied NADH reacts with NAD(P)H oxidase, the membrane orientation of vascular 
NAD(P)H oxidase is still a matter of debate (Griendling et al., 2000). In agreement 
with the proposal that the classical inside-out orientation is not applicable in non-
phagocytic cells (Satriano et al., 1993), several authors have shown superoxide 
generation following the addition of exogenous NAD(P)H to isolated arteries (Didion 
et al., 2002a; Pagano et al., 1997). 
The NADH-induced relaxations in the present study were unaffected by 
L-NAME + hydroxocobalamin, and blocked by KCl, thereby favouring a direct 
relaxant effect of H2O2 through BKCa channels (i.e., in an EDHF-like manner) rather 
than an NO-dependent effect. The lack of effect of catalase towards NADH is more 
difficult to explain, but may relate to its inability to fully block excessive H2O2 
generation following the addition of NADH. The relaxations observed following the 
addition of xanthine and XO to the organ bath might be explained in the same way, 
i.e., a predominance of H2O2 generation, in particular because Pomposiello et al. 
(Pomposiello et al., 1999) reported earlier that both 30 mM KCl and catalase prevent 
xanthine + XO-induced relaxations in PCAs. 
In conclusion, our data, when taken together, do not support the idea that acute 
Ang II-induced vasoconstriction depends on superoxide release and subsequent NO 
inactivation. This does not exclude the possibility that superoxide, following its 
intracellular generation, contributes as a signaling messenger to the longterm growth 
and remodeling effects of Ang II (Liu et al., 2003). In addition, superoxide 
dismutation, particularly in endothelial cells (Cai et al., 2002), results in the 
generation of the membrane-permeable vasodilator H2O2. Dismutation of NAD(P)H 
oxidase-derived superoxide, whether spontaneous or mediated via SOD, not only 
explains why NADH causes vasodilation, but may also underlie the vasodilator effects 
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that have been observed previously through activation of endothelial AT1 receptors 
(Boulanger et al., 1995). 
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CHAPTER 8 
Thesis Summary and General Discussion 
8.1. Summary in English  
Introduction and aim (Chapter 1) 
ACE inhibitors are widely used for the treatment of hypertension and heart failure. 
Their beneficial effects are usually attributed to blockade of Ang I-to-II conversion. 
However, since ACE also degrades the vasodilator bradykinin, bradykinin 
accumulation may also underlie ACE inhibitor-induced effects. In addition, recent 
studies suggest that ACE inhibitors potentiate bradykinin independent of their effects 
on bradykinin hydrolysis, through induction of ACE-B2 receptor ‘crosstalk’. Such 
crosstalk might also be enhanced by the ACE-inhibiting peptide Ang-(1-7), a 
metabolite of both Ang I and Ang II. Simultaneously, this peptide may exert effects 
via as yet unidentified ‘Ang-(1-7) receptors’.  
It was the aim of this thesis to study bradykinin potentiation by ACE inhibitors 
and Ang-(1-7). Bradykinin potentiation by inhibitors of neutral endopeptidase (NEP), 
a second enzyme contributing to bradykinin catabolism, was also addressed. In 
addition, we verified whether bradykinin-induced vasodilation and Ang II-induced 
vasoconstriction are mediated via NO and superoxide, respectively. Finally, we 
investigated whether enzymes other than ACE contribute to Ang I-II conversion. 
Studies were performed in human and porcine coronary arteries, as well as in porcine 
atrial trabeculae.  
Bradykinin-related aspects (Chapters 2-5) 
ACE inhibitors as well as Ang-(1-7) enhanced the bradykinin-induced relaxations of 
porcine coronary arteries. These drugs not only shifted the bradykinin concentration-
response curve to the left, but also induced relaxant effects in vessels that, following 
repeated exposure to bradykinin, no longer responded to bradykinin (desensitized 
preparations). The effect of Ang-(1-7) was half that of an ACE inhibitor, due to the 
fact that Ang-(1-7) blocks only one of the two active centers of ACE. Other, non-
ACE-related effects of Ang-(1-7) were not observed. Remarkably, despite the many 
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reports on ACE inhibitor-induced bradykinin potentiation independent of hydrolysis, 
we were unable to show potentiation when using ACE-resistant bradykinin analogues. 
Yet, ACE inhibitors did not affect the half-life of bradykinin added to porcine 
coronary arteries in organ baths. We therefore propose that ACE and B2 receptors co-
localize in the endothelial membrane, allowing ACE to determine the bradykinin 
concentration in the immediate vicinity of the B2 receptor. According to this concept, 
ACE inhibition causes a rise in the bradykinin concentrations that are seen by the B2 
receptor, allowing relaxation to occur even in desensitized preparations. NEP-B2 
receptor co-localization most likely does not occur, since NEP inhibitors did not 
potentiate bradykinin in porcine coronary arteries. Sterol-binding agents, capable of 
disrupting caveolae, did not prevent the ACE inhibitor-induced potentiation of 
bradykinin, suggesting that ACE-B2 receptor co-localization occurs outside of 
caveolae.  
Bradykinin exerted a modest, short-lasting negative inotropic effect in porcine 
atrial trabeculae. This effect, as well as the vasorelaxant effect of bradykinin in 
porcine coronary arteries, was only partially blocked by an inhibitor of NOS, 
L-NAME. Since more complete inhibition was obtained with the NO scavenger 
hydroxocobalamin, and in view of the fact that desensitization occurred more rapidly 
in the presence of L-NAME, our data raise the possibility that bradykinin-induced 
effects depend on NO from storage sites (e.g., S-nitrosothiols) in addition to de-novo 
synthesized NO.    
Angiotensin-related aspects (Chapters 6-7) 
Ang I and II equipotently constricted human coronary arteries. The chymase-specific 
substrate Pro11-D-Ala12-Ang I was less potent than the endogenous angiotensins. 
Separate ACE or chymase inhibition modestly shifted the Ang I concentration-
response curve to the right, whereas a much larger rightward shift was observed when 
both enzymes were inhibited. Remarkably, despite the similar potency of Ang I and II, 
the Ang II levels in the organ bath during the Ang I experiments were <5% of the 
Ang I levels. This suggests that tissue Ang II rather than organ bath fluid Ang II 
determines vasoconstriction. In support of this concept, the vascular interstitial Ang II 
levels were found to be equal for a given constriction induced by either Ang I, Ang II, 
or Pro11-D-Ala12-Ang I. Yet to reach a certain interstitial Ang II level >2 times more 
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Pro11-D-Ala12-Ang I than Ang I was required. Moreover, only chymase inhibition 
diminished the Ang II levels in the organ bath reached in the presence of Pro11-D-
Ala12-Ang I or Ang I, suggesting that Ang II generated by chymase is ‘lost’ in the 
organ bath. Apparently therefore, ACE-mediated Ang I-II conversion occurs more 
efficiently (i.e., closer to AT1 receptors, with little loss into the organ bath) than 
chymase-mediated conversion.  
Using a wide range of inhibitors and mimetics of superoxide 
generating/degrading enzymes, we were unable to support the idea that superoxide 
mediates the acute vasoconstrictor effects of Ang II in human and porcine arteries. In 
fact, activation of various superoxide-generating pathways resulted in vasodilation 
rather than vasoconstriction, possibly due to (spontaneous) dismutation of superoxide 
into the vasodilator H2O2. This does not mean that superoxide is unable to cause 
vasoconstriction, since inhibition of superoxide dismutation reduced the relaxant 
effect of NO, thereby confirming that superoxide causes vasoconstriction though NO 
inactivation.  
8.2. Samenvatting in het Nederlands 
Introductie en doel (Hoofdstuk 1) 
ACE remmers worden veel gebruikt bij de behandeling van hypertensie en hartfalen. 
Hun gunstige effecten worden doorgaans toegeschreven aan de blokkade van de 
omzetting van Ang I in Ang II.  Echter, aangezien ACE ook de vaatverwijdende stof 
bradykinine afbreekt, zou de accumulatie van bradykinine ook een rol kunnen spelen 
bij de effecten van ACE remmers.  Tevens suggereren recente studies dat ACE 
remmers bradykinine potentiëren, onafhankelijk van hun effect op de hydrolyse van 
bradykinine, namelijk via de inductie van ACE-bradykinine type 2 (B2) receptor 
"crosstalk".  Dergelijke crosstalk zou ook versterkt worden door het ACE-remmende 
peptide Ang-(1-7), een metaboliet van zowel Ang I als Ang II.  Tegelijkertijd zou dit 
peptide kunnen werken via tot nog toe onbekende "Ang-(1-7) receptoren".  
Het doel van dit proefschrift is om de bradykinine potentiëring door ACE 
remmers en Ang-(1-7) te bestuderen.  Tevens wordt de bradykinine potentiëring door 
remmers van neutraal endopeptidase (NEP), een ander enzym dat bijdraagt aan 
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bradykinine katabolisme, besproken.  Vervolgens wordt geverifieerd of de 
bradykinine-geïnduceerde vasodilatatie en de Ang II-geïnduceerde vasoconstrictie 
gemedieerd worden door respectievelijk NO en superoxide. Tenslotte wordt 
onderzocht of andere enzymen dan ACE een rol spelen in de Ang I-II conversie.  De 
experimenten worden uitgevoerd met humane en varkenskransslagaders, alsmede met 
atriale trabekels van het varken. 
Aspecten gerelateerd aan bradykinine (Hoofdstukken 2-5) 
Zowel ACE remmers als Ang-(1-7) versterkten de bradykinine-geïnduceerde relaxatie 
van kransslagaders van het varken.  Door de voorgaande stoffen trad niet alleen een 
linksverschuiving van de concentratie-effect curves op, maar werd ook een relaxerend 
effect geïnduceerd in bloedvaten die, na herhaalde blootstelling aan bradykinine, niet 
langer reageerden op bradykinine (gedesensitiseerde preparaten).  Vergeleken met een 
ACE remmer was het effect van Ang-(1-7) de helft, veroorzaakt door het feit dat 
Ang-(1-7) slechts één van de twee actieve centra van ACE blokkeert.  Andere, niet-
ACE gerelateerde, effecten van Ang-(1-7) werden niet geobserveerd.  Ondanks de 
vele studies die ACE remmer-geïnduceerde bradykinine potentiëring onafhankelijk 
van hydrolyse gerapporteerd hebben, is het opmerkelijk dat wij niet in staat waren om 
potentiëring aan te tonen gebruik makend van ACE-resistente bradykinine analogen.  
Aan de andere kant beïnvloedden ACE remmers niet de halfwaarde tijd van 
bradykinine, toegevoegd aan kransslagaders van varkens in een orgaanbad. 
Daarom stellen wij voor dat ACE en B2 receptoren gecolokaliseerd zijn in het 
endotheliale membraan, ervoor zorgend dat ACE de bradykinine concentratie bepaalt 
in de onmiddelijke aanwezigheid van de B2 receptor.  Volgens dit concept veroorzaakt 
ACE inhibitie een stijging van de bradykinine concentratie welke bemerkt wordt door 
de B2 receptor, waardoor relaxaties zelfs in gedesensitiseerde preparaten voorkomen.  
Er is hoogstwaarschijnlijk geen sprake van NEP-B2 colokalisatie, aangezien NEP 
remmers bradykinine niet potentieerden in kransslagaders van het varken.  Sterol-
bindende middelen, die caveolae kunnen vernietigen, voorkwamen de ACE remmer 
geïnduceerde bradykinine potentiëring niet, wat suggereert dat ACE-B2 receptor 
colokalisatie voorkomt buiten de caveolae. 
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Bradykinine veroorzaakte een bescheiden, kortdurend negatief inotroop effect op 
atriale trabekels van het varken.  Dit effect, maar ook het vaatverwijdende effect van 
bradykinine in kransslagaders van het varken, werd slechts gedeeltelijk geblokkeerd 
door L-NAME, een NOS remmer.  Aangezien een completere inhibitie werd gezien 
met de NO scavenger hydroxycobolamine en gezien het feit dat desensitisatie veel 
sneller optrad in de aanwezigheid van L-NAME, kan geconcludeerd worden dat de 
bradykinine-geïnduceerde effecten afhankelijk zijn van NO in opslagplaatsen (bv. In 
de vorm van S-nitrosothiolen) en van de-novo gesynthetiseerd NO. 
Aspecten gerelateerd aan angiotensine (Hoofdstukken 6-7) 
Ang I and II contraheerden humane kransslagaders op een equipotente wijze.  Het 
chymase-specifieke substraat Pro11-D-Ala12-Ang I was minder potent dan de endogene 
angiotensines.  Separate ACE of chymase remming veroorzaakte een bescheiden 
rechtsverschuiving van de Ang I concentratie-effect curve, terwijl een meer 
uitgesproken rechtsverschuiving werd geobserveerd na remming van beide enzymen 
tegelijkertijd.  Het is opmerkelijk dat, ondanks de gelijke potenties van Ang I en II, de 
Ang II concentraties <5% van de Ang I concentraties waren gedurende de Ang I 
experimenten.  Dit suggereert dat voornamelijk Ang II in het weefsel, en niet in de 
orgaan bad vloeistof, de vasoconstrictie bepaalt.  Dit concept wordt bevestigd door de 
bevinding dat de Ang II concentraties in het vasculaire interstitium gelijk bleven bij 
constricties geïnduceerd door Ang I, Ang II of Pro11-D-Ala12-Ang I.  Echter om een 
bepaalde concentratie van Ang II in het interstitium te bereiken was een 2 maal hogere 
concentratie Pro11-D-Ala12-Ang I dan Ang I benodigd.  Tevens werden de Ang II 
concentraties in de orgaan baden, bereikt in de aanwezigheid van Pro11-D-Ala12-Ang I 
of Ang I, alleen geëlimineerd door chymase inhibitie, wat suggereert dat Ang II, 
gegenereerd door chymase, "verdwijnt" in het orgaan bad.  Het lijkt er dus op dat de 
ACE gemedieerde conversie van Ang I naar Ang II efficiënter (of: dichterbij de AT1 
receptoren, met minder verlies in het orgaan bad) verloopt dan de chymase 
gemedieerde conversie. 
Gebruik makend van verscheidene remmers en mimetica van superoxide 
aanmakende/afbrekende enzymen, waren wij niet in staat om het idee te onderbouwen 
dat superoxide de acute vasoconstrictieve effecten van Ang II medieert in slagaderen 
van de mens en het varken.  De activatie van superoxide-genererende pathways 
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resulteerde zelfs in vasodilatatie in plaats van vasoconstrictie, waarschijnlijk 
veroorzaakt door (spontane) dismutatie van superoxide naar de vaatverwijder H2O2.  
Dit betekent niet dat superoxide niet in staat is vasoconstrictie te bewerkstelligen, 
aangezien de inhibitie van superoxide dismutatie het relaxerende effect van NO 
verminderde, wat bevestigt dat superoxide vasoconstrictie veroorzaakt door NO 
inactivatie. 
8.3. General discussion 
Despite the many studies on ACE inhibitor-induced bradykinin potentiation 
independent of hydrolysis, we were unable to confirm this finding in intact porcine 
coronary arteries. Various explanations for this discrepancy may be put forward. First, 
in many studies bradykinin analogues (e.g., [Hyp3-Tyr(Me)8]-bradykinin) were used 
that are not ACE-resistant (Danser et al., 2000; Dendorfer et al., 2001a; Gobeil et al., 
2002). Second, most studies that investigated ACE-B2 receptor crosstalk made use of 
transfected cells that overexpress both ACE and B2 receptors (Deddish et al., 1998; 
Marcic et al., 1999; Minshall et al., 1997b). Such high expression levels could lead to 
interactions that normally do not occur. For instance, co-expression of both NEP and 
B2 receptors in CHO cells resulted in NEP-B2 receptor crosstalk (Deddish et al., 
2002), whereas in isolated porcine coronary arteries, despite the presence of NEP in 
porcine vessels (Miyamoto et al., 2002), NEP inhibition did not affect bradykinin-
induced relaxations. Furthermore, expression levels strongly affect ligand-induced 
sequestration of B2 receptors in transfected cells, so that B2 receptor desensitization 
and/or resensitization will be different in transfected cells (Faussner et al., 2003).  
If ACE inhibitor-induced bradykinin potentiation is a matter of metabolism, why 
does ACE inhibition neither increase the tissue bradykinin levels in patients 
(Campbell et al., 1999) nor alter the half-life of bradykinin in organ bath fluid in the 
presence of coronary arteries? The most likely explanation is that ACE co-localizes 
with B2 receptors in a compartment in which degradation dramatically impairs 
bradykinin availability. Application of an ACE inhibitor under such conditions will 
immediately increase the bradykinin concentrations in the micro-environment of the 
B2 receptors (Figure 1), but not at the tissue level. In support of this concept, the 
existence of a tissue compartment with highly effective bradykinin degradation has 
been demonstrated  in  the  isolated  rat  heart  during  bradykinin  distribution  studies 
  
N
A
D
(
P
)
H
N
A
D
(
P
)
H
o
x
i
d
a
s
e
o
x
i
d
a
s
e
AI AII
NAD(P)H
oxidase
AII
O2-
NO
AT1
SOD
H2O2
NOS
RELAXATION
AT1
CONSTRICTION
A
T
1
A
I
I
A
I
I
BK
NAD(P)H
oxidase
AI
B2
ACE
NO
AT1
NOS
O2-
RELAXATION
BK
BK
BK
BK
BK
degradation
products Ang (1-7)
O2- REMODELLING/GROWTH
A
T
1
AI
ACEi
An
g 
(1
-7
)
REMODELLING/GROWTH
CONSTRICTION
en
do
the
lia
l c
ell
sm
oo
th
 m
us
cl
e 
ce
ll
B2 ACE BK
BK
A
C
E
A
C
E
NO pools
NO pools
mast cellchymase
AIAIIACEi(-) ACEi(+)
NAD(P)H
oxidase AT1 ACE
ACEi
O2-
SOD
H2O2
?
N
A
D
(
P
)
H
N
A
D
(
P
)
H
o
x
i
d
a
s
e
o
x
i
d
a
s
e
A
T
1
A
I
I
A
I
I
A
I
I
A
I
I
A
T
1
A
C
E
A
C
E
  
Figure 1: Unifying scheme 
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(Dendorfer et al., 1997b). A potential candidate for the ACE and B2 receptor-
containing compartment are caveolae, since both components have been demonstrated 
in these structures (Benzing et al., 1999; Haasemann et al., 1998). However, 
disruption of caveolae with cholesterol-depleting agents did not affect bradykinin 
potentiation by ACE inhibitors. Thus, co-localization must occur elsewhere, for 
instance in coated pits or non-caveolar lipid rafts. 
The high local efficacy of ACE is not restricted to the inactivation of bradykinin: 
in the organ bath setup, ACE also effectively activated Ang I locally, resulting in 
vascular (interstitial) Ang II levels that were up to 27-fold higher than the Ang II 
levels in the organ bath (Schuijt et al., 2002; Tom et al., 2003). Since interstitial rather 
than circulating Ang II was found to determine vasoconstriction, these data suggest 
that ACE and AT1 receptors, like ACE and B2 receptors, co-localize in the same 
compartment (Figure 1). Further evidence for the close anatomical localization of 
ACE, B2 receptors and AT1 receptors comes from a recent observation on AT1-B2 
receptor heterodimerization, resulting in enhanced G-protein activation and altered 
receptor sequestration (AbdAlla et al., 2000). Chymase did not co-localize with AT1 
receptors, and thus Ang II generation by this enzyme is less efficient, i.e., chymase 
needs to generate more Ang II to exert a certain effect, because chymase-derived 
Ang II is exposed to significant metabolism on its way to AT1 receptors. This 
conclusion implies that the high (tissue) Ang II levels that are sometimes observed 
during ACE inhibition, if due to chymase, do not necessarily result in AT1 receptor 
activation. 
ACE also degrades Ang-(1-7), a metabolite of both Ang I and Ang II. Ang-(1-7) 
inhibits the ACE C-domain, and is cleaved by the ACE N-domain. Since bradykinin is 
cleaved by both ACE domains, potentiation will be maximal at ACE inhibitor 
concentrations that block both domains, and half-maximal in the presence of 
Ang-(1-7). All Ang-(1-7)-induced effects described in this thesis were of metabolic 
origin (i.e., related to ACE inhibition): Ang-(1-7) did not potentiate ACE-resistant 
bradykinin analogues, and no direct effects of Ang-(1-7) could be detected. The latter 
finding indicates that the recently identified Ang-(1-7) receptor (Mas protooncogene) 
is absent in human and porcine coronary arteries.  
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Finally, AT1-B2 receptor co-localization may result in interaction(s) at the post-
receptor level. Bradykinin-induced relaxations, as well as its negative inotropic 
effects, were largely due to de-novo synthesized NO and NO from storage sites. AT1 
receptor activation in endothelial cells also results in NO release (Boulanger et al., 
1995). NAD(P)H-derived H2O2 has been reported to be the mediator of this latter 
release (Cai et al., 2002). At the same time, H2O2 might act as ‘endothelium-derived 
hyperpolarizing factor’ (Matoba et al., 2002), i.e., it may mediate bradykinin-induced 
relaxations in the absence of NO.  
Ang II, through activation of NAD(P)H oxidase and/or xanthine oxidase, 
stimulates superoxide generation in the vascular wall. Although superoxide induces 
vasoconstriction through NO inactivation, the acute Ang II-induced constrictor effects 
in human and porcine arteries could not be attributed to superoxide. This does not 
exclude the possibility that superoxide, following its intracellular generation, 
contributes to the long-term growth and remodelling effects of Ang II. Indeed, Liu et 
al. (Liu et al., 2003) recently provided evidence that Ang II-enhanced NAD(P)H 
oxidase plays a role in the induction of ICAM-1 expression, leukocyte infiltration, and 
vascular hypertrophy, independently of changes in blood pressure. 
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